Rationally designed aplyronine analogues for use in antibody-drug conjugates by Pettigrew, Talia Rosemaree
Rationally designed aplyronine analogues
for use in antibody–drug conjugates
A dissertation submitted in partial fulfillment of the requirements for the degree
of Doctor of Philosophy at the University of Cambridge
TALIA PETTIGREW
SEPTEMBER 2018
TRINITY COLLEGE DEPARTMENT OF CHEMISTRY

Declaration
I hereby declare that this dissertation is the result of my own work and includes nothing which
is the outcome of work done in collaboration except as declared in the Preface and specified in
the text. It is not substantially the same as any that I have submitted, or, is being concurrently
submitted for a degree or diploma or other qualification at the University of Cambridge or any
other University or similar institution except as declared in the Preface and specified in the text.
I further state that no substantial part of my dissertation has already been submitted, or, is being
concurrently submitted for any such degree, diploma or other qualification at the University of
Cambridge or any other University or similar institution except as declared in the Preface and
specified in the text. In accordance with the Board of Graduate Studies guidelines, this document




This dissertation is the result of many people’s efforts, and I would like to take advantage of this
chance to thank some of them.
Firstly, I thank Professor Ian Paterson for accepting me into his group and giving me the op-
portunity to take on a project in natural product synthesis. I quickly came to appreciate the
opportunities to learn and work together in a friendly and stimulating environment. In particular,
his help and advice while compiling this dissertation has been deeply appreciated.
Thanks also to Professor David Spring for welcoming me into his group, giving me the chance
to expand my chemical knowledge and to collaborate with other researchers. Both of my super-
visors have invested in building a positive working environment in their research groups, which
has allowed me to develop a strong social support network for which I am grateful. I thank
Professor Jonathan Goodman as well for his help and encouragement.
We have been fortunate in having excellent technical support from Nic Davies, Matt Pond and
Naomi Hobbs. Members of the Paterson group have given many hours of their time to keep Lab
122 running smoothly. For running NMRs I thank Simon Williams, Callum MacGregor, Andrew
Phillips, Leroy Han and Nelson Lam. Thanks as well to all the members of Team Aplyronine
and Team ADC, most especially to Rachel Porter as my aplyrologue buddy and proofreader
extraordinaire.
This project has been carried out with assistance from AstraZeneca. In particular I am indebted
to Jeremy Parker for inviting me to carry out a placement at AstraZeneca’s process chemistry
facility in Macclesfield, UK. It was a valuable learning experience – one which I would not have
had an opportunity to take up otherwise – and his support in both the scientific and practical
aspects of sojourning in the North were much appreciated.
For supporting my early forays into chemistry and for encouraging me to apply to Cambridge, I
am grateful to James de Voss, Joanne Blanchfield and Mary Garson. Thanks are due to Deborah
Longbottom and Rachel MacDonald for helping me with any PhD issue large or small, and for
fostering such a supportive community in the Department of Chemistry.
I am grateful to Trinity College for granting me an External Research Studentship, and to Cam-
bridge Australia Scholarships. Thanks also to the University of Cambridge and to Ian Paterson
for financial support.
ii
Many thanks to Patersons and Springles past and present for being excellent colleagues and
friends. I’ve looked forward to going to the lab every day because all my mates are there. I would
also like to thank my dear friends Emma Durham and Bianca Provost for being a boundless
source of kindness and advice, and Adam Yip and Bing Yuan Han for being my constant and
trusty companions for the last four years.
Thank you to Mum and Dad for encouraging me always and especially for teaching me to keep
chipping away at it. Finally, Mitch is the reason this dissertation has been completed, and if
I were to thank him for everything, it would take another dissertation at least this size, and
hopefully much more eloquent. I’m sure my words can hardly do them justice, but I treasure





























The aplyronines are a family of antimitotic marine macrolides which show highly potent antipro-
liferative effects at picomolar concentrations in human cancer cell lines. Through a novel dual
protein-targeting mechanism of action, their exquisite potency renders the aplyronines promising
drug candidates.
However, the scarcity and structural complexity of the aplyronines brings challenges in sup-
plying material to enable these studies, and calls into question their viability as commercial
targets. Based on structure–activity relationship studies for the aplyronines and some related
actin-binding macrolides, we have designed simplified analogues with the aim of reducing the
synthetic effort, whilst retaining the extraordinary potency of the natural products. Our highly
convergent route has led to a substantial reduction in the step count and improved scalability.
Importantly, recent advances in cancer chemotherapy have led us to consider conjugating the
aplyronines to monoclonal antibodies to produce improved antibody–drug conjugates to target
specific tumour cells.
Chapter 1 places this project in the context of marine natural products research for applications in
the clinic. Background is given on the extensive work previously undertaken on the aplyronines
in our group and others. Based on this, the rational design of analogues is justified and a plan
is laid out for their efficient synthesis. The field of targeted cancer therapy is introduced, with
particular reference to the antibody–drug conjugate approach.
Chapter 2 discusses the methods used to construct key fragments for these designed aplyronine
analogues. The southern fragment contains two of three key structural simplifications, while
the side chain contains the final modification. Details are also given for the re-synthesis of the
northern fragment, originally devised for the natural product, to supply this research.
Chapter 3 recounts how these fragments were combined and elaborated to a highly advanced
intermediate. We examine the selection of an optimal protecting group strategy for the north-
ern region from two options, leading to the scaled-up synthesis of a fully protected macrocylic
compound. Finally, attachment of the modified side chain provides the full carbon skeleton.
Chapter 4 culminates in endgame manipulations to furnish the desired analogues, and explores
the potential of these compounds to be advanced to the clinic for cancer therapy. Strategies for
conjugation to antibodies to develop a targeted therapy are considered, along with prospects for




According to the accepted IUPAC conventions, the two metal enolates A and B will be referred
to as (E)- and (Z)-enolates, respectively (Figure 1). In all cases the metal–oxygen substituent













Figure 1: Naming convention for enolates
Syn- and anti-diastereomers
The convention devised by Masamune1 for assigning the relative stereochemistry of vicinal
stereocentres as syn and anti is used in this dissertation. A syn-relationship is defined by two
substituents (R1 and R2) pointing in the same direction relative to the plane represented by the
main chain drawn in a zigzag conformation, as shown in Figure 2. An anti-relationship is de-
fined by two substituents pointing in opposite directions relative to the plane. Hence, the two









Figure 2: Naming convention for diastereoisomers
vi
Aldol adduct stereochemistry
For aldol reactions where an α-chiral ketone directs the stereochemical outcome, the aldol adduct
is referred to as shown in Figure 3. In these cases, the pre-existing ketone stereocentre is labelled
as “1” for reference. This convention recognises the origin of the stereochemistry while also































Figure 3: Naming convention for aldol adducts
Compound numbering
The naming and numbering of compounds follow priorities set out by IUPAC throughout this
dissertation. The numbering system used for aplyronine intermediates and analogues follows
that proposed by Yamada and co-workers in their original publication covering the isolation and
























































































HeLa human cervical adenocarcinoma cell line
HMBC heteronuclear multiple-bond correlation spectroscopy
ix
HMPA hexamethylphosphoramide
HPLC high-performance liquid chromatography
HRMS high-resolution mass spectroscopy





IC50 half maximal inhibitory concentration



































NMR nuclear magnetic resonance
nOe nuclear Overhauser effect
Nu nucleophile
obs obscured
P unspecified protecting group
PAB para-aminobenzyl
PABQ para-aminobenzyl quaternary ammonium













Red-Al sodium bis(2-methoxyethoxy)aluminium hydride
Rf retention factor
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1.1 Marine natural products
The oceanic environment is a source of fascination to the scientific community, representing a
vast and even now largely unexplored resource. To date, only a small fraction of the estimated
total number of marine species have been described. Regrettably, current threats to biodiversity
due to climate change and habitat destruction mean that there is growing urgency to study these
species. Underwater exploration has been pursued in earnest only in the last few decades, since
the advent of modern snorkelling along with the introduction of scuba and submarine technology.
Though there is much yet to learn, we do know that marine organisms are masters of biosynthesis,
producing all manner of structurally complex and biochemically surprising secondary metabo-
lites. As such, they offer tantalising challenges to the synthetic chemist. Invertebrates such as
sponges and molluscs quickly became a prized source of natural products, with over 11 000
novel structures discovered from these creatures between 1990 and 2014.3 A large number of
these compounds, often secondary metabolites, are used by their hosts in a system of chemical
defences against predators, competitors and microorganismal parasites. They therefore grant
an evolutionary advantage to organisms, whether synthesised de novo or sequestered from prey
species or symbionts.4 Indeed, many natural products originally isolated from filter feeders such
as sponges may in fact be of bacterial or fungal origin.5–7 Microorganisms are prolific producers
of all classes of secondary metabolites, which play an essential role in communication. Modes
of social interaction including commensalism, amensalism, neutralism, cooperation, competi-
tion, and predation may all be modulated by the exchange of chemical information.8 The ability
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to form consortia and other symbioses is a key characteristic for microbial survival, and hence
chemical signalling is extremely important in all types of marine environments.9–11
Great breakthroughs came with the recognition that marine natural products often show broad
cross-phylum biological activity, and can act as extremely potent biochemical effectors in human
systems. Studies on the mechanisms of action of biologically active natural products showed that
they can bind efficiently to many cellular proteins and inhibit or enhance enzymatic activity for
the treatment of disease. In a sense, this is not surprising, because at a fundamental level humans
and all other known organisms have many common goals. In general we wish to avoid predators,
deter parasites, benefit from symbioses, attract mates, and respond to changes in our environment
and accordingly hasten or slow growth. Given the common evolutionary origin of all living
species, and the resulting similarity in biochemical structures across taxa, it is understandable
that natural products which have resulted from a selective process could have potent biological
effects in other species, even distantly related ones. In the modern age, humans have controlled
many of the external dangers to our survival, leaving internal threats (i.e. to health) as important
determinants of the length and quality of our lives. For instance, cancer is now one of the most




































































Figure 1.1: Marine natural products which have been developed as anticancer drugs
2
Marine natural products have made an impact in the field of cancer treatment, due to their cy-
totoxic effects via modes of action such as interruption of microtubule assembly or DNA dam-
age.13 The first anticancer drug of marine origin was trabectedin (Yondelis, 1), approved for
treatment of soft tissue sarcoma in 2007 (Figure 1.1). In 2010, eribulin mesylate (Halaven, 2),
a synthetic analogue of marine natural product halichondrin B (3), was approved for metastatic
breast cancer treatment. This example typified a successful function-oriented synthesis.14 Scarce
supply of the compound from natural sources and the large investment of resources, time and cost
in producing it by total synthesis meant that economies had to be found if the product were ever
to reach the market for clinical use. Structure–activity relationship (SAR) studies of the ana-
logues and intermediates generated during the total synthesis of halichondrin B by Kishi and
co-workers15 were used to identify the parts of the molecule most necessary for bioactivity. This
led to the development of an optimised synthetic route towards the structurally simpler analogue



























PKC Ki = 1.35 nM
40−89 steps
designed analogue
PKC Ki = 0.25 nM
19 steps LLS
Figure 1.2: Function-oriented development of bryostatin analogues with similar or improved
biological activity (PKC = protein kinase C)16,17
The level of complexity inherent in many of the natural products in question means that, although
they may be accessible in the laboratory by total synthesis, commercial-scale manufacture may
seem to be beyond the limits of practicality.18 As a result these compounds may be question-
able candidates even at the earliest stages of pharmaceutical development. Function-oriented
synthesis is an extremely valuable approach by which chemists may achieve molecular function
with synthetic economy, thus addressing the supply issue.19,20 A further example is the develop-
ment of “bryologs”, analogues of the clinically relevant bryostatins, by Wender and co-workers.
At a time when total syntheses of the natural products required over 70 steps, the researchers
succeeded in generating their first simplified analogue with similarly potent growth inhibition
activity in under 30 steps (Figure 1.2).17 Indeed, a recent publication from the Wender group
3
reveals how these studies, after many years of development, have enabled the synthesis of bryo-
statin 1 and analogues to supply current clinical needs (ca. 20 g per year).21 Following these
successful examples, a number of marine natural products and their derivatives are currently in
the pipeline for further development or in various stages of preclinical testing.22,23
1.2 Targeted therapies
Despite great advances in medical treatment throughout the twentieth century, two issues that
persist are drug resistance and off-target toxicity. An ideal drug therapy would be one that
reaches all affected cells, and carries out its desired function exclusively in those target cells.
However, this concept is very difficult to achieve in practice, which has serious clinical implica-
tions. Resistance develops when not all cells of interest are eliminated, as the survivors become
progenitors for drug-resistant populations. Meanwhile, toxicity arises when the treatment has
undesired effects in non-target cells.
A regrettably typical example of the fate of many natural product lead compounds was suffered
by discodermolide (4, Figure 1.3). This potent microtubule stabiliser was targeted for develop-
ment by Novartis.24–28 A dauntless campaign to access 60 g of material by total synthesis was
met with disappointment, however, when Phase I clinical trials were halted due to severe lung
toxicity.29 Although cytotoxicity is in fact the desired effect of such anticancer compounds, a











Figure 1.3: Discodermolide, a potent microtubule stabilising agent which was discontinued
from pharmaceutical development due to off-target toxicity
Many of the most effective chemotherapeutics target proteins which are highly conserved across
cancerous and normal cells, such as actin and tubulin. Typically the cytotoxic effects are strongest
in rapidly dividing cells, conveying the desired anticancer properties. However, the lack of dif-
ferentiation between many normal cell proteins and their malignant counterparts causes healthy
4
tissues to be affected. This results in suboptimal clinical outcomes and unpleasant or even dan-
gerous side effects for the patient, for instance nausea, myeloid suppression, peripheral neuropa-
thy, and organ toxicity.30 It is desirable to achieve the maximum benefit with minimal exposure
to a given anticancer agent. The lowest dosage that leads to a positive therapeutic outcome is
known as the minimum effective dose. Exceptionally potent compounds are desired in order to
lower the dose needed to achieve a clinical effect. Meanwhile, the maximum tolerated dose of
a drug is dictated by the dose at which harm is caused to normal tissues. This places an upper
limit on exposure (Figure 1.4). A complementary approach to widening the therapeutic window
is increasing selectivity for neoplastic cells, minimising the risk to normal cells and allowing the
agent to be better tolerated by the patient.30
Figure 1.4: Approach to maximising the therapeutic index of drugs30
As a result, recent approaches to cancer drug discovery have become focused on the development
of targeted therapies, with the aim of selectively delivering potent anticancer agents to the tumour
site. These can include certain tumour-targeted small molecules*, monoclonal antibody thera-
pies, and importantly, conjugated species which contain a targeting portion linked to a cytotoxic
effector.33 These conjugates consist of a receptor-binding (bio)molecule such as an antibodies,
peptide, small molecule or polymer, which is linked to anticancer therapeutic effectors such as
small molecule drugs, radionuclides, or protein toxins.33,34
The use of these targeting strategies will often rely on molecular profiling of a patient’s spe-
cific disease subtype, allowing treatment to be tailored to individual characteristics (Figure 1.5).
Targeted therapy therefore falls under the banner of personalised medicine, and has immense
potential to improve treatment outcomes.32 This methodology is by no means limited to cancer
therapy and could be applied more widely: for instance, to autoimmune conditions and infectious
diseases.
*These are generally limited to cases where tumour enzymes have particular mutations not shared with healthy
cells, thus the binding mode of the small molecule drug makes it necessarily selective for a tumour-specific target.
Imatinib, an inhibitor of a mutant tyrosine kinase for treatment of chronic myeloid leukaemia, is an example.31,32
5
Figure 1.5: Targeted therapy relies on molecular profiling of disease and enables stratified or
individualised medical treatment35
1.3 Antibody–drug conjugates
Figure 1.6: Structure of an antibody-drug conjugate36
Antibody-drug conjugates (ADCs) have emerged as a highly promising avenue for targeted ther-
apies. The field has grown rapidly over the past decade, with four ADCs currently available
on the market and over 50 in clinical trials.37 These entities consist of a monoclonal antibody
attached to a cytotoxic small molecule payload via a chemical linker (Figure 1.6). Antibodies
can be selected or genetically engineered to have high selectivity for receptors which are either
overexpressed or, rarely, solely expressed on the cancer cell surface and not in healthy tissues,
thereby delivering the payload to the site of interest.
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The ADC is administered intravenously and is transported in the bloodstream to the tumour,
where it undergoes antigen-specific binding and internalisation into the cell via receptor-mediated
endocytosis (Figure 1.7). Depending on the antigen of interest, a number of pathways are then
possible. Often, the conjugate is trafficked to the lysosome where the linker undergoes enzymatic
or chemical cleavage. This releases the therapeutic agent into the cytosol, where it binds to its
intracellular target and ultimately causes cell death.36
Figure 1.7: Mechanism of action of an ADC38
The immunoconjugate approach brings a number of benefits as a form of targeted therapy.
Firstly, due to the larger contact surface areas involved in protein-protein interactions, antibodies
exhibit extremely high selectivity for their target receptors relative to small molecule and peptide
drugs.39 They also have long plasma half-lives, up to three weeks in circulation.30 Antibodies
alone can be used as clinical therapeutics, but in cancer indications these tend to have much
more limited mechanisms of action and show lower clinical efficacy than ADCs, as they lack the
attached cytotoxic payload. Payload wastage due to metabolism and excretion from the system
is reduced relative to using the naked small molecules, which is of great benefit given the time
and resource costs of producing these complex molecules.22
Challenges in ADC design chiefly lie in identification of an appropriate target receptor, engineer-
ing of a suitable antibody, payload selection, and development of compatible linker chemistry.
The three key components of an ADC, namely the antibody, linker and payload, will be discussed
in the following sections.
7
Figure 1.8: Structural model of an ADC with 4 auristatin drug molecules attached to a human
IgG1 monoclonal antibody. The ribbon diagram represents the antibody, while the stick repre-
sentations are given for the linker and payload. The antigen binding sites are shown in colour.40
1.3.1 Antibody selection
The majority of the biomolecules used for conjugation are based on immunoglobulin G (IgG)
scaffolds, which consist of two identical heavy chains and two identical light chains arranged in
a characteristic Y-shape. Antigen binding sites are located at each end of the fork, and can be
altered to maximise the affinity of the antibody for the chosen receptor (Figure 1.8). Advances in
genetic engineering have led to the generation of fully human monoclonal antibodies. These bind
target antigen with high specificity while minimising or even eliminating host immune response,
which was a major drawback of previously used murine antibodies (Figure 1.9).30,33,41
Figure 1.9: Desired properties of an ADC, and comparison of early and more recent ADC
characteristics41
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Much recent interest in the field has centred upon creating homogeneous immunoconjugates, in
which a controlled number of drug molecules are attached at pre-determined sites on the anti-
body.42 The first generation of ADCs used native amino acids such as lysines and cysteines to
attach the linker–payload unit at various points on the antibody, leading to stochastic mixtures
in terms of drug position, proximity and number. These heterogeneous distributions of species
generally showed drug-to-antibody ratios (DARs) ranging between 0 and 9 (Figure 1.10).43 By
contrast, more recent developments in site-specific conjugation involve antibody design to in-
troduce discrete, chemically accessible cysteines or non-natural amino acids containing reactive
functional groups for attachment of the drug in a controlled manner.36,44 Alternatively, meth-
ods using novel linker designs with native antibody sequences limit conjugation to sites com-
patible with the chosen chemistry.43 Some typical examples, including cysteine alkylation and
re-bridging, are shown in Figure 1.11.
Figure 1.10: Theoretical distributions for native lysine and site-specifically conjugated antibod-
ies. (A) Forty potential conjugation sites exist on the protein surface, leading to highly hetero-
geneous product distributions. (B) An engineered antibody with precisely two conjugation sites,
leading to homogeneous products with a DAR of exactly 2.42
1.3.2 Linker design
In most early cases, and in some current examples, ADCs have contained non-cleavable linkers.
These can convey the advantage of extended plasma half-life, but rely upon enzymatic degra-
dation of the full antibody to release their payload.36 Much more common in modern ADC
constructs is to use a cleavable linker strategy. There has been a proliferation of research around
the development of linker chemistry which is completely serum-stable, but readily labile in the
9
Figure 1.11: Typical methods for ADC construction from native antibodies45
intracellular environment.46,47 We shall return to this topic in more detail in Chapter 4.
1.3.3 Natural products as cytotoxic payloads
Natural products and their derivatives are very strongly represented among the 34 ADCs for
which structures have been published.36 As discussed above, these compounds are in a strong po-
sition to achieve the exquisitely potent bioactivities wanted for ADCs, as they have been through
the long and comprehensive screening process of natural selection.
To craft an effective ADC, the payload should ideally be extremely potent, which in traditional
drug development might go hand in hand with non-specificity. The advantage of the targeting
approach is that it is selective by design. This opens up the possibility of reconsidering drug
candidates that have previously been excluded due to systemic toxicity in clinical trials, as was
the case with discodermolide (Section 1.2). High potency improves a treatment’s therapeutic
index (refer Figure 1.4) and is preferable due to pharmacokinetic limitations on the number
of drug molecules that can be attached to each antibody. Importantly, good water solubility is
required for intravenous administration; products that are too hydrophobic tend to aggregate.48,49
The field is expanding rapidly, and new classes of payloads have been added. However, the range
of options remains relatively limited. As such, novel payloads are needed to expand the range of

































































































Figure 1.12: Current FDA-approved ADCs Adcetris, Kadcyla, and Besponsa. Mylotarg (not
shown), like Besponsa, contains the calicheamicin-derived DNA damaging agent ozogamicin
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used classes of cytotoxic warheads present in ADCs currently under development is the auris-
tatins, synthetic derivatives of the marine pentapeptide dolastatin 10 which was isolated from the
sea hare Dolabella auricularia.30,33,40 A member of this analogue family, monomethyl auristatin
E, induces cytotoxicity by inhibition of microtubule dynamics and features in Adcetris (bren-
tuximab vedotin, Figure 1.12), currently on the market for treatment of Hodgkin lymphoma.30
The plant-derived maytansinoids operate by a similar mode of action and feature in a num-
ber of ADCs, including Kadcyla (ado-trastuzumab emtansine), recently approved for metastatic
breast cancer.30,33,40 Also present in multiple ADCs are the calicheamicins, bacterial-derived
antitumour antibiotics which cause double-strand DNA breakage leading to cell death.30,40 The
analogue ozogamicin appears in Besponsa (inotuzumab ozogamicin), first released in 2017, and
Mylotarg (gemtuzumab ozogamicin), which was re-introduced to the market in 2017 based on
new evidence after having been exluded due to toxicity. All of these compound classes exhibit
low picomolar antiproliferative activity and were considered unsuitable for use as single agent
therapeutics due to potential off-target toxicities. However, owing to their exceptional potencies
they were excellent candidates for development in immunoconjugates.
1.3.4 Further considerations
It has been shown that the antigen receptor need not be internalised into the tumour cell: in-
stead, the warhead may be liberated in the extracellular space and diffuse into the surroundings,
facilitating bystander killing.34 Non-internalisation may be advantageous in eradicating hetero-
geneous tumours containing antigen-negative cells. This process may also allow the drug to
penetrate deeper into neoplastic sites distant from blood vessels and to directly kill endothelial
cells in the tumour neovasculature.30,50 However, issues of off-target toxicity to neighbouring
healthy tissues may be more of a concern than with counterpart ADCs that deliver payloads into
the cytoplasmic matrix.
Notably, ADCs can target malignant epithelial cells over healthy cells even where both express
the target antigen. The loss of intercellular junctions in tumours leads to random distribution of
normally apically-restricted receptors across the entire plasma membrane, granting access via
the bloodstream to targeted drugs (Figure 1.13).46
Although they have mainly been used in oncology to date, there are significant opportunities
to expand ADCs to other fields of medicine, including autoimmune and infectious diseases.
Recently, the first antibody–antibiotic conjugate was reported, with potentially huge significance
in the current climate of concern over antibiotic resistance.51,52
12
Figure 1.13: Normal cells can block ADC passage through intercellular junctions, while ma-
lignant cells lack this level of protection. This promotes selectivity with judicious choice of the
target receptor.46
The high cost of ADC therapy is a serious issue with important ethical implications. These will
not be dealt with in this discussion, other than to note that this form of treatment is as yet in very
exploratory stages of development. It is to be expected that as the technology matures, the costs
of development and production should decrease significantly.
1.4 The aplyronines
In the ongoing search for effective cytotoxic ADC payloads, especially those with novel modes
of action, the aplyronines have surfaced as a compelling candidate. This structurally interesting
class of marine macrolides bears similarities to a number of known marine natural products, but
exhibits a unique binding mode which gives rise to its highly potent antitumour activity.53
1.4.1 Isolation and structure elucidation
The aplyronines were originally isolated from the sea hare Aplysia kurodai by Yamada and co-
workers in 1993.2 Specimens were collected off the Pacific coast of Mie Prefecture, Japan, and
subjected to repeated partitioning and chromatographic separation steps, guided by in vitro cy-
totoxicity against the HeLa-S3 cell line. This led to the isolation of aplyronines A–C (5−7,
13
Figure 1.14: Aplysia kurodai swimming at 20 m, Jeju Island, South Korea54
Table 1.1). In 2000, Yamada reported the isolation of five further congeners in very low abun-
dance, aplyronines D–H (8–12).55,56
Structurally, the family differs almost solely in the number and type of amino acid residues at
C7, C9 and C29. Each congener consists of a 24-membered macrolactone and a functionalised
11-carbon side chain, bearing a total of fifteen stereocentres. Analysis of IR, UV and 1D 1H and
13C NMR data for 5 allowed the identification of key structural features, including an α,β,γ,δ-
unsaturated ester with (E,E)-geometry, two additional (E)-olefins, an acetate ester, two additional
esters, two hydroxyl groups, three methoxy groups, two dimethylamino groups, and a terminal
N-methyl-N-vinylformamide. Rotamers at the N-methyl-N-vinylformamide terminus as well as
scalemic mixtures of the C7 and C29 amino acids cause the NMR spectra of 5 to appear as a
complex mixture of four diastereomers. Detailed 2D NMR spectral analysis, including 1H–1H
COSY and HMBC experiments, as well as degradation studies assisted in the elucidation of the
overall structure. The full relative and absolute stereochemical assignments were confirmed via
enantioselective synthesis of the degradative fragments by Yamada and co-workers, culminating
in the first total synthesis of aplyronine A, 5.58–62 The structures of congeners B and C (6 and 7)
were also confirmed by Yamada’s total synthesis,63 and aplyronines D–H (8−12) were assigned
by analogy to the known aplyronine A.56
1.4.2 Biological activity
From their earliest discovery, the aplyronines were noted to show potent in vitro activity against
the HeLa-S3 cell line (see Table 1.1).2,57 It is notable that small differences in the amino acid
profile of each of the aplyronines have a significant effect on their biological activities. For
instance, aplyronines A (5) and C (7) differ only in the presence of the trimethylserine moiety at
C7, yet the former shows almost 50-fold greater cytotoxicity against HeLa-S3 cells. Similarly,
aplyronine D (8) differs from its congener aplyronine A only by one methyl group on the C29
amino acid, but is six-fold more toxic.
14














Congener R1 R2 R3
Isolation yield




A (5) TMSer H DMAla 75 0.45
B (6) H TMSer DMAla 4.3 2.9
C (7) H H DMAla 0.9 22
D (8) TMSer H DMGly 2.6 0.071
E (9) = 22-methylaplyronine A 4.0 0.18
F (10) TMSer H MMAla 0.7 0.18
G (11) DMSer H DMAla 1.6 0.12
H (12) H DMSer DMAla 0.6 9.8



















∗   1.3−1.1 : 1 S/R
∗∗ 2.5−4.0 : 1 S/R
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Due to the low natural abundance of the other congeners, further biological testing has to date
been restricted to aplyronine A. Promising results emerged from in vivo testing in mouse xenografts
of five tumour types (Table 1.2).64 Potent dose-dependent growth inhibitory activity was shown,
especially in P388 leukaemia, Lewis lung carcinoma and Ehrlich carcinoma, and in the former
two, particularly high survival rates were observed. This remarkable antitumour activity has led
aplyronine A to be considered a promising preclinical candidate.65











P388 leukaemia i.p. 0.08 59.9 545 4/6
Control — 11.0 0/7
Colon C26 carcinoma i.p. 0.08 40.0 255 0/6
Control — 15.7 0/10
Lewis lung carcinoma i.p. 0.04 60.1 556 6/6
Control — 10.8 0/8
B16 melanoma i.p. 0.04 46.8 201 0/6
Control — 23.3 1/9
Ehrlich carcinoma i.p. 0.04 59.7 398 2/6
Control — 15.0 0/8
a Schedule: intraperitoneal (i.p.) days 1–5. Aplyronine A (5) was dissolved in DMSO (0.08 mg
mL−1) and then diluted with a physiological solution of NaCl.
1.4.3 Structure–activity relationship studies
Fluorescence experiments by Karaki and co-workers in 1996 identified that aplyronine A binds
to actin, the most abundant eukaryotic cellular protein.66,67 These findings have since been sup-
ported by various studies, including one resulting in the publication of an X-ray structure of the
actin–aplyronine complex (Figure 1.16).68–71 Two forms of actin are found in eukaryotic cells:
monomeric globular actin (G-actin) and polymeric filamentous actin (F-actin). The dynamic
equilibrium between the two is regulated by interactions with various other cellular proteins to
maintain the vital cellular functions of the actin cytoskeleton.72 Interconversion is modulated
by ATP in a concentration-dependent process known as “treadmilling”, which allows directional
growth of filaments (Figure 1.15).73 Takata and co-workers found that aplyronine A intercalates
its side chain into a hydrophobic cleft between G-actin subdomains 1 and 3, sequestering the
monomers and inhibiting polymerisation to F-actin. It also causes rapid depolymerisation of F-
16
actin by capping and severing existing filaments.68 Disruption of the complex actin modulation
pathway interferes with cell motility and cytokinesis, and can ultimately lead to apoptosis.74,75
Figure 1.15: Schematic of the dynamic equilibrium between monomeric and filamentous actin72
Figure 1.16: X-ray structure of the actin-aplyronine A complex57,68,76
Structure–activity relationship (SAR) studies on the aplyronines were undertaken by Yamada
and co-workers, largely based on intermediates and analogues generated during their fragment
and total syntheses. This enabled an analysis of the aplyronine pharmacophore, identifying
structural features which are necessary for both actin depolymerising activity and cytotoxicity.
These results are summarised in Figure 1.17.64,77–82
Perplexingly, it appeared from these SAR studies that for potent cytotoxicity, actin binding is
a necessary but insufficient condition. This mystery deepened further when Kigoshi and co-






















replacement with different terminal 
polar group tolerated
−OH decreases 
cytotoxicity & actin binding
saturated analogue significantly less cytotoxic
removal / moving to C9 / replacement with 
DMGly significantly reduces cytotoxicity
Macrolactone: alone, no actin binding or 
cytotoxicity. Increases cytotoxicity and 
actin binding activity of side chain
removal tolerated
−OAc decreases actin 
binding and cytotoxicity
Features essential for cytotoxicity
Features essential for actin binding 
and cytotoxicity
Side chain: essential for actin binding and 
cytotoxicity. Alone, modest decrease in 
actin binding efficiency and non-cytotoxic.
Figure 1.17: Summary of SAR studies on aplyronine A64,77–82
fused with the side chain of mycalolide B (Figure 1.18).82–84 The researchers had hoped to
achieve more potent actin-depolymerising activity and thus an improved cytotoxicity profile
compared to aplyronine A. Instead they found no direct correlation between these two effects:
although the hybrid showed somewhat more potent actin-depolymerising activity than aplyro-




















Figure 1.18: Kigoshi’s aplyronine A–mycalolide B hybrid82,83
In 2013, Kigoshi and co-workers made a breakthrough when they reported that aplyronine A
forms an unprecedented 1:1:1 heterotrimeric complex with actin and tubulin, another abundant
cell protein with vital functions as part of the cytoskeleton (Figure 1.19).53 They suggest that
after actin binding occurs, the trimethylserine moiety protruding into bulk solvent may gener-
ate a new tubulin binding site on the actin–aplyronine complex. Inhibition of tubulin dynamics,
perhaps by capping microtubules or copolymerisation into the microtubule lattice, further desta-
bilises cytoskeletal processes and eventually results in cell death (Figure 1.19).85 Side chain ana-
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logues designed to strongly bind actin may not necessarily produce the conformational changes
required for this protein–protein interaction (PPI), which would account for the previously un-
predictable relationship between actin binding efficiency and cytotoxicity. Its unique mode of
action as a PPI inducer gives aplyronine A all the more potential as an anticancer therapeutic, as
it could be applied to new disease indications and could help overcome known drug resistance
mechanisms. Further studies will provide insight into the formation of this complex and the
optimal functionalities needed to exploit the cytoskeletal depolymerising effect.
Figure 1.19: Heterotrimeric complex between aplyronine A, actin and tubulin,53 and the pro-
posed mechanism of microtubule assembly inhibition85
1.4.4 Related actin-binding natural products
The aplyronine side chain bears a significant resemblance to those of a number of other potent
actin-binding marine macrolides, notably reidispongiolide A (14), mycalolide B (15), and scy-
tophycin C (16, Figure 1.20).72,86–88 These compounds all feature a complex macrolactone core
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with a highly conserved 11-carbon hydrophobic side chain terminating in a polar N-methyl-N-
vinylformamide group, with only minor differences in side chain functionality and stereochem-
istry. They bind actin at the same site, and exhibit a similar mode of action to aplyronine A (vide
supra, Section 1.4.3).72,89,90 However, to date none of these natural products has been shown
to induce formation of a ternary complex such as the aplyronine–actin–tubulin trimer described
above.53 This makes aplyronine A exceptional in its mechanism of action and a clear candidate
for development towards new anticancer treatments.
1.4.5 Analogue development
In order to further probe the biological activity and therapeutic potential of the aplyronines, it is
proposed that novel analogues be developed. Ideally these “aplyrologues” would be structurally
simpler than natural aplyronine A, whilst retaining or even improving its potent biological ac-
tivity. This calls for a function-oriented synthetic approach (see Section 1.1). Simpler targets
and more streamlined syntheses are of course preferable, especially if large-scale production is
to ensue, due to the associated economies of time, effort, resources and environmental impact.17
Creating simplified analogues presents an opportunity to further increase the efficiency of the
synthetic route developed in the Paterson group.
Discovery of one or more suitable analogues, in particular those which can be prepared easily and
on large scale, will aid in the consideration of this family of natural products for development as
ADC payloads. This process would also need to include consideration of the appropriate linker
chemistry, which will require analysis of various analogues for their potency and stability. It is to
be hoped that this process will produce an even better ADC payload candidate than aplyronine A.
1.5 Previous synthetic efforts
The first total synthesis of aplyronine A (5) was successfully brought to completion by Yamada
and co-workers in 1994.2,58,61,62 This was swiftly followed by syntheses of congeners B and C
from an advanced common intermediate, and provided confirmation of the structural and stereo-
chemical assignments of all three natural products.63,77 In addition to delivering further material
for biological testing, which was in short supply given the extremely low isolation yields, the


























































Figure 1.20: Selected actin-binding natural products with a characteristic side chain57,90
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Paterson and co-workers published the total synthesis of aplyronine C in in 2013.91 The com-
pletion of aplyronines A and D followed.92 Marshall,93,94 Calter95–100 and Fuchs101–106 have
carried out partial syntheses of aplyronine fragments, generally following the major disconnec-
tions of the Yamada and Paterson strategies. Recently, Kigoshi has also completed a revised total
synthesis of aplyronine A, building upon the earlier mycalolide B hybrid synthesis (see Section
1.4.3).107
1.5.1 Yamada approach
Yamada’s synthetic approach relied upon a late-stage Horner–Wadsworth–Emmons reaction to
install the (E,E)-dienoate, followed by a modified Yamaguchi macrolactonisation (Scheme 1.1).
Other disconnections included sulfone alkylation and multiple uses of the Julia olefination to join
the key fragments. The three stereotetrads were constructed using a common eight-step sequence
involving Evans aldol methodology, starting from the appropriate enantiomer of oxazolidinone
17, as well as the Sharpless asymmetric epoxidation.
Ultimately, the synthesis of aplyronine A required a total of 98 steps (47 steps LLS) and gave an
overall yield of 0.39% from Evans imide (S,S)-17. The level of convergence in the route is to be
commended, and its length justified by the need to be highly flexible in order to allow for any
necessary modifications to the stereochemistry, which at the time remained unconfirmed. With
the configuration confidently assigned, there remained much scope for improvement upon this
first total synthesis of the aplyronines.
1.5.2 Paterson approach and modifications for analogue synthesis
Studies towards the total synthesis of the aplyronines in the Paterson group began in 1995, and
are ongoing today. A key moment in this long-term project was the publication of the total syn-
thesis of aplyronine C in 2013.91 Since that work, aplyronines A and D have also been completed
as part of a scalable second-generation route, featuring a revised protecting group strategy.92,108
Specific details of the forward synthesis will be given in the text where relevant, but for context,
a brief retrosynthetic overview is given here (Scheme 1.2).
An initial disconnection was to be a Keck esterification to attach the C29 amino acid residue,











































































































Scheme 1.1: Total synthesis of aplyronine A by Yamada and co-workers61,62
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The final esterification step would ambitiously rely on the greater reactivity of the less hindered
C7 hydroxyl over that at C9.
In the early approach to aplyronine C,109 it was envisaged that the C27–C28 bond would be ac-
cessible via HWE coupling of macrocyclic aldehyde 19 and β-ketophosphonate 22. However,
later work showed an aldol disconnection to be more appropriate, and in the successful synthetic
route the coupling was achieved via the boron-mediated aldol reaction of 19 and ketone 23. Im-
portant disconnections within the C1–C27 macrocycle 19 were a Yamaguchi macrolactonisation
and HWE coupling to selectively install the (E)-trisubstituted olefin. This revealed the C1–C14
phosphonate 20 and C15–C27 aldehyde 21 as key fragments, in addition to the C28–C34 side chain
fragment 23.
Each of these three key fragments (20, 21 and 23) contained a set of three or four contiguous
stereocentres, which were efficiently constructed through a combination of substrate-controlled
aldol reactions and 1,3-anti diastereoselective reductions. Of particular note was the use of
all-syn tin(II) aldol methodology to set the C23–C26 and C29–C32 stereoclusters.110 Common
starting materials were used to construct the three stereotetrads, with the required enantiomer of
appropriately protected Roche ester derived ethyl ketone 24 or 26 inducing the desired absolute
configuration (Figure 1.21). The remaining stereocentres were either sourced from the chiral







R = PMB24 25
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Figure 1.21: Roche ester-derived starting materials for construction of stereotetrads
This route gave access to aplyronine C (7) in 29 steps LLS and 3.6% overall yield from ke-
tone 24.111 This compares favourably with the Yamada aplyronine A synthesis (47 steps LLS,
0.39% overall yield) which, as discussed, was necessarily lengthy. The group synthesis has
since been improved during diversification and scale-up studies with a focus on streamlining
the protecting group strategy. Although this led to a lower recorded overall yield of 2.7%, that
figure represents a more realistic output on scales amenable to providing gram quantities of the
aplyronines.92,108,112 As described in Section 1.4.5, further synthetic efficiencies were then an-
ticipated through simplification of the scaffold in the development of analogues. The structural
modifications we proposed are described below.


























































































Scheme 1.2: Paterson approach to the total synthesis of the aplyronines
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to make essential protein contacts in the actin or tubulin binding sites (see Figure 1.16, Section
1.4.3).53,64,71,78–82 It was therefore anticipated that simplifying this region of the molecule should
have little effect on binding efficiency, whilst conferring a number of synthetic advantages. Al-
tering the C17–C21 backbone to a plain hydrocarbon chain eliminates two stereocentres and an
olefin from the original structure. This would remove the need to use a chiral starting material to
supply the stereocentre at C17 in the southern fragment, and avoid several synthetic steps.113
A challenging step in the Paterson aplyronine synthesis was the formation of the 24-membered
macrolactone. Upon submission of the C23/C25 diol substrate to macrolactonisation (Scheme 1.2),
the C25 hydroxyl group was found to be the preferred reaction site, leading to an undesired 26-
membered ring as the predominant product.114 Substituting this hydroxyl group for a methyl
ether would block the site towards macrolactonisation, promoting reaction at the desired C23
alcohol instead. This would improve synthetic efficiency by avoiding the need for an isomerisa-
tion step to form the desired 24-membered ring. Although the side chain region is key for actin
binding affinity, it is reasonable to expect that this modification should not have a detrimental
effect. In the related natural products reidispongiolide A and mycalolide B, a methoxy group
replaces the equivalent C25 hydroxyl group in the aplyronines (Figure 1.20, Section 1.4.4); these
two natural products interact with actin with comparable binding efficiency,72 which suggests
that this substitution should be well tolerated.
Similarly, reidispongiolide A and scytophycin C both feature a methoxy group in place of the
aplyronines’ C31 acetoxy group. This was the source of many difficulties in the natural product
synthesis, in most cases stemming from facile acetate elimination. Installation of a methoxy
group in aplyronine analogues could help protect the site from undesired reactivity, as well as
reducing the need to manipulate protecting groups.
1.6 Aims
The key objective of this project was to devise and synthesise analogues of the aplyronines that
retain the highly potent biological activity of the natural products while simplifying the scaffold
and allowing for a more streamlined synthesis, enabling their use as novel payloads for ADCs.
Three main modifications to the aplyronine structure were proposed (Figure 1.22):
(1) simplification of the C17–C21 region to an unfunctionalised carbon chain, eliminating two
stereocentres and an olefin;
26
(2) replacing the C25 hydroxyl group with a methyl ether; and










































Figure 1.22: Modifications to the aplyronine scaffold for analogue development
The proposed C15–C27 (29) and C28–C34 (32) analogue fragments were to be incorporated into
the established Paterson aplyronine synthesis. HWE coupling of 29 to the C1–C14 fragment
20 or alternative target 2892 and macrolactonisation steps to give the macrocycle (30 or 31)
would be followed by aldol coupling with 32 and endgame modifications to give analogues
(Scheme 1.3). The potential for late-stage diversification allows for the synthesis of a number
of different analogues, particularly by varying the amino acids at C7 and C29. Furthermore, the
side chain fragment could be varied, for instance by substituting natural product fragment 23
for analogue fragment 32 to give an analogue that retains the C31 acetoxy group found in the
natural product. Other modified fragments could be included with appropriate functionalisation
for ADC linkage.
With a library of analogues in hand, we would need to carry out cytotoxicity assays to determine
whether our synthesis-informed design had been successful in retaining biological function.































R1 = Me, Ac
R2 = DMGly, (S)-DMAla, (R)-DMAla, ...
























Scheme 1.3: Target fragments 20 (or 28), 29 and 32 for assembly into a variety of analogues
28
Chapter 2
Synthesis of key fragments
2.1 Southern fragment analogue (C15–C27)
Two of the three modifications to the aplyronine structure 8 discussed in Section 1.6 are found in
the C15–C27 region (Figure 2.1). The first goal of this work was therefore to efficiently synthesise
the simplified fragment 29 on gram scale to provide enough material for further investigations
and for elaboration to the full analogue. The key disconnections from the Paterson aplyronine
synthesis were applied to take advantage of previously optimised chemistry. This would entail
the use of a 1,4-syn-3,4-syn selective aldol reaction to install the correct stereochemistry at C23
and C24, followed by a substrate-controlled 1,3-anti reduction of the resulting β-hydroxy ketone.
The C15 aldehyde function would ultimately be necessary in the key fragment 29 for the planned
coupling to the northern C1–C14 phosphonate in a HWE olefination.
2.1.1 Aldol coupling
The chiral ketone 33 required for the diastereoselective aldol reaction was accessed from com-
mercially available (S)-Roche ester 34 in 3 steps (Scheme 2.1). The primary alcohol was pro-
tected as the benzyl ether (BnTCA, TfOH, 96%) and converted to Weinreb amide 36 (N,O-
dimethylhydroxylamine hydrochloride, i-PrMgCl, 69%). The desired ketone 33 was then ac-
cessed via mono-addition of an ethyl Grignard reagent (EtMgBr, 75%).
The long-chain aliphatic aldehyde 39 was obtained in two steps (Scheme 2.2) by mono-protection
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(a) BnTCA, TfOH, Et2O, 0 °C → rt, 2 h; (b) MeO(Me)NH·HCl, i-PrMgCl, THF, −15 °C, 16 h; (c) EtMgBr, Et2O, 0 °C, 16 h
(75%)(96%) (69%)
34 35 36 33
Scheme 2.1: Synthesis of ethyl ketone 33 from (S)-Roche ester 34
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dation (DMSO, COCl2, Et3N, 76%).116 PMBCl was used as the limiting reagent in the presence
of three equivalents of diol in dilute solution to favour mono-protection of the diol and min-
imise formation of a bis-PMB protected byproduct (ca. 6% observed). Conveniently, the excess









(a) PMBCl, NaH, TBAI, THF/DMSO (2:1), 0 °C → rt, 72 h; (b) DMSO, (COCl)2, Et3N, CH2Cl2, −78 °C → rt, 4 h
O
37 38 39
Scheme 2.2: Synthesis of aldehyde 39 from 1,9-nonanediol (37)
Attention then turned to the aldol coupling of ketone 33 and aldehyde 39. In the Paterson aplyro-
nine C synthesis, the C23–C26 stereotetrad had been constructed using a Sn(OTf)2 mediated syn
aldol reaction of chiral ketone 26 with aldehyde 41 to give adduct 44 in excellent yield (88%) and
diastereoselectivity (9:1 dr).113 Selective formation of the (Z)-enolate 40 means that only two
diastereomeric products are possible (Scheme 2.3). The Zimmerman–Traxler transition states117
TS-42 and TS-43 clearly show that the all-syn isomer 44 is the product of the less sterically con-
gested TS-42. The high levels of stereoselectivity could be attributed to the conformationally
restricted transition state, as the silyl ether oxygen is understood to be internally chelated to the
Lewis-acidic tin centre.111,118
Despite this earlier success, however, a number of drawbacks are associated with the use of
Sn(OTf)2. Asymmetric aldol reactions mediated by this Lewis acid appear to be highly depen-
dent on reagent quality. The procedure followed to prepare the reagent is lengthy, typically
taking 6−8 days, and involves hazardous reagents. Working with Sn(OTf)2 also brings disad-
vantages such as the formation of problematic emulsions upon aqueous workup and consequent
generation of large volumes of toxic tin(II) waste. In this case, efforts to prepare the Sn(OTf)2
reagent were met with poor reagent quality, with attendant low yields and diastereoselectivity.
These difficulties led us to reconsider the methodology for this aldol reaction. Results of initial
testing with alternative Lewis acids are shown in Table 2.1.
A chiral boron reagent was considered based on earlier work in the Paterson group using ketone
substrate 33.119 For the boron aldol reaction, (+)-Ipc2BOTf was selected as the Lewis acid in or-
der to give the 1,4-syn, 3,4-syn aldol product 47 based on the literature precedent. The opposite
enantiomer of the boron Lewis acid is expected to give the 1,4-anti-3,4-syn product 48 in aldol
reactions with ketone 33. It transpired that the product was difficult to separate chromatographi-





















































Scheme 2.3: Tin(II)-mediated aldol coupling in the Paterson aplyronine C synthesis113
Table 2.1: Optimisation studies for aldol coupling of ethyl ketone 33 to aldehyde 39




























Entry Conditions Isolated dr (47:48)a Yieldb (%)
1 Sn(OTf)2, Et3N, −78 °C – nr
2 (+)-Ipc2BOTf, i-Pr2NEt, 0 °C 3:1 79
3 Ti(i-PrO)Cl3, i-Pr2NEt, − 78°C 5:1 78
4 TiCl4, i-Pr2NEt, −78 °C 1:1 53
a Based on 1H NMR analysis of isolated material. b Overall yield of the diastereomeric mixture.
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reaction yield difficult. Although this method may have shown better potential under further
optimisation, this was deferred for the time being in order to investigate the prospect of using a
titanium Lewis acid to effect the transformation.
Results in our group following a publication by Urpí, Romea and co-workers showed that ti-
tanium(IV) reagents offer a desirable alternative to tin(II) reagents to establish the 1,3,4-syn
stereochemistry of the required product.120 Urpí and Romea reported that titanium Lewis acids
such as TiCl4 and Ti(i-PrO)Cl3 can be used to generate (Z)-enolates from ketones such as 33 at
low temperature (Table 2.1). Upon reaction with an aldehyde, these will diastereoselectively give
the 1,3,4-syn polypropionate motif.120 These Lewis acis were tested, using i-Pr2NEt as a base
in CH2Cl2 at −78 °C (Table 2.1, entries 3 and 4). Consistent with Urpí’s findings, Ti(i-PrO)Cl3
showed promising results, giving a good yield (78%) and a diastereomeric ratio of 5:1. The more
powerful Lewis acid TiCl4 was found to give a non-synthetically useful ratio of diastereomers
(1:1 47/48), along with a lower yield of aldol addition product. The softer Lewis acid was there-
fore settled upon as the best avenue for further investigation, based on its relative operational ease
of use, reproducibility and the accessibility of the reagent. The respectable 5:1 dr was expected
to be improved upon in the optimisation process.
The reaction is understood to proceed via a chelated transition state similar to that which has
been described for Sn(OTf)2 aldol reactions (see Scheme 2.3), enhancing the selectivity for the
major isomer 52 via the favoured transition state TS-50.110 Formation of the minor isomer 53
is disfavoured due to its more sterically congested transition state TS-51 (Table 2.2). Based on
Lee’s work on this reaction,118 it was hypothesised that the diastereoselectivity might be further
improved by using a more electron-rich protecting group at the chelating β-hydroxy site, such
as a PMB ether in place of the benzyl ether in 33. This did not appear to be borne out by
the results of this aldol coupling, however: a similar dr was achieved in each case (Table 2.2,
entries 1−3). The main reason to reconsider the protecting group strategy arose from concurrent
studies in the group suggesting that the benzyl ether at this position might later prove difficult
to remove while leaving other functionality in the elaborated fragment intact.112 Use of a PMB
ether, which would be selectively cleavable in the presence of DDQ, therefore seemed preferable.
This would necessitate a change in protecting group for aldehyde 39 for differentiation purposes.
An orthogonal TBS ether was selected for this purpose due to its favourable properties with
regards to ease and efficiency of protection and deprotection in the current system as well as
stability under the required conditions. The required aldehyde 49 was synthesised in 2 steps
(TBSCl, imidazole, 83%, then DMSO, (COCl)2, Et3N, 91%).
The selectivity of the Ti(i-PrO)Cl3-mediated aldol (≥10:1 dr, 67% yield, Table 2.2) was akin
33




























































Entry R1 R2 Scale (mg ketone) Isolated dr (52:53)a Yield (%)b
1 Bn PMB 100 5:1 78
2 Bn TBS 100 10:1 70
3 PMB TBS 100 10:1 63
4 PMB TBS 500 12:1 63
5 PMB TBS 1600 10:1 67
6 PMB TBS 3700 18:1 85
a Based on 1H NMR analysis of isolated material. b Overall yield of the diastereomeric mixture.
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to that of the Sn(OTf)2-mediated aldol reaction (9:1 dr, 88% yield) in the Paterson aplyronine
C synthesis.113 The relative ease of carrying out this reaction made it vastly preferable to the
tin(II) methodology, and much more amenable to scale-up. Interestingly, the yield and diastere-
oselectivity of the reaction with PMB ketone 25 were comparable to those of the benzyl ketone
33 with TBS-protected aldehyde 49 (Table 2.2, entry 2 vs entry 5). Nevertheless, the predicted
difficulties in selectively removing the benzyl protecting group influenced us to proceed with a
PMB protecting group strategy.
The moderate yields of the desired aldol adduct 54 could be partially explained by deprotection
of either the PMB or TBS groups during the aldol reaction, giving small amounts of byproducts
55 and 56 (Scheme 2.4). This was not entirely unexpected, given the chance that the chelated
titanium could promote cleavage of the electron-rich PMB ether. Similarly, titanium chelating
to the C15 oxygen could cause the silyl ether linkage to be cleaved. Fortunately, the resulting
primary alcohols could be re-protected without difficulty to give the desired product 54 in 99%
and 64% yield respectively. This amounted to an effective yield of 91% in initial studies. During
later scale-up efforts, improved yields of the desired product 54 were recorded without the need
for re-protection steps. The conditions were optimised by minimising the time of exposure of the
substrates 25 and 49 to Ti(i-PrO)Cl3 (1.5 h), while keeping the other reaction conditions constant
(i-Pr2NEt, CH2Cl2, −78 °C, Scheme 2.4). In this way, a 3.5 g batch yielded 85% of 54 in 18:1 dr
in a single manipulation (Table 2.2, entry 6; also Scheme 2.4).
The advanced Mosher method was used to rigorously confirm the configuration of the newly
formed C23-hydroxyl stereocentre. This method was first described by Mosher and co-workers121,122
and later extended to the use of high-field NMR systems by Kakisawa and colleagues.123–125 A
chiral carbinol is derivatised with each enantiomer of α-methoxy-α-trifluoromethylphenylacetic
acid (MTPA-OH) to form diastereomers, which differ by 1H NMR spectroscopy. The relevant
conformation is one in which the trifluoromethyl group, the ester carbonyl and the carbinol me-
thine proton are syn-coplanar, such that the phenyl ring of the Mosher ester exerts a magnetic
shielding effect on any protons on the same side of the plane (Scheme 2.5). In the (S)-MTPA
ester, protons in substructure R1 will be relatively more shielded than their equivalents in the
(R)-MTPA ester, resulting in an upfield shift; the opposite is true for protons in substructure R2.
This difference in shift for the two diastereomers can be expressed as ∆δSR (δS − δR). When
calculated for as many protons on each side of the chiral alcohol as possible, the sign of this
value is diagnostic for the position of each R-group relative to the MTPA plane.
Accordingly, the (S)- and (R)- Mosher esters 57 and 58 were prepared under Steglich condi-









































































Scheme 2.5: Model for analysis of absolute configuration by the advanced Mosher method123,126
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Scheme 2.6: Determination of C23 stereochemistry by formation of Mosher esters126
2.1.2 1,3-anti reduction
With aldol adduct 54 in hand, a directed reduction of the C25 ketone was carried out to set
the configuration of the full C23–C26 stereotetrad. A number of selective 1,3-anti reduction
approaches are available for β-hydroxy ketones, one such being the samarium-mediated Evans–
Tishchenko reduction.128 This protocol is renowned due to its ability to differentiate between the
two resulting alcohols, in this case giving the C23 propionate ester 59. This would be required
in order to selectively introduce the C25 methyl ether modification for the proposed aplyronine











































Scheme 2.7: Evans–Tishchenko reduction mechanism for β-hydroxy ketone 54128
The mechanism for the Evans–Tishchenko reduction is thought to involve intramolecular hydride
transfer in a 6,6-chair-type hemiacetal transition state TS-60 (Scheme 2.7).128 Initially, SmI2 is
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oxidised to a Sm(III) species, evidenced by a change from the blue-green colour of Sm(II) to the
yellow Sm(III) upon addition to propionaldehyde. Coordination of the aldehyde and hydroxy
ketone to the metal centre and hemiacetal formation set the scene for the intramolecular hydride
transfer from the hemiacetal to the carbonyl group via TS-60. Dissociation of the complex
delivers the 1,3-anti diol with the directing hydroxyl protected as the propionate ester 59.
The reaction typically proceeds with very high stereochemical control due to the coordination of
the oxophilic samarium to both the hemiacetal and ketone carbonyl oxygens. Even in the pres-
ence of α-methyl groups of either syn or anti configuration, the level of asymmetric induction
from the β-hydroxy stereocentre dominates to reliably give the 1,3-anti product in high diastere-
omeric excess.
As anticipated, the selective reduction of ketone 54 using SmI2 (10 mol%) and EtCHO on multi-
gram scale proceeded to give 59 in excellent yield (95%) and diastereoselectivity (>20:1 dr).
Although some past examples have shown migration of the propionate ester from the directing
hydroxyl to the newly formed hydroxyl, such difficulties were fortunately not observed in this
case.112 Conveniently, the minor 1,4-anti diastereomer carried through from the aldol reaction
was found to be more readily separable from the desired 1,4-syn product by flash chromatography
after reduction to the corresponding diol monoester. With the full C23–C26 stereotetrad in place
in 59, further manipulation was now required to complete the desired C15–C27 fragment 29.
2.1.3 Elaboration to the full C15–C27 analogue fragment
For the southern fragment analogue, a methyl ether was desired at C25 in place of the hydroxyl
group present in the natural aplyronines. Upon observing that the C23 propionate ester moiety
did not undergo undesired migration to the C25 hydroxyl, the decision was taken to carry this
through as the C23 protecting group.
Methylation of C25 alcohol 59 was carried out using Meerwein salt and Proton Sponge
(Scheme 2.8). This reaction initially proceeded to give methyl ether 61 in very good yield on
small scale (86% from 50 mg of 59; 91% brsm). Some issues were encountered upon scale-up,
with a drop in yield to 55% from 1 g of 59. In addition, the reaction was reluctant to go to
completion: after extending the reaction time to 16 h, starting material was still present by TLC
analysis. These problems were ameliorated when the reaction time was reduced back to 4 h, as




















(a) Me3O·BF4, Proton Sponge, CH2Cl2, rt, 3 h; (b) THF/H2O/3M HCl (5:2:1), rt, 1 h; 
























Scheme 2.8: Synthesis of the C15–C27 southern fragment analogue 29
separated in very good yield from any remaining starting material, even on larger scale: a yield
of 89% (99% brsm) of 61 was achieved on a batch of over 8 g.
The fully protected substrate 61 had been deliberately designed to allow selective deprotection at
either the C15 or C27 ends in order to elaborate the fragment for coupling to the C1–C14 fragment
in a HWE reaction or to the C28–C34 side chain via a boron-mediated aldol condensation. The
HWE coupling was pursued first, as this approach had good precedent in previous aplyronine
studies.114 The southern fragment–side chain coupling would subsequently be investigated by
Rachel Porter.129
A screen of conditions to selectively cleave the C15 silyl ether protecting group in 61 was un-
dertaken (Table 2.3). Despite concerns about the stability of the potentially acid-labile C23 pro-
pionate ester, all methods were found to give the C15 alcohol 62 in excellent yield without ex-
traneous deprotection being observed. Simple THF/aqueous acidic conditions (Table 2.3, entry
3) were considered the most preferable due to the fast reaction time and operational ease, giving
93% yield of 62 on 32 mg scale and, eventually, 99% yield on 2 g scale. The final step was to
oxidise the revealed primary alcohol in 62 to the C15 aldehyde in fragment 29. This was easily
achieved under Dess-Martin (DMP, NaHCO3) or Swern (DMSO, (COCl)2, Et3N) conditions to
give 29 in almost quantitative yield (Scheme 2.8).
With fragment 29 in hand, two of the three modifications to the aplyronine skeleton discussed in
Section 1.6 were set in place, ready for incorporation into the full analogues. Before this could
39



















Entry Conditionsa Scale (mg) Reaction timeb Yield (%)
1 cat. PPTS, MeOH 18 26 h >99
2 TBAF (1.1 eq), THF 16 26 h >99
3 THF/H2O/3M HCl (5:2:1) 32 30 min 93
4 THF/H2O/3M HCl (5:2:1) 2000 1 h 99
a All reactions carried out at rt. b Time to completion by TLC analysis.
be constructed, however, stocks of the C1–C14 northern phosphonate 20 and C28–C34 side chain
fragment 32 (see Scheme 1.3, p. 28) were required. Dr Mike Housden was preparing the required
phosphonate for HWE coupling, for shared use between the analogue and natural product studies
concurrently in progress in the group. Therefore, attention now turned to preparation of the side
chain fragment 32 in a divergent synthetic approach that would allow for inclusion of a third
modification to the native aplyronines, which could be incorporated into analogues.
2.2 Side chain analogue (C28–C34)
Since the completion of the Paterson aplyronine C synthesis, stocks of the C28–C34 fragment
23 had been depleted during further investigations. In order to provide sufficient material to
advance this project and other aplyronine work concurrently being undertaken in the group,
it was therefore necessary to re-synthesise this fragment on multi-gram scale. This brought
opportunities to investigate the parallel titanium aldol chemistry in place of the previously used
tin aldol reaction, and to explore the route towards a side chain analogue with methyl ether
functionality at C31.
2.2.1 Titanium aldol coupling
As discussed in Section 2.1.1, ongoing issues with Sn(OTf)2 made an alternative method for
the aldol coupling an alluring prospect. Given the success achieved with Ti(i-PrO)Cl3 as the
Lewis acid in the 1,3,4-syn selective aldol reaction in the southern fragment, employing a similar
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protocol was expected to deliver pleasing results. With plentiful stocks of the (S)-ethyl ketone
25 in hand at the time, preliminary studies of the titanium aldol reaction with acetaldehyde
were carried out on the enantiomeric substrate to establish the feasibility of this approach. The
reaction was performed on various scales to probe reproducibility and scalability (Table 2.4)
before progressing to the desired (R)-enantiomer of the Roche ester-derived ketone 24.
























Entry Conditions Scale (ketone 25) Isolated dr (63:64)a Yield (%)b
1 Sn(OTf)2, Et3N 2.18 g 15:1 97c
2 Sn(OTf)2, Et3N 200 mg 3.5:1 30
3 Ti(i-PrO)Cl3, i-Pr2NEt 200 mg 14:1 77
4 Ti(i-PrO)Cl3, i-Pr2NEt 560 mg 15:1 82
5 Ti(i-PrO)Cl3, i-Pr2NEt 2.00 g 12:1 >80d
a Based on 1H NMR analysis of isolated material. b Overall yield of the diastereomeric mixture.
c Results reported by Fink.111 d Some product lost after purification.
Fink had previously noted that the diastereoselectivity of the reaction was dependent on the qual-
ity of tin(II) triflate (Table 2.4, entry 1), and this finding was indeed borne out in these studies.
Difficulties in procuring good quality reagent meant that the author was unable to replicate the
previous covetable result (entry 2).
Gratifyingly, the titanium methodology gave a very good yield and selectivity for the formation
of adduct 63 on multi-gram scale. The diastereoselectivity of this reaction (12−15:1 dr) was
comparable to that previously achieved with tin(II) (15:1 dr).91 Yields for this reaction appeared
to improve somewhat upon scale-up (Table 2.4, entries 3−5).
Thus, the correct enantiomer of aldol adduct 69 was subsequently prepared as shown in
Scheme 2.9. PMB protection of (R)-Roche ester 65 with PMBTCA and PPTS (88%; 95% brsm)
was followed by conversion to the Weinreb amide (94%) and addition of the Grignard reagent
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to give the ethyl ketone 24 (87%). A small amount of inseparable byproduct 66 (16:1 24/66)
was generated during the Grignard addition, perhaps due to the large scale and attendant diffi-
culty in maintaining constant low internal temperature for the exothermic reaction. However,
this byproduct could be carried through the aldol step without deleterious effect and afterwards












































(a) PMBTCA, PPTS, CH2Cl2, 0 °C → rt, 16 h; (b) MeO(Me)NH·HCl, i-PrMgCl, THF, −15 °C, 2.5 h; 















Scheme 2.9: Preparation of ketone 24, and titanium aldol reaction with acetaldehyde in the
correct enantiomeric series
The proposed transition states TS-67 and TS-68 are analogous to those described earlier for
titanium(IV) in Table 2.2 and tin(II) in Scheme 2.3. As discussed previously, the less congested
transition state TS-67 is favoured, resulting in isolation of the all-syn aldol product 69 in 84%
yield and 16:1 dr on multi-gram scale (Scheme 2.9). The identity of the major isomer 69 was
confirmed by comparison of NMR and optical rotation data to the previously made tin(II) aldol
product.91,111
An Evans–Tishchenko reduction of the aldol adduct 63 was also tested in order to establish
conditions for the more valuable substrate 69. The results were pleasing, giving product ent-71
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in 84% yield and very high selectivity for the 1,3-anti diol monoester (>20:1). These conditions
(SmI2, EtCHO) were therefore applied in the desired enantiomeric series (Scheme 2.10), and
even showed an improvement to 98% yield on scale. This provided over 7 g of intermediate 71













(a) SmI2, EtCHO, THF, −20 °C, 1.5 h
(98%)
69 71
Scheme 2.10: Evans–Tishchenko reduction of C28–C33 aldol adduct
2.2.2 Diversification to natural and analogue side chain components
The C31 alcohol 71 represented a key branching point in our plan for synthesising the differen-
tially functionalised natural and analogue fragments. From this point, we could either carry on
to the C31 acetate fragment 23 via the known route in 8 steps,91 or to the methyl ether-containing
fragment 32 in a proposed 6 steps (Scheme 2.11). The shorter route is, of course, more attrac-
tive from a step economy point of view. Two steps could be saved by avoiding a protecting
group manipulation that was found to be necessary for the elimination-sensitive acetate ester. A
more robust methyl ether group was expected to survive the required conditions without further
protection. This would therefore lead to a saving of the time and cost of resources for these
protection steps. As detailed in Section 1.5.2, the methyl ether was expected to be equivalent to
the acetate ester in terms of actin binding efficiency, as evidenced by its presence in the similar
actin-binding natural product reidispongiolide A.
For the present work, therefore, the analogue fragment 32 was to be prepared. Nevertheless,
ongoing studies in the group towards the natural products would eventually require access to
fragment 23. Thus, the material was split equally across the two routes. Half of the material was
protected as the triethylsilyl ether 72 under standard conditions (TESOTf, 2,6-lutidine, 94%,
Scheme 2.12) and set aside for use elsewhere.92,112 The remainder was converted to the C31
methyl ether 73 using Meerwein salt and Proton Sponge (90%, 94% brsm). This reaction pro-
ceeded smoothly and the product could readily be stored at −20 °C for many months without
significant degradation, allowing its direct use in subsequent steps without further purification.




























Scheme 2.11: Diversification from common intermediate 71 to fragment 23 via the known
route91 or analogue fragment 32
acid-type PMB cleavage during the workup procedure.130 However, the byproduct was present




































Scheme 2.12: Division of material towards silyl ether 72 for natural product fragments and
methyl ether 73 for analogues
2.2.3 Preliminary investigations towards N-vinylformamide installation
From this point, it was necessary to install the N-methyl-N-vinylformamide moiety at the C33


























(a) DDQ, CH2Cl2/pH 7 buffer (2:1), rt, 1 h; (b) DIBAL, CH2Cl2, −78 °C, 45 min; (c) (COCl)2, DMSO, Et3N, CH2Cl2, 










Scheme 2.13: Introduction of N-methyl-N-vinylformamide moiety in compound 78
had found that the most efficient way of doing so was by using a double Swern oxidation, which
would concurrently oxidise a C29 alcohol to a ketone and a C33 alcohol to an aldehyde, without
risking formation of a cyclic hemiacetal via any reactive intermediates.111,116 Thus, the protect-
ing groups were cleaved from each end of the substrate (DDQ, then DIBAL, Scheme 2.13) to
give diol 75 in 88% yield over 2 steps. The Swern oxidation was then carried out under standard
conditions (DMSO, (COCl)2, Et3N), taking care during the workup to wash away any triethy-
lamine hydrochloride salt from the product which could quench the ylid in the subsequent Wittig
reaction. The crude material was then used immediately to minimise the risk of epimerisation of
either of the two α-chiral carbonyls.
After trialling a number of conditions to append the challenging N-methyl-N-vinylformamide
unit, Fink had achieved the best results by using phosphonium salt 77 to form the ylid for a Wit-
tig reaction.111 This generated the required alkene, but as expected favoured the (Z)-substituted
product (8:1 Z/E), and hence required isomerisation to the thermodynamically favoured E-
product. Fortunately, conditions were found to effect this isomerisation in quantitative yield.
This transformation had proven to be impossible with the C31 acetate in place, necessitating the
use of a TES ether. However, we were hopeful that the methyl ether would prove resistant to
elimination and reproduce the success of Fink’s synthesis (63% over 8 steps from intermediate
71) while saving two steps.
Thus, aldehyde 76 was reacted with the ylid from 77 at low temperature to obtain alkene 78
(21% over two steps from diol 75, 8:1 Z/E). This mixture of double bond isomers was then
stirred with catalytic iodine in the dark for 68 h (Scheme 2.14), at which point 1H NMR analysis
showed full conversion to the (E)-enamide 32 (74% isolated yield). At this stage, the low yields
of these two steps were attributed to the small scale and exploratory intent of the reactions, and
were confidently expected to improve upon further investigation. However, it soon transpired
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(a) I2, CH2Cl2, dark, 68 h
78 32
Scheme 2.14: Isomerisation of (Z)-N-vinylformamide 78 to the desired (E)-N-vinylformamide
32
It was at this point that Rachel Porter joined the project, and expanded upon these very prelimi-
nary results in much more detail.129 The full particulars of her work on this challenging fragment
and its further applications in the synthesis of aplyronine analogues will be discussed in an up-
coming publication.131 Ultimately, Porter was able to complete the efficient synthesis of side
chain fragment 32 in 5 steps and 57% yield from fully protected intermediate 73. This provided
a reliable route to multi-gram stocks of the fragment which could be returned to on a number of
occasions when further material was needed.
2.2.4 Process scale synthesis of Roche ester ethyl ketone
During the course of this project, an opportunity arose to undertake the large-scale synthesis
of intermediates using the process chemistry facilities at AstraZeneca’s Macclesfield campus.
We decided to target the two enantiomers of PMB-protected Roche ester ethyl ketone, 24 and
25. These chiral starting materials provide the basis for the diastereoselective synthesis of the
three polyketide stereotetrads in our aplyronine analogues. They are also common intermediates
in a number of total syntheses under investigation in our group. Having a stockpile of these
precursors would allow us to access complex intermediates more directly, bypassing the need
to carry out the three-step synthesis every time. A batch of 100 g of each enantiomer of Roche
ester was generously provided for the purpose of constructing these two key intermediates via
the three-step route outlined in Scheme 2.15.
To accomplish this, it would be necessary to make a number of modifications to the procedure
generally used in our research laboratory. The typical workflow for this process would involve
four chromatographic purification steps, comprising an alumina-based flash column to isolate






























(a)        , PPTS (25 mol%), CH2Cl2, 20 °C, 4 h; (b) i-PrMgCl, MeO(Me)NH·HCl, 2-MeTHF, −10 °C, 5 h; 
(c) EtMgBr, 2-MeTHF, −10 °C, 18 h; (d) Cl3CCN, DBU (1 mol%), CH2Cl2, 20 °C, 1 h
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Scheme 2.15: Large-scale synthetic route to access the key fragments 24 and 25
each reactive step. The goal of this process-scale synthesis was to accomplish the transformation
without any chromatography steps. In many cases this might be achieved simply and practically
by crystallisation methods, but not so here: all of the intermediates exist as oils under standard
laboratory conditions. The challenge, therefore, would be to devise a method which would
cleanly provide each intermediate in the synthesis, with full conversion of starting materials,
and allow its separation from any other components of the reaction mixture that could cause
problems at the next step. As part of this method development, we planned to make use of more
process-friendly solvents: for instance, substituting the diethyl ether commonly used on small
scale for the non-peroxidisable solvent methyl tert-butyl ether (MTBE). The process efficiency
of the route was to be improved by using high reaction concentrations, minimising the use of
solvents as far as possible.
The first step, it transpired, was to be the most challenging with regards to the aims laid out
above. It was necessary to protect the Roche ester hydroxyl as a PMB ether before exposing the
substrate to Grignard reagents, but the PMBTCA reagent can be readily hydrolysed, returning
the p-methoxybenzyl alcohol (PMBOH, 83) starting material. A new method was needed to tele-
scope the reagent directly into the protection step, ideally without carrying through any PMBOH,
which would be undesirable in the later Grignard steps. Most of the methods attempted did not
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achieve full conversion of PMBOH. Despite conscientious efforts, we were unable to replicate
the conditions used by Novartis researchers in their 70 kg synthesis of 81 as an intermediate for
discodermolide (PMBOH, NaH, Cl3CCN, MTBE).24 After trialling various conditions, it was
found that using catalytic DBU (PMBOH, DBU, Cl3CCN, CH2Cl2)132 gave full conversion of
PMBOH to PMBTCA in under 1 h, monitored by GC analysis. The DBU loading could be
dropped as low as 1 mol% without any decrease in conversion or reaction rate.
The Roche ester starting material 65 (or 34) could then be added directly to the reaction mixture,
and acidification with the mild acid pyridinium p-toluenesulfonate (PPTS) catalysed the conver-
sion to 79 or 81. A number of acid catalysts (PPTS, camphorsulfonic acid, p-toluenesulfonic
acid) were screened, and portionwise addition of 25 mol% PPTS over 2−6 h was found to give
the best conversion of the Roche ester starting material. Nevertheless, full conversion was eva-
sive as there was always a risk of self-attack of the PMB reagent to form bis-PMB ether 85, and
the reactions generally stalled with 3−5% Roche ester remaining. Thus, the reaction vessel at
this point contained a mixed solution of product 79, starting material 65, byproduct 85, DBU,












































Scheme 2.16: Workup procedure for the PMB protection of Roche ester 65
The workup for this step was challenging, and was eventually divided into a number of steps.
First, a batch solvent swap distillation replaced the CH2Cl2 solvent with n-heptane. This re-
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sulted in a heptane fraction which contained approximately 50−60% yield of the product 79 as
well as some bis-PMB ether 85. This could be concentrated and used directly in the next step, as
the byproduct is unreactive and can readily be removed at a later stage. The remainder formed
an oily residue which could be separated and purified by filtration and trituration to remove
the trichloroacetamide (TCA), followed by a simple gradient flash column to isolate a further
20−30% of the desired product and recover the remaining starting material 65. Thus, our objec-
tive to complete this synthesis without any form of chromatographic purification was not met in
the end. Nevertheless, the gradient column method could be automated to ultimately obtain the
product with a minimal investment of further practical effort. The overall corrected yield for this
reaction, determined by quantitative NMR analysis, was 79−85%.
From this point, the next two steps were carried out with relative ease. To form the Wein-
reb amide 80, i-Pr-MgCl (2.0 M in THF) was used as a base to deprotonate Weinreb salt
MeO(Me)NH ·HCl in the presence of PMB-protected Roche ester 79 in 2-MeTHF. The tem-
perature was controlled to −10 °C or below via active cooling through a jacketed vessel. Upon
completion, as determined by GC analysis, the reaction was quenched with aqueous NH4Cl, and
a simple extraction allowed the isolation of product 80 in 96−99% corrected yield.
Difficulties with reagent supply hampered the completion of the final step to provide ethyl ketone
24 on the full batch of material. However, it was possible to carry out this step on a 30 g batch
to demonstrate the feasibility of this approach. Thus, EtMgBr (3.4 M in 2-MeTHF) was added
slowly to 80, controlling the internal temperature to below −10 °C to ensure mono-addition of
the Grignard reagent. Again, an aqueous quench and biphasic extraction were all that was needed
to obtain the desired ethyl ketone as a viscous oil (78.7 wt% 24) in 91% corrected yield. The
mass balance of the resulting oil was comprised of the bis-PMB ether 85 carried through from
the first step and residual solvent (2-MeTHF) . This material was later submitted directly to aldol
reactions in our research laboratory, giving yields comparable to those obtained with column-
purified starting materials.131 The highly non-polar contaminant 85 could be removed by silica
chromatography after the aldol reaction. The same was true of the Weinreb amide material,
which could also be diverted to other useful intermediates, such as forming the methyl variant in
place of the ethyl ketone.133,134
By this route, a stockpile of useful intermediates for our aplyronine synthesis and other projects
in our group were generated in high yields and large quantities (Table 2.5). These materials have
been stored at −20 °C for over 1 year to date without significant degradation. This has provided
a convenient reserve which has been drawn upon as needed to further our research goals.
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Table 2.5: Stocks resulting from large-scale synthesis efforts
Material Compound Quantity
(R)-Roche ester (recovered) 65 3.5 g
(S)-Roche ester (recovered) 34 3.5 g
(R)-Weinreb amide 80 200 g
(S)-Weinreb amide 82 190 g
(R)-ethyl ketone 24 26 g
2.3 Northern fragment (C1–C14)
The third and final fragment which would be needed to construct our aplyronine analogues was
to be the northern fragment. The northern region of the molecule is understood to play a key role
in promoting the interaction of the actin–aplyronine complex with tubulin. Indeed, SAR studies
on aplyronine A had shown that modifications to the C7 amino acid or saturation of the dienoate
have deleterious effects on the activity of the compounds.78 We therefore planned to retain this
region intact from the existing Paterson synthesis of the natural products.
Nevertheless, this left two feasible options open, resulting from the extensive studies that had
previously been undertaken in the group. At the time this work commenced, an earlier synthetic
route utilising a para-methoxyphenyl (PMP) group to protect the C7 and C9 alcohols was in use
in the group, concurrently with a more recently developed strategy involving bis-TES protec-
tion of the same diol. These were both being investigated for studies towards a more efficient
total synthesis of the natural products. Fortunately, this meant that intermediates for each were
available to allow access to the required coupling partners in relatively short order. Since it was
unclear at this early stage which of the two would be the better for an analogue synthesis, we set
about testing both fragments to determine the best way forward.
2.3.1 PMP-protected northern fragment synthesis
For initial testing, phosphonate 20 was prepared from intermediate 86 (Scheme 2.17), which was
generously provided by Rachel Porter. The synthesis of this fragment was carried out according
to the established protocol113 and was analogous to that of the bis-TES fragment, which will be
summarised below (Section 2.3.2).
The conversion into the required phosphonate was achieved in 5 steps (Scheme 2.17 and














(a) DDQ, CH2Cl2/pH 9.2 buffer, rt, 30 min (65%); (b) PPh3, imidazole, I2, Et2O/MeCN (1:1), 0 °C → rt, 2h (82%); 
(c) DIBAL, CH2Cl2, −78 °C, 1.5 h (72%); (d) TBSOTf, 2,6-lutidine, CH2Cl2, −78 °C, 1 h (92%)
86 87
Scheme 2.17: Synthesis of iodide 87 in 4 steps via the established route
ing group in the later alkylation step. This was achieved by oxidative cleavage of the primary
PMB ether (DDQ, CH2Cl2/pH 9.2 buffer (4:1), 65%) followed by an Appel-type substitution
(PPh3, I2, imidazole, 82%) to install the iodide.135 In the PMB deprotection step, pH 9.2 buffer
was needed in place of the standard pH 7 solution to inhibit migration of the PMP acetal to the
terminal C9/C11 diol promoted by weakly acidic DDQH (Scheme 2.18).118,136 The methyl ester
at the C1 end was then fully reduced to the primary alcohol (DIBAL, −78 °C, 72%) and protected
as the TBS ether under standard conditions (TBSOTf, 2,6-lutidine, 92%). It was necessary to
carry out the procedure in this order, as opposed to forming the potentially more sensitive iodide
last. Formation of the allylic TBS ether before exposing the substrate to DDQ to remove the
PMB group would have risked competitive deprotection and oxidation of the silyl ether, giving
rise to the kinetically favoured dienal 89 (Scheme 2.19). Indeed, this serendipitous discovery by
Dr Michael Woodrow in the course of the aplyronines project was to be capitalised upon later in
the synthesis to give access to the seco-acid needed to close the macrolactone.137 At this stage,
however, such a transformation was not desired, and as such the fragment was prepared in the
order shown. The iodide could successfully be carried through the two synthetic steps, but was
indeed found to degrade upon storage in the freezer for more than a few weeks. Thus, it was best
to store material at earlier or later stages as was needed at any given time.
From the protected iodide 87, it was then possible to install the requisite β-ketophosphonate
moiety via a substitutive alkylation with linker piece 90, according to the conditions of Grieco.138
This had proven to be a challenging step in previous aplyronine studies, particularly for Dr
Lydia Lee,118 who found that the product tended to form as a mixture of regioisomers (20 and
91, Scheme 2.20). This was contrary to the expectation of much greater reactivity at the less
sterically hindered (and less acidic) terminal position, based on Grieco’s findings. After extensive
optimisation studies, the best result for this transformation as reported by Lee was 88% yield with
a 4:1 ratio of 20 and undesired regiomer 91. This reaction was regularly performed on batches of
200−400 mg of iodide 87. Fortunately, the method turned out to be reproducible, reliably giving








































(a) DDQ (1.0 eq), CH2Cl2/pH 7 buffer, 0 °C → rt, 30 min
88 89
Scheme 2.19: Woodrow’s discovery of the kinetically favoured deprotection and oxidation of
electron-rich silyl ether 88137
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the unwanted minor regioisomer was unreactive in the immediately subsequent HWE coupling
step, and could readily be separated from the coupled product afterward. This outcome was
therefore considered workable for the ongoing synthesis.
Thus, the reaction was carried out under the conditions established by Lee.118 The dianion was
formed from 90 using NaH followed by n-BuLi at 0 °C, and was then added to the iodide 87 at
−78 °C in the presence of HMPA. The reaction was encouraged to go to completion by warming
gradually to −10 °C. This enabled the isolation of product 20 and the undesired regioisomer 91
in 76% combined yield as a 4:1 mixture that was inseparable by column chromatography. This
was comparable with Lee’s results, providing sufficient quantities of phosphonate 20 to continue






































Scheme 2.20: Alkylation of iodide 87 to form phosphonate 20
The PMP-protected northern fragment 20 was thus attained in 5 steps and 21% yield from in-
termediate 86. This was then to be compared with the equivalent bis-TES fragment 28 as we
progressed towards forming the advanced macrocyclic intermediate.
2.3.2 TES-protected northern fragment synthesis
Thanks to the efforts of Dr Mike Housden, a generous stock of the intermediate 96 with the
full C7–C10 stereotetrad in place was available for aplyronine studies. A summary of Housden’s
synthesis of this fragment is shown in Scheme 2.21.
The first key step in the synthesis requires the coupling of (R)-Roche ester derived ethyl ketone 24




















                                                                     , −78 → −20 °C, 12 h; (b) SmI2, EtCHO, THF, 0 °C, 2 h; 




































Scheme 2.21: Housden’s synthesis of intermediate 96 according to the established protocol113
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as described above (Section 2.2), and the aldehyde could be accessed in 4 steps and 86% yield
from 5-hexyn-1-ol (93). To couple these two fragments, the high levels of diastereoselectivity
attainable through boron aldol chemistry were used to advantage. Enolisation of ketone 24 with
dicyclohexylboron chloride (Cy2BCl) and triethylamine (Et3N) gives the (E)-enolate, which can
react with aldehydes such as 92 through a boat-like transition state TS-97 to give the 1,4-syn-
3,4-anti product 94. This model for the high levels of stereoinduction observed in reactions of
this type was developed by Paton and Goodman with the aid of density functional theory (DFT)
calculations.139–141 Their work showed that a stabilising hydrogen bond between the formyl
proton and the β-alkoxy group can influence the facial preference of enolate attack, such that
1,3-allylic strain is minimised. Thus, the aldol adduct 94 was accessed in 87% yield and >20:1
dr. The northern stereotetrad was completed using an Evans–Tishchenko reduction to establish
the anti-configuration of the C7/C9 diol (98%, >20:1 dr).128
The conjugated alkyne was then isomerised to the corresponding dienoate 95 by Rychnovsky’s
protocol (PPh3, PhOH, 94%),142 followed by hydrolysis of the propionate ester and installation
of the desired triethylsilyl protecting groups (76%, 2 steps).This translated to an overall yield of
61% over the 5 steps to 96 achieved by Housden.92
One advantage of this protecting group strategy was the early installation of the TES ethers that
would be needed in the endgame. The rigid PMP ether protecting group had been selected by
Woodrow in an attempt to bias the substrate towards macrolactonisation at the intended site.143
After this step, it had been necessary to insert two manipulations in order to switch to the silyl
ethers which would be readily cleaved in the final stages of the synthesis. These considerations
were no longer essential in the new synthetic route, as only one site would be available for
macrolactonisation, and the more flexible substrate was expected to react as intended. It would
thus be advantageous to avoid the protecting group swap that would otherwise be required at a
much further advanced stage. Nevertheless, the chemistry of the PMP-protected substrate had
been comprehensively tested in previous work, and so it remained a valid contender for the
northern substrate that would be taken forward to more complex intermediates.
Housden’s helpful stockpile material could then be converted as needed into the phosphonate
28, which would form the coupling partner for the southern aldehyde 29. This transformation
was carried out in 5 steps, in much the same way as for the PMP-containing fragment (Section
2.3.1). Thus, the PMB protecting group was cleaved (DDQ, 97%) and the resulting hydroxyl
substituted for an iodide (PPh3, I2, imidazole, 89%). The methyl ester was reduced (DIBAL,


































(a) DDQ, CH2Cl2/pH 7 buffer, rt, 40 min; (b) PPh3, imidazole, I2, Et2O/MeCN (1:1), 0 °C → rt, 2 h; 
(c) DIBAL, CH2Cl2, −78 °C, 1.5 h; (d) TBSOTf, 2,6-lutidine, CH2Cl2, −78 °C, 1 h; 










Scheme 2.22: Synthesis of phosphonate 28 from intermediate 96
This material then stood in readiness for the alkylation step, and at this stage it seemed appro-
priate to attempt optimising conditions for this reaction. It would be advantageous to stretch the
stock material as far as possible if improved conditions could be found. Furthermore, this newer
substrate, although functionally equivalent to the PMP-protected fragment, had appeared to show
somewhat different reactivity in the alkylation step in the hands of other researchers due to the
greater steric bulk of the silyl protecting groups.112,144 For instance, the reaction was sluggish at
−78 °C, and generally had to be run at much higher temperatures to promote reactivity. A range
of conditions was trialled in an attempt to improve upon the results achieved to date, and these
are summarised in Table 2.6.
The influence of HMPA as a cation solvating agent was considered. Due to the carcinogenicity
of HMPA and its potential to cause difficulties on scale-up, we preferred to avoid its use if at all
possible. To our surprise, it was found that the selectivity of the reaction was unaffected when
HMPA was not used, while the yield even appeared to be improved (Table 2.6, entries 1 and 2).
Meanwhile, the iodide concentration was posited to have an effect; in this study, higher concen-
tration appeared to have a mildly positive effect on conversion (entry 3). Raising the temperature
from −20 °C to 0 °C also seemed to assist with conversion (entry 4). However, puzzlingly,
the effective yield of 28 under these conditions was equivalent to that at lower temperature and
without HMPA (entry 2). It was hoped that in combination, the factors of higher concentration
and temperature would have an additive effect (entry 5); but the increased yields could not be
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NaH, n-BuLi, THF, 
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1 HMPA (2 eq), 0.09 M, −20 °C 50 mg 2.2 : 1 68 (47)
2 0.09 M, −20 °C 50 mg 2.2 : 1 84 (58)
3 HMPA (2 eq), 0.35 M, −20 °C 50 mg 2.4 : 1 79 (56)
4 HMPA (2 eq), 0.09 M, 0 °C 65 mg 2.8 : 1 80 (59)
5 HMPA (2 eq), 0.2 M, 0 °C 150 mg 3.8 : 1 65 (51)
6 0.2 M, 0 °C 1.16 g 2.5 : 1 69 (49)
7 0.2 M, 0 °C 2.20 g 3.0 : 1 60 (45)
a Determined by integration of 1H NMR signals in the purified mixture. b Isolated yields.
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replicated, although the selectivity saw a sudden improvement to 3.8:1, the best achieved in these
studies. Finally, in hopes that the selectivity seen in entry 5 would be met by higher yields with
economies of scale, these conditions were applied to larger quantities of iodide 99 (entries 6
and 7). This was carried out without the addition of HMPA, as it had been seen to have little
effect on the selectivity. Unfortunately, a return to the more typical levels of regioselectivity and,
disappointingly, lower yields were obtained in these larger-scale reactions.
Ultimately, the reaction appeared to be capricious, and results could not be definitively tied to any
one particular aspect of the reaction conditions. Dr Nika Anžiček had also tried to find improved
conditions to access the phosphonate fragment, but to no avail.112 It was necessary at this point
to accept a moderate yield for this step so that we could press on toward more advanced stages
of the analogue synthesis. This leaves open the opportunity in future studies to further optimise
this step, or to consider alternative disconnections to introduce the desired phosphonate to carry
forward for HWE coupling.
The successful acquisition of the northern fragment 28 (and PMP version 20) signalled the com-
pletion of the three fragments needed for coupling and advancement towards the full aplyronine
analogues. Indeed, the phosphonate-containing fragments proved unsuitable for long-term stor-
age in the freezer due to gradual degradation, so we were motivated to press on to the planned
HWE coupling with the southern aldehyde 29 and further. This fragment coupling and the de-
velopment of advanced intermediates for the synthesis of aplyronine analogues will be discussed
in the next chapter.
2.4 Summary and conclusions
The highly stereocontrolled preparation of aldehyde 29 was achieved in 5 steps and 68% yield
from ethyl ketone 25 (Scheme 2.23). It is estimated that to make 1 g of fragment 29 via this
route would require 8 days, which amounts to half the time required to access equivalent frag-
ment 21 for the Paterson aplyronine C synthesis,113 approximately 16 days. This work ex-
tended upon previous efforts towards constructing the aplyronine C23–C26 stereotetrad using
tin(II)113,118 and titanium(IV)92 aldol methodologies. The titanium aldol approach was found to
be the more favourable and provided aldol adduct 54 in good yield and pleasing diastereoselec-
tivity on multi-gram scale. Further elaboration to aldehyde 29 provided a new C15–C27 southern
















































































Paterson aplyronine C synthesis:
3 steps
PMB
10 steps total (8 steps LLS)








Scheme 2.23: Summary of southern fragment syntheses113
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Methodology to construct the C29–C32 stereotetrad using a titanium(IV) Lewis acid provided
similarly high diastereoselectivity when compared to the previously used tin(II)-mediated aldol
reaction.91,111 The newly adopted protocol represents an operationally simpler procedure, and
furnished 69 in multi-gram quantity. This allowed for elaboration to either the third-generation
C28–C34 side chain fragment 23 via the established route or to structurally altered fragments
for aplyronine analogue synthesis. Fink previously completed the synthesis of 23 as shown in
Scheme 2.24 via a 10-step route in 61% yield. In all, this synthesis would take approximately
9 working days.111 For this dissertation, the fragment 32, which contains a C31-methyl ether
equivalent to that found in the natural product scytophycin C, was synthesised in 8 steps from
ketone 24. This approach shortened the route by two steps by circumventing the need to install
the acetoxy group after the Wittig reaction. On the basis of these studies, it was also expected that
the methyl ether would be less fragile than the acetate in later steps with advanced intermediates,
being less prone to elimination under various conditions. This proof-of-concept synthesis was
later refined by Rachel Porter, who was able eventually to generate a batch of 1 g of ketone
32 for fragment coupling in 42% overall yield and in only 6.5 days (Scheme 2.24). To date,
approximately 7 g of side chain fragment 32 have been prepared via this reliable route. Given its
low molecular weight relative to the macrocycle-containing fragment, this quantity is sufficient
to match with 25 g of macrocycle. The material is sufficiently stable to be stored in the freezer for



























































Scheme 2.24: Previous synthesis of fragment 23 by Fink91 and route to analogue fragment 32
discussed in this work, subsequently completed by Porter129
The two alternative northern fragments 20 and 28 were also re-synthesised in 21% and 41%
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yield respectively in 5 steps from the equivalent intermediates 86 and 96 (Scheme 2.25). This
was consistent with the findings of earlier studies, and would enable us to identify which would
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Scheme 2.25: Summary of the re-synthesis of northern fragments 20 and 28 for this work
The aim of this project as a whole was to synthesise function-oriented analogues of the aply-
ronines that simplify the scaffold and overall synthetic route. Of the three key structural modifi-
cations laid out at the beginning of this work, two have been included in the C15–C27 fragment
analogue 29, and the third was incorporated into the C28–C34 side chain analogue 32. The north-
ern fragment was also synthesised in two versions (20 and 28) containing different protecting
groups, for comparison in fragment coupling studies to determine the better route to take for-
ward. With these three fragments in hand, the scene was set to push forward towards advanced




Fragment coupling to construct advanced
macrolactone intermediates
3.1 Coupling of southern and northern fragments
The three key fragments for our envisioned “aplyrologues” were in hand, and to move the project
forward, the southern and northern pieces would need to be combined and advanced to form
the macrolactone. At the time this work was begun, two possible northern fragments (20 and
28, Scheme 3.1) were available for inclusion in a route that would more closely resemble ei-
ther the first- or second-generation aplyronine synthetic strategies.91,92 An initial consideration,
therefore, was which fragment to carry forward in working towards constructing our desired
analogues, and we embarked upon an exploration of this chemistry.
3.1.1 Initial studies: comparing PMP and bis-TES protected fragments
The strategy from this point was to use a Horner–Wadsworth–Emmons (HWE) reaction to cou-
ple the southern aldehyde 29 with β-ketophosphonate 28 or 20 to form the enones 103 and
104 (Scheme 3.1). The HWE olefination reaction gives high selectivity for (E)-enones via the
mechanism shown in Scheme 3.2.145 Deprotonation of the acidic β-ketophosphonate 105 gives
a stabilised enolate-type carbanion 106. Addition of this species to the electrophilic carbon of
an aldehyde leads to the formation of an oxaphosphetane, which collapses to give predominantly










R = TES         (91%, >20:1 E/Z)




























Scheme 3.1: Horner–Wadsworth–Emmons reaction to form enones 103 and 104
The current understanding of the stereoselectivity of the HWE reaction is that the relatively
high stability of the phosphonate carbanion makes the initial rate-determining step reversible,
allowing the reaction to proceed along the two diastereomeric pathways under thermodynamic
control. Minimisation of steric interactions between the bulky phosphoranyl group and the alde-
hydic proton is favoured, but leads to an oxaphosphetane intermediate in which the aldehyde R
group eclipses the β-carbonyl. Conversion of this intermediate into the (Z)-enone is sluggish.
By contrast, approach of the aldehyde as per the top pathway is less favoured, but results in an
intermediate in which steric clash between the large substituents is avoided, and allows fast con-
version into the (E)-enone 107 in the stereospecific step. Equilibration of intermediates therefore
drives the reaction towards this product almost exclusively.
The HWE reaction is classically carried out using an alkoxide, sodium hydride or a lithium base,
but milder conditions have been developed to accommodate sensitive substrates for complex
natural product synthesis. Our group has found that barium hydroxide is effective under very
mild conditions (wet THF, rt), giving high (E)-selectivity for disubstituted olefins.146,147 Our
Ba(OH)2 methodology is compatible with highly functionalised substrates,148–150 and has been
used to construct even the more challenging trisubstituted olefins.146 The successful application
of this HWE variant in the aplyronine natural product synthesis (96% yield, >20:1 E/Z) led us to
expect similar success for these closely related reactants.92 A test reaction of aldehyde 29 with
the simple phosphonate 90 lent support to this prediction, giving the (E)-enone 109 in 91% yield
as a single diastereomer (Scheme 3.3).
Each of the β-ketophosphonates 28 and 20 was therefore deprotonated with Ba(OH)2 in anhy-
drous THF for 1–2 h, before addition of the southern aldehyde 29 in wet THF (THF/H2O 40:1)
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Scheme 3.3: Test reaction to establish conditions for the HWE olefination
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regioisomers 91 and 100 (see Section 2.3), which were unreactive under the reaction conditions.
Molar ratios in the crude product mixture were determined by integration of characteristic sig-
nals in the 1H NMR spectra, and in each case the unreactive isomer was recovered quantitatively
after workup and column chromatography. As the aldehyde component 29 was the more readily
accessible (in 5 steps from Roche ester ethyl ketone 25, as opposed to 10 steps for the phos-
phonates 20 and 28), it was used in slight excess (1.1 eq). Extended reaction times (48–72 h)
were used mainly for convenience, as it was found that under these mild conditions, the reactants
could be left to stir over the weekend without detrimental effect. The results were pleasing, with
the bis-TES product 103 being isolated in 91% and the PMP version 104 in 83% yield. The
(Z)-enone was not detectable by spectroscopic methods in either case, thus displaying excellent
diastereoselectivity (>20:1 E/Z).
However, a key difference did arise during the comparison of the two substrates. The PMP-
containing enone 104 proved difficult to separate from any unreacted aldehyde 29, and repeated
careful chromatographic separations were needed to isolate this product in useful amounts.
Keeping the stoichiometry of the reaction as close as possible to 1:1 did not appear to offer a
remedy, as in these cases the starting materials would not be fully consumed. Attempts were
made to differentiate the two compounds by submitting the troublesome mixture to a Pinnick
oxidation in order to mildly and selectively oxidise the aldehyde to lower its retention factor.
Yet these efforts were met with low yields of coupled product (30%) and extensive degradation
to unidentified side products (Scheme 3.4). The best option was merely to subject the mixed
material to somewhat laborious sequential chromatography steps. This difficulty had not been
encountered previously in the course of the aplyronines project; presumably, the substitution of
the hydrophobic alkyl chain in the southern fragment analogue rendered these two compounds
very similar in retention factor.
By contrast, the lower polarity of the multiple silyl ether-containing enone product 103 allowed
its easy separation from both starting materials. This was a strike against the PMP option, but
investigations were continued to fully consider the implications of each route.
3.1.2 Selective reduction and installation of the C13 methyl ether
With the two fragments coupled, the next step in the sequence was a selective reduction of
the C13 ketone to the (S)-alcohol. The lack of existing stereodirecting substitution in this re-
gion of the molecule led us away from considering a substrate-controlled approach, and in-
stead towards the well-established chemistry of the Corey–Bakshi–Shibata asymmetric reduc-
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Scheme 3.4: Attempt to isolate enone 104 from starting material 29 by a Pinnick oxidation
tion (Scheme 3.5).151–153 In this reaction, high levels of enantioselectivity are achieved in ke-
tones with a clear size difference between their two substituents. In enones such as 103 and 104,
the trisubstituted olefin constitutes the large substituent (RL), while the alkyl chain represents the
small (RS).
In this reaction, the chiral oxazaborolidine catalyst 112 supplants the Lewis basic ligand in
BH3 · SMe2 or BH3 ·THF to form a nitrogen–borane adduct (Scheme 3.5). The effects of this
coordination are threefold: (1) the borane reagent is activated as a hydride donor relative to the
starting complex, (2) the Lewis acidity of the endocyclic boron is increased, promoting coordi-
nation of a ketone substrate, and (3) the borane is positioned in a chiral environment close to the
coordinated ketone. Face-selective hydride transfer proceeds through a 6-membered cyclic tran-
sition state TS-113, which may take either a chair- or boat-like conformation.154 The selectivity
stems from the preferential coordination of the ketone 111 such that the large group is distant
from the oxazaborolidine methyl group (or other boron substituent), where it can adopt a pseu-
doequatorial position and thus minimise steric interactions. The catalyst is regenerated upon
liberation of an alkoxyborane, which is converted to the alcohol 114 via a simple methanolic
workup with release of volatile trimethoxyborane.
In our system, use of the (R)-MeCBS catalyst 112 with BH3 · SMe2 in THF at −10 °C gave high
yields of the alcohols 115 (99%) and 116 (81%), with only a single diastereomer observed in
each case (Scheme 3.6). This was assigned at this stage as the 13S-alcohol by analogy to very
similar aplyronine substrates studied by Lee and Anžiček, leaving more detailed configurational
analysis until a later stage (vide infra, Section 3.1.6).112,118 Although this reaction is catalytic in
nature with respect to the oxazaborolidine, the decision was taken at this stage to use the CBS
“catalyst” in stoichiometric quantities to ensure high reaction rate and selectivity. Under these
conditions, the reactions quickly went to completion, with reaction times of under 1 h. There
remains scope to improve the atom economy of this step by lowering the catalyst loading by as
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(1.2 eq), BH3·SMe2, THF, −10 °C, 45 min
R = TES         (99%,  >20:1 dr)










Scheme 3.6: CBS reduction of enones 103 and 104
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From the C13 alcohol 115 or 116, a straightforward conversion using the methylating reagent
Meerwein salt (Me3O ·BF4) and Proton Sponge furnished the desired methyl ethers 117 and 118































Scheme 3.7: Installation of C13 methyl ether
3.1.3 Advancement towards the macrocycle
With the necessary functionality having been incorporated in the carbon skeleton, it was now
time to work towards closing the 24-membered macrocyclic ring by a macrolactonisation proce-
dure. To achieve this, it would be necessary to unmask the C23 alcohol and reveal a carboxylic
acid at C1. A three-step conversion to the seco-acid 120 was planned: deprotection of the C23
ester, tandem silyl ether deprotection and oxidation of the allylic TBS ether, and oxidation of the
resultant aldehyde (Scheme 3.8). This stepwise approach would allow the use of mild conditions
compatible with the various functional groups already present in the intermediate. However, the
















♦ C23 ester deprotection
♦ C1 deprotection & oxidation
   (silyl ether → aldehyde → 
   carboxylic acid)
119 120
Scheme 3.8: Plan for synthesis of the seco-acid in three steps
We therefore set out to investigate removing the propionate ester from the bis-TES substrate 117.
Since the installation of the propionate ester in the southern fragment, we had been encouraged
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by its stability under a variety of reaction conditions. Previous work had suggested that such a
protecting group might be labile when exposed to acids or bases, and at each stage we had been
prepared to see loss or migration of the ester as a side reaction. However, this was not observed:
it had been possible to carry through the ester directly to this point without any need for a switch
in hydroxyl protection. It was convenient indeed that this moiety was already orthogonal to the
methyl, silyl and aryl ethers present elsewhere in the molecule. We therefore reasoned that we
could simply hydrolyse the ester 117 to alcohol 121 at this point (Table 3.1).
In this expectation we were deceived. Attempts at hydrolysis under increasingly harsh conditions
(entries 1-3, Table 3.1) were unsuccessful, and invariably, starting material was returned. In an
effort to push the substrate to react at all, exposure to a high concentration of KOH did indeed
result in ester hydrolysis – but not before the loss of all three silyl ethers, giving tetrol 123 (entry
3). All signs suggested that continuing in this vein would be futile, and so we decided to switch
tack to a metal hydride reduction approach. Fortunately, reduction with DIBAL did give the
desired products 121 in 75% yield (entry 4) and 122 in 99% yield (entry 5). In anticipation that
a milder hydride source might give an even better result, the reaction was attempted with lithium
borohydride on the equivalent PMP-containing substrate, but regrettably slow conversion and a
wider range of side products were observed, with accordingly lower yield (59%, entry 6).
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Entry Substrate Conditions Product Yield (%)
1 117 K2CO3, MeOH, rt, 20 h – nr
2 117 LiOH, THF/H2O (2:1), rt, 6 d – nr
3 117 KOH, MeOH, rt, 72 h 123 92
4 117 DIBAL, CH2Cl2, −78 °C, 1 h 121 75a
5 118 DIBAL, CH2Cl2, −78 °C, 1 h 122 99a
6 118 LiBH4, Et2O, 0 °C→ rt, 24 h 122 59
7 117 DIBAL, CH2Cl2, −78 °C, 1 h 121 98b
a Test reaction, 10−15 mg scale b Preparative reaction, 1.36 g scale
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Thus, we surmised that the DIBAL reduction strategy would be the best way to forge ahead with
the synthesis. This would fortunately be a fast and simple step, and on larger scale the yield of
121 was almost quantitative (entry 7, Table 3.1). This also resolved the question of which order
to carry out the three steps towards the seco-acid, as the use of DIBAL would be incompatible
with any functionality needed beyond the C1-TBS ether.
We had meanwhile begun to investigate the viability of the silyl ether to aldehyde conversion by
oxidation of the bis-TES substrate 117 with DDQ (Scheme 3.9).137 Initial results were promis-
ing, with 61% yield (79% brsm) of the enal 124 achieved on small scale. These conditions were





















Scheme 3.9: Concomitant deprotection and allylic oxidation of substrate 117
The reactivity of the allylic silyl ether on exposure to DDQ was a serendipitous discovery by Dr
Michael Woodrow as part of the aplyronines project.143 The proposed mechanism is as shown
in Scheme 3.10, and involves single-electron transfer steps to translocate a hydride from the
activated methylene of 125 to DDQ. Loss of the silyl group then reveals the aldehyde 126.
Previous studies had shown that the conversion is fast, generally going to completion in 15 min
or less. We therefore anticipated that aldehyde 127, with the PMB ether intact, would be the
























Scheme 3.10: Proposed mechanism for oxidation of allylic silyl ethers with DDQ137
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The reaction is operationally simple. Solid DDQ is added to the silyl ether and stirred in biphasic
CH2Cl2 and aqueous buffer solution under ambient air at 0 °C. As the desired reaction was
expected to be kinetically favoured, with competing PMB cleavage proceeding more slowly, the
mixture was usually left to stir for only 10–15 min, and never more than 30 min. Workup and
column chromatography were generally straightforward.
Despite this practical simplicity, controlling the desired chemoselectivity of the reaction proved
something of a challenge, and some efforts were needed to optimise the conditions to a satis-
factory level. In early studies, yields ranging from 58–73% were obtained in the bis-TES series
(127), and 59% in the PMP series (128). After a short time the reactions appeared to stall. Al-
though starting material was still observed by TLC analysis, any efforts to push the reaction to
completion would result in appearance of a lower Rf spot, surmised to be 129, the product of
pentadienylic oxidation followed by PMB deprotection. It was deemed more judicious to recover
and recycle the starting material than to push it towards overreaction and risk wasting material,
so the reactions were generally quenched after a set time of 15 min. This resulted in the recovery
of 10–20% starting material by mass (equating to 82–84% yield brsm).
However, concern was raised when attempts to recycle the recovered material resulted in sig-
nificantly lower yields, or the reactions failed entirely. Initially this was put down to the small
scale of the reactions, and left for later optimisation. As the work progressed to a larger scale,
it became apparent that the recovered material had suffered some off-target reactivity to give a
byproduct or mixture of byproducts that was spectroscopically similar to the original substrate.
Inspection of the 1H NMR spectra suggested that under the reaction conditions, the silyl groups
may have migrated to give byproducts that were similar in retention factor to the starting mate-
rial, but not synthetically useful at this stage. Based on this reasoning, the reaction conditions
were reconsidered. It was not possible to lower the temperature to suppress unwanted reactiv-
ity, as the aqueous medium would freeze at lower temperatures. We therefore decided to revisit
Lee’s work,118 in which she had managed to suppress unwanted protecting group migration dur-
ing a DDQ reaction by using pH 9.2 buffer instead of the usual pH 7 solution. Lee reasoned
that the migration might be promoted by the weakly acidic DDQH generated during the reaction
(Scheme 3.10). Testing these conditions in our system gave reassuring results. While the yields
remained similar to those already observed, the recovered material was spectroscopically identi-
cal to starting material, and could be successfully recycled to increase the overall throughput. In
the end, a 62% yield (81% brsm) was achieved on a scale of 1 g of 121, with starting material
being recycled to achieve an effective yield of 75%. This was satisfactory for the advancement
of the project and the matter was considered closed at this point. However, it ought to be noted
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that even these optimised conditions did not lead to full mass recovery, whether in the form of
starting material, desired product or as-yet-identifiable byproducts. The source of this material
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(a) DDQ, CH2Cl2/pH 7 buffer, 0 °C, 15 min; (b) NaClO2, NaH2PO4·2H2O, 2-methyl-2-butene, t-BuOH/H2O (1:1)
R1 =                 R2 = PMB   (60%, 89% brsm)R =
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Scheme 3.11: Two-step conversion of TBS ethers 121 and 122 to carboxylic acids 130 and 131
After this point, our goal was to obtain the seco-acids 130 and 131 as substrates for macro-
lactonisation. The Pinnick oxidation was ideal for this purpose, given its mild conditions and
chemoselectivity for aldehydes in the presence of many other potentially sensitive functional
groups.
Oxidation of aldehydes using sodium chlorite was first described by Lindgren and Nilsson.155
The procedure was generalised by Pinnick, who found that these mild oxidation conditions could
be applied to complex aldehydes with a high level of chemoselectivity, without damaging other
sensitive functional groups.156 In particular, he described its application to α,β-unsaturated alde-
hydes without affecting the E/Z configuration of the olefin. The mechanism as it is currently
understood is shown in Scheme 3.12.
Under mildly acidic conditions, sodium chlorite (NaClO2) exists at equilibrium with chlorous
































HOCl 2 ClO2 2 ClO2 Cl OH+ + +
HOCl + HO
Cl
Scheme 3.12: Mechanism of the Pinnick oxidation of aldehydes to carboxylic acids156
adduct, which then undergoes a pericyclic transformation to form the carboxylic acid, with loss
of hypochlorous acid (HOCl). This byproduct can participate in a number of unwanted side reac-
tions, including inactivating the sodium chlorite reagent by oxidation to chlorine dioxide (ClO2),
and halooxygenation of any olefins in the starting material to generally unwanted halohydrins
(Scheme 3.12, see box). For this reason, sacrificial additives such as 2-methyl-2-butene are
usually added to the reaction mixture as scavengers for the hypochlorous acid generated.157,158
In this case, the Pinnick oxidation reactions of 127 and 128 proceeded smoothly when left to stir
overnight at room temperature. Large excesses of each reagent were used, and on some occasions
further reagent had to be added to ensure full conversion. Care was taken to also add further 2-
methyl-2-butene in excess. Upon completion, a simple aqueous workup allowed isolation of the
products 130 and 131 in apparently quantitative yield. The acids could be purified by column
chromatography with acetic acid as a minor additive to avoid streaking. However, typically
the crude product was sufficiently clean to submit directly to the next reaction, avoiding an
unnecessary chromatographic step. With the seco-acids 130 and 131 in hand, it was now possible
to explore the macrocyclisation of this advanced intermediate.
3.1.4 Macrolactonisation
The final step in the current reaction sequence was to close the macrolactone to obtain the fully
protected macrocyclic compounds 132 and 133 (Scheme 3.13). Previously, Yamaguchi’s esteri-
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Scheme 3.13: Formation of the fully protected macrocyclic intermediates 132 and 133
in the aplyronine natural product synthesis, and were therefore applied once again here. By
this protocol, the carboxylic acid 134 is activated towards nucleophilic attack by conversion to
a mixed anhydride species 135 (Scheme 3.14).159 Adding the substrate to a solution of DMAP
promotes the intramolecular reaction (136→ 137), with the high dilution factor and slow addi-
tion rate minimising the risk of oligomerisation. The Yonemitsu variant of this reaction enables
esterification as a one-pot procedure, bypassing isolation of the mixed anhydride.160 A more re-
cent publication showed that the regioselectivity of nucleophilic attack by the alcohol may in fact
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Scheme 3.14: Mechanism of the Yamaguchi macrolactonisation
In our systems 130 and 131, this translated to addition of the mixed anhydride to a large excess
of DMAP over 3−12 h via syringe pump. This resulted in yields ranging from 60−80% for the
bis-TES product 132, and 47−55% for the PMP product 133, each calculated over 2 steps from
the corresponding aldehyde. It is unclear at this point why the isolated yields were higher in the
TES series, but nevertheless, this served to further bolster the case for its use over that of the
PMP-protected material.
An adventurous attempt was made at improving the efficiency of this sequence by subjecting
the C23/C27 diol 138 to the macrolactonisation conditions (Scheme 3.15). We maintained a slim
hope that the substrate might show a conformational preference for forming the 24-membered
ring found in the aplyronines, as opposed to the 28-membered ring resulting from cyclisation at
the C27 hydroxyl. If successful, this could have simplified the DDQ oxidation step by dispelling
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the need to halt the reaction before PMB ether cleavage could occur, and would circumvent
the later PMB deprotection step. Thus, the diol 129 was formed in a pleasing 87% yield by
exposing alcohol 121 to excess DDQ, and oxidised under Pinnick conditions to the seco acid
138 (Scheme 3.15). The results of Yamaguchi macrolactonisation were, however, disappointing:
the desired product 139 was isolated in only 14% yield, while an alternative esterified product,
deduced to be the 28-membered macrolactone 140, was obtained in 64% yield (a 4.4:1 ratio in
favour of the undesired product). This result was easily explained on the basis that the primary
C27 hydroxyl is the more readily accessible of the two alcohols. Thus, our hopes for this shortcut









































(a) DDQ (3 eq), CH2Cl2/pH 7 buffer (4:1), 0 °C → rt, 1 h; (b) NaClO2, NaH2PO4·2H2O, 2-methyl-2-butene, 






Scheme 3.15: Attempt to form alcohol 139 by Yamaguchi macrolactonisation of the diol 138
3.1.5 Selection of protecting group strategy for the onward synthesis
It was clear that we would need to select one or the other of the bis-TES and PMP protecting
group strategies to simplify further work. Continuing to carry through two different but func-
tionally equivalent intermediates would double the amount of effort in terms of experimental
time and resources, as well as characterisation analysis. The PMP-protected northern segment
20, despite being somewhat more easily accessible than the bis-TES version via the alkylation
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route (Sections 2.3.2 vs 2.3.1), had turned out to be much more troublesome at the HWE cou-
pling stage. This was due to the difficulties in pushing the reaction to completion and separating
leftover starting material from the coupled product.
Furthermore, although at the beginning of these investigations, this fragment 20 was in use in the
natural product synthesis and therefore available in relative abundance, colleagues working on
the next-generation synthesis had gradually moved more towards favouring the bis-TES material
28. This was in part because its use forestalls a later protecting group switch after the forging of
the macrolactone. This would therefore lead to an overall reduction by two synthetic steps which,
although simple and high-yielding, nonetheless involve apparently unnecessary manipulations.
With these thoughts in mind, it was concluded that the bis-TES-protected northern fragment 28
was the better choice for continued work towards the full analogues. As such, the synthesis of
macrocycle 132 was now carried out on a larger scale to supply material to push towards the
desired analogues.
3.1.6 Fully protected macrocycle scale-up
A campaign to scale up the macrocycle 132 synthesis was now embarked upon, following the
route that has been described above. An overview of the results is presented in Scheme 3.16.
Each step was carried out with cautious increases in the mass of substrate and minor changes
to conditions to probe the reproducibility of this route. In most cases, reactions were carried
out in 50−200 mg batches, then increased two- to five-fold in each repeat. Ultimately, the final
three steps to form the macrolactone 132 were carried out on over 1 g of TBS ether 121 in a
single batch. Almost all of the steps showed equal or improved yields on larger scale, with
one exception being the alkylation to form northern phosphonate 28 (see Section 2.3.2), which
remained variable and will be a focus for improvement in future studies.
In brief, the HWE olefination of the northern and southern fragments 28 and 29 gave enone 103 in
91% yield (Scheme 3.16). This was followed by CBS reduction of the enone at C13 to give allylic
alcohol 115 in 99% yield. At this stage, it was deemed prudent to unambiguously determine the
configuration of the C13 alcohol before carrying on further with the synthesis. This was achieved
by Mosher ester analysis, as discussed in Section 2.1.1. Hence, the (S)- and (R)-MTPA esters
141 and 142 were formed from the corresponding enantiomers of Mosher’s acid (Scheme 3.17).
The sign of ∆δSR for protons on each side of the derivatised alcohol was consistent with its
















































(a) Ba(OH)2, THF, rt, 2 h, then       , THF/H2O (40:1), rt, 24−72 h; (b) (R)-MeCBS oxazaborolidine, BH3·SMe2, THF, −10 °C, 
45 min; (c) Me3O·BF4, Proton Sponge, CH2Cl2, rt, 2 h; (d) DIBAL, CH2Cl2, −78 °C, 1 h; (e) DDQ, CH2Cl2/pH 9.2 buffer (4:1), 
0 °C, 10 min; (f) NaClO2, NaH2PO4·2H2O, 2-methyl-2-butene, t-BuOH/H2O (1:1), rt, 16 h; (g) TCBC, Et3N, THF, rt, 1 h, then 






Scheme 3.16: Overview of the synthesis of advanced intermediate 132 on gram scale
alcohol 115 and reduction of the C23 propionate ester 117 then gave intermediate 121 in 90%
yield over the 3 steps.
Finally, a three-step sequence involving allylic TBS ether deprotection and oxidation with DDQ,
Pinnick oxidation to obtain the seco-acid, and Yamaguchi macrolactonisation gave the macro-
cyclic intermediate 132 in 52% yield.
Thus, the fully protected macrocycle 132 was obtained in 7 steps and a respectable 43% yield
from northern phosphonate 28 and southern aldehyde 29. This represented an average yield of
89% per step. A total of 800 mg of macrocycle was generated in this way, with approximately
500 mg resulting from a single batch. The material could readily be stored at this stage until
needed for further investigations.
78
a
(a) (S)- or (R)-MTPA-OH, DCC, DMAP, CH2Cl2, rt, 20 h
(S)-MTPA ester (90%)






































Scheme 3.17: Determination of absolute configuration at C13 by Mosher’s ester analysis
3.2 Macrocycle to side chain coupling and elaboration
3.2.1 Side chain attachment by aldol coupling and dehydration
With a sizeable amount (ca 800 mg) of fully protected macrolactone 132 in hand, it was now
possible to investigate in detail the coupling to the side chain piece 32. The planned analogues
were to branch from a late-stage common intermediate. We would now advance the synthesis
to this highly advanced compound. To this end, the macrocycle 132 was deprotected at the C27
position (DDQ, CH2Cl2/pH 7 buffer, 0 °C, 90%) and oxidised under Swern conditions (DMSO,
(COCl)2, Et3N) to the aldehyde 31 in 93−98% crude yield (Scheme 3.18). This aldehyde had to
be handled with caution, as the C26 stereocentre was observed to epimerise readily on exposure


























Scheme 3.18: Synthesis of aldehyde 31 from fully protected macrocycle 132
The analogue fragment 32 (Section 2.2) was to be the ketone coupling partner for this reaction,
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giving rise to hybrid-type analogues with side chains resembling that of scytophycin C (see
Sections 1.5.2 and 4.1.1). A possible coupling with the C31-acetate fragment as seen in the
natural aplyronines was deferred to a later stage, to be investigated further pending the bioactivity
results for the hybrid analogues.
The two fragments 31 and 32 were to be coupled via a boron-mediated aldol reaction. It was
necessary for this reaction to proceed in a chemoselective fashion, given the range of potentially
sensitive functionalities already present in each substrate. However, the diastereoselectivity was
of little importance, as the new stereocentre introduced at the C27 position would soon be reduced
to a methylene unit. Based on the extensive previous efforts to forge this linkage under such
challenging constraints, boron aldol chemistry had proven to reliably give high yields of the
desired coupled product, as a result of its broad functional group tolerance which allows a highly





































Scheme 3.19: Boron aldol coupling of the macrocycle 31 and side chain 32 to forge the C27 – C28
bond
The reaction proceeds through formation of boron enolate 143, and its subsequent reaction with
aldehyde 31 to form β-hydroxy ketone 144 upon workup of the boron aldolate (Scheme 3.19).
Typically, an oxidative workup is used;163 however, we had concerns about the stability of the
delicate functionality in our system under these conditions. In late-stage boron aldol coupling
reactions during previous syntheses of related natural products in our group, both standard oxida-
tive (MeOH, pH 7 buffer, H2O2, 94%, rhizopodin)164 and non-oxidative (MeOH, pH 7 buffer,
70%, reidispongiolide A)86 workup conditions had been used. During synthetic work on the
aplyronines, the precedent had been to use a non-oxidative workup.108,111 Porter’s investiga-
tions towards coupling the side chain and southern fragment before macrocycle closure sup-
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ported that this degree of caution was prudent, and further showed that stirring with silica and
exposure to air could mildly reveal the desired β-hydroxy ketone without compromising the
N-vinylformamide.129,165
The macrocyclic aldehyde 31 was by far the more precious of the two coupling partners, being
accessible in 18 linear steps as opposed to only 8 steps for ketone 32. It was therefore chosen as
the limiting substrate for the reaction. During early testing on small scale, a large enough excess
of the ketone 32 (2−6 eq) was used to ensure full conversion of the valuable aldehyde 31, but it
was eventually found that only slightly superstoichiometric quantities (1.2 eq) were sufficient to
push the reaction to completion. In either case, any excess enolate would regenerate the starting
ketone 32 upon quenching, such that the material could be recovered for re-use later on.
In the event, ketone 32 was enolised with Cy2BCl and Et3N at 0 °C, then added to aldehyde
31 at −78 °C. The mixture was stirred at this temperature for 1 h, then slowly allowed to warm
up to −20 °C, with monitoring of reaction progress by TLC analysis. This resulted in full con-
sumption of the aldehyde after 2−3 h. When complete, the reaction was subjected to a very
mild, non-oxidative workup by addition of silica and stirring under ambient air for 1 h, follow-
ing the conditions which had been developed by Porter.129 The aldol adduct 144 was obtained
after column chromatography as an inconsequential mixture of diastereomers at the C27 position
(ca 3:1 dr). A large increase in polarity due to the introduction of the terminal N-methyl-N-
vinylformamide moiety made the product 144 difficult to separate chromatographically from the
excess ketone 32. This was of little consequence, however, as the ketone was unreactive in the
next step, and so the material could be carried through as a mixture and then separated at that
stage.
With this in mind, a Burgess dehydration was undertaken on 144 to form (E)-enone 147, the
product of a stereospecific syn-elimination of the newly formed C27-hydroxyl group. This reac-
tion makes use of the internal salt 145 (Scheme 3.20) to give olefins from secondary or tertiary
alcohols, forming the conjugated product if adjacent to a carbonyl.166,167 The mechanism be-
gins with formation of a sulfamate ester, with Et3NH+ as a counterion. An intramolecular syn-
elimination of the β-hydrogen atom occurs via a 6-membered cyclic transition state, TS-146.
The (E)-selectivity stems from the preference for the large R groups to eclipse hydrogens in the
Ei transition state.
As the reaction does not require acidic conditions, it is compatible with a wide range of acid-
sensitive functional groups, including the ester, amide and several methyl ether moieties present

















































Scheme 3.20: Mechanism of the Burgess elimination reaction166
temperature, minimising the risk of substrate degradation. This made the Burgess elimination
ideal for our desired conversion.
Consequently, the mixture of aldol adduct 144 and remaining ketone 32 was stirred with Burgess
salt in THF at rt, leading to moderate conversion tempered by slow reaction rate and eventual
stalling (Scheme 3.21). By this method, a yield of 43% was calculated over 2 steps from alde-
hyde 31. To improve the yield, the reaction mixture was warmed gently to 30 °C, leading to
improved reaction progress without observation of new byproducts. However, stalling was still
an issue, and when it occurred the best course of action was to halt the reaction and resubmit the
crude mixture after a simple workup. In this way, yields of 63−73% (over 3 steps) in total after
1 recycle were achieved on scales of up to 65 mg based on alcohol precursor 139.
3.2.2 Conjugate reduction to the C29 ketone
To complete the aplyronine analogue backbone, a conjugate hydride addition to reduce the enone
147 to C29 ketone 148 would be required. This would need to be done cautiously, as any condi-
tions that would achieve this conversion could potentially also set the pentadienoate or the sen-
sitive vinylformamide at risk. Fortunately, earlier studies on both the aplyronines and the related






















































Scheme 3.21: Synthesis of advanced intermediate 148, with the full carbon skeleton in place
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hydride hexamer, [CuH(PPh3)]6)168–170 was capable of carrying out this challenging transfor-
mation chemoselectively.
Mechanistically, the copper complex supplies a soft hydride nucleophile to the β-carbon of the
enone 149 (Scheme 3.22). The resulting copper enolate 150 reacts with excess tetramethyld-
isiloxane (TMDS) to regenerate the active catalyst, stabilising the reactive intermediate as the
silyl enol ether 151 which protects against overreduction.171 This species is then protonated to


























149 150 151 152
Scheme 3.22: Mechanism of conjugate reduction with Stryker’s reagent168
As a complementary approach to its isolation as an air-sensitive pure solid,172 Stryker’s reagent
and related copper hydride sources can be formed in situ using organosilanes, such that the re-
actions can be made catalytic in copper.171,173–175 For this work, the reagent was prepared as
a solution in toluene via the method described by Yun.176 According to this protocol, tetram-
ethyldisiloxane (TMDS) is added to Cu(OAc)2 ·H2O and PPh3 in toluene solution. A colour
change is observed from the aqua-blue copper(II) acetate to a brick red colour characteristic of
the copper(I) complex, indicating that the active reagent has been formed. The presence of ex-
cess TMDS in the solution provides a stoichiometric hydride source, allowing the copper species
to be used in catalytic quantities and regenerated in situ during the reaction. For the purposes of
this project it was found that the solution could be used fresh or stored at −20 °C for approxi-
mately 1 month, and that the colour of the solution was indicative of its quality. Indeed, it was
clear that the quality of the Stryker’s solution was important, as on one occasion when an older
batch of starting materials was used to form the reagent, degradation of the N-vinylformamide
moiety was observed. In a few cases, the integration of signals for H2–H5 in the 1H NMR spec-
trum appeared to diminish, while signals in the upfield region increased. This seemed perhaps to
indicate attack on the dienoate, but the high polarity of these compounds and their tendency to
exist as stable rotamers made it difficult to visualise or separate different components by chro-
matographic methods. For this reason the reaction of 147 was carried out first on test scale to
ensure success with the particular reagent batch, before carrying on to more preparative scale
reactions.
In practice, aliquots of Stryker’s solution equating to 20 mol% Cu(I) were added to the enone
84
147 at rt, and the conversion was monitored by TLC analysis (Scheme 3.21). Where necessary,
further aliquots of reagent could be added. No special precautions were taken to de-gas the re-
action solvent, as this method was not observed to be particularly air sensitive. The reaction was
generally complete within 2−3 h and the mixture could be loaded directly onto a silica column
without the need for aqueous workup. In this way the complex fragment 148 was obtained in
excellent yield (80−92%).
3.3 Summary
With this objective achieved, the full skeleton of our desired unnatural aplyronine congeners
had been established. Only modifications to the functional appendages of the highly advanced
intermediate 148 would be needed to complete our planned analogues using a late-stage diversi-
fication strategy. We were poised to finish the first of our much-anticipated library of aplyronine
analogues to submit to biological testing in comparison with the natural products.
From this point, the synthesis would split into various branches, together representing a divergent
family of analogues. The endgame strategy and the the branches of inquiry that follow will be
the focus of Chapter 4. We shall discuss the outcomes of studies to finalise the first round of




Completion of the synthesis and
conclusions
4.1 Endgame
Having set the correct connectivities and stereochemistry for the full carbon chain, our aplyro-
nine analogues were at last within reach. As was set forth in Section 1.6, the library of analogues
that were targeted in this work would be differentiated at this late stage by the chemistry of the
side chain, as well as the pendant amino acids at C7 and C29. We decided in the first instance
to target scytophycin-type hybrid analogues with the C29 ketone intact, followed by aplyronine
A/D analogues with esterification through the 29R-hydroxyl group. These efforts will now be
described.
4.1.1 Completion of scytophycin-type hybrid analogues
From ketone 148, the product of the conjugate reduction with Stryker’s reagent (see Section
3.2.2), two steps would be required to form the epimeric analogues 154 and 155, with a ketone
at C29 and an (S)- or (R)-N,N,O-trimethylserine (TMSer) ester at C7 (Scheme 4.1). The first step
would require cleavage of the two silyl protecting groups at C7 and C9 to form diol 153 for our
library of analogues. This was achieved on treatment of 148 with HF · py in 82% yield. This
compound bears two free hydroxyl groups in the northern region, as does aplyronine C, and
therefore represents the first of our desired aplyrologues for biological testing.
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Due to the significantly higher levels of cytotoxicity observed in the natural congeners containing
a C7-TMSer moiety (aplyronines A and D), we were keen to incorporate this functionality next.
Each enantiomer of TMSer had been prepared by Dr Simon Williams in this laboratory, and a
small stock of these useful intermediates was available for the studies reported here. Williams
had found that, with careful monitoring, acylation could be achieved site-selectively at the C7 al-
cohol, as it is less hindered than that at the C9 position.108 This could be done under either Keck
(DCC, DMAP, DMAP ·HCl)177 or Yonemitsu (DMAP, TCBC, Et3N)160 esterification condi-
tions, with the latter proving more reliable.
Thus, the (S)-TMSer was installed in 154 according to Yonemitsu’s protocol. These conditions
are a variant of those developed by Yamaguchi: instead of pre-forming the mixed anhydride with
TCBC followed by exposure to nucleophilic DMAP, in this case all of the components are com-
bined simultaneously. Higher concentrations are also generally used. In this way, the (S)-epimer
154 was formed in 29% yield (99% brsm) without any by-product formation (Scheme 4.1). The
configuration of the amino acid chiral centre was retained under the reaction conditions, as had
been observed by Williams.92,108 The low conversion at this stage can be attributed to the small
scale of the reaction and the desire to proceed cautiously in light of the highly advanced nature
of the material. It is likely that this result can be improved upon in future studies: Williams
was able to achieve 50−80% conversion with almost quantitative starting material recovery in
the synthesis of aplyronines A and D. This initial attempt generated a sufficient sample for full
characterisation and preliminary biological testing.
It still remains unclear whether the scalemic mixture of amino acid epimers observed in the
aplyronines is a true reflection of the natural composition of these compounds, or an artefact of
the isolation process. As we desired to investigate these effects further in our testing library,
the naturally occurring (S)-(+)-enantiomer of TMSer was pursued first. The (R)-epimer 155 is
expected to be formed shortly via the same procedure.
4.1.2 Studies towards C29-esterified analogues
Meanwhile, investigations into synthesising analogues extending from a C29-(R) hydroxyl group
were begun. Inspection of the crystal structure of actin-bound aplyronine A suggests that the
configuration of this stereocentre allows the pendant amino acid to point into bulk solvent. This
suggests that inversion of the configuration could result in a significant change in the binding











































Scheme 4.1: Synthesis of analogues 153, 154 and 155 with C29 ketone moiety
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provide further SAR information, our first priority was to form the (R)-alcohol to create mimics
that would not differ too greatly from the natural aplyronine congeners.
Dr Sarah Fink had performed this reduction in a stereoselective manner by using zinc borohy-
dride to carry out a substrate-directed hydride transfer.178 Fink had reasoned that high stereose-
lectivity for the formation of either C29 epimer would be acceptable, as the desired amino acids
could then be introduced either through standard esterification procedures, or by a Mitsunobu
reaction.179,180 In the event, reduction with Zn(BH4)2 gave the desired (R)-alcohol in 90% yield
and 10:1 dr on small scale. However, studies by Williams on both the real system and side chain
models, and by Rachel Porter on analogue side chain–southern fragments, found this reaction
to be highly capricious.108,129 Results varied between 40−90% yield and 1:1 → 10:1 dr, and
appeared to depend heavily on the quality of the reagent, which was impossible to determine
other than by testing directly on the limited quantities of precious substrates. Thus, this step
was expected to present further challenges in the ongoing synthesis. Propitiously, an outcome
of Porter’s work was that the epimers 156 and 157 (Figure 4.1) were separable by column chro-


















Figure 4.1: Chromatographically separable side chain analogues synthesised by Porter129
Initial testing of the zinc borohydride reduction in our analogue system 148 was afflicted by
similar limitations to those experienced by Williams and Porter. Test reactions achieved yields
of 76% (1.1:1 dr) and 57% (ca 2:1 dr, Scheme 4.2) of alcohol 158. The two diastereomers did
appear to be separable by careful silica chromatography, but this was a non-trivial process. The
compounds are difficult to visualise by TLC analysis due to their high polarity and tendency to
streak or to appear as two spots, presumably because they exist as two stable rotamers at the
N-vinylformamide terminus. Analysis by 1H NMR does show a clear difference between the
two isomers, with H29 and H31 appearing at significantly different chemical shifts.
A preliminary attempt was also made to form the diester 27 in three steps (Scheme 4.2). A
small sample of the putative alcohol 158 was subjected to the Yonemitsu esterification condi-



























(a) Zn(BH4)2, Et2O, 0 °C, 3 h; (b) DMGly, DMAP, TCBC, Et3N, THF/toluene, rt, 2.5 h; (c) HF·py, THF, 0 °C → rt, 16 h; 







































Scheme 4.2: Studies towards the synthesis of diester 27
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mitted directly to HF · py in anticipation of forming the diol monoester 160. However, no signal
that would correspond to H29 in the esterified product was observed by 1H NMR. Inspection of
the spectra along with the high polarity of the compound indicated that the esterification step
may have failed, giving triol 161 as the likely product. This compound was not fully charac-
terised for the purposes of this project, but could be included in future testing libraries if deemed
appropriate.
The difficulty in obtaining clean samples of each C29-epimer (158 and 159) for analysis has
hampered the continuation of this work. These investigations will now be taken up by Rachel
Porter, whose work towards synthesising further unnatural aplyrologues and the results of their
testing in biological assays will be detailed in an upcoming publication.131
4.2 Planned biological testing
The next stage of this work will be to test the synthetic analogues in cytotoxicity assays. In the
first instance, testing will be carried out in the HeLa-S3 cell line, to allow for direct comparison
with the natural products. Extending upon this, we will submit the compounds to AstraZeneca’s
CLIMB panel for testing against a wide range of cell lines. These cell lines represent many
different families of cancers and would give an early indication of any particular diseases of
interest for further development. Previous results for the aplyronines in both this panel and
the NCI-60 cell line panel have demonstrated their broad-spectrum cytotoxic activity in human
tumour models. As a result we expect that, if comparably active in the HeLa-S3 line, the current
analogues would show a similarly broad range of potential disease applications.
Figure 4.2 shows the library of analogues either currently in hand (153 and 154) or expected to
be completed in the near future for submission to bioactivity testing. The (R)-TMSer epimer
155 will shortly be completed and fully characterised following the procedure for compound
154. These constitute our “scytophycin hybrid”-type analogues, with C31 methyl ether and C29
ketone functionalities. In addition, the analogues with pendant amino acids at C29 as in the
aplyronines will be prepared via the methods discussed in Section 4.1.2. The first of these will
be the aplyronine D-like analogues, with DMGly at C29 and the free alcohol or TMSer at C7
(162, 163 and 164). These may be accompanied by the aplyronine A-like variants containing
DMAla at C29 (165–170). The DMGly-containing analogues will be prioritised because of the
apparently greater cytotoxicity of aplyronine D in earlier assays, with the corollary benefit that
the lack of a chiral centre in the amino acid somewhat deconvolutes the process of synthesising
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and characterising the products.
Our analogues have been rationally designed to be more synthetically accessible without af-
fecting the pharmacophore. If this hypothesis is indeed borne out, we expect to see that their
antiproliferative activity will be similar to that of the natural products, which show picomolar
IC50 values in the HeLa-S3 cell line. There is only a small likelihood of an improvement in ac-
tivity, although the inherent complexity of predicting ligand binding in biological systems means
that such an improvement could arise unexpectedly. If, contrary to our intentions, we have in-
deed modified the aplyronine pharmacophore in such a way as activity is lowered, this would be
reflected in a significant increase in IC50. If this is the case, there could be a number of causes:
(1) essential actin or tubulin binding contacts may have been removed or transformed,
(2) the overall shape of the molecule may have changed, such that its preferred conformation
is not compatible with actin binding,
(3) the molecule may still bind to actin, but in an altered binding mode so that interaction with
tubulin is no longer possible, or
(4) cell permeability has been reduced.
Depending on the results of biological testing, we may need to look further into these possible
impediments. Deeper considerations would be assisted by additional data from actin binding
studies of the sort which have previously been carried out on aplyronine tail analogues in col-
laboration with Prof. Gerard Marriott.181 We also anticipate that a crystal structure of the actin–
aplyronine–tubulin ternary complex will soon be available, and understand that work towards
this challenging target is ongoing.108,182 On the basis of this information, we shall generate new
hypotheses relating to structure–activity relationships for the aplyronines, and thus design a sec-
ond round of analogues which would overcome any obstacles that become evident.
If, on the other hand, the biological activity of our analogues is as we hope, we will nonetheless
have recourse to design further analogues – in this case to further simplify the synthesis and
perhaps generate even more potent analogues. Our goal would be to test the limits of structural
abridgement, finding the optimal balance between process simplicity and cytotoxic activity.
In either case, we expect that these results will lead to the suggestion of new analogues based on
function-oriented design principles. Some preliminary ideas regarding the form of these second-

















































Figure 4.2: Library of analogues, both in-hand and planned, for imminent submission to biolog-
ical testing
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4.3 Modifications to generate a second round of analogues
In terms of designing a second round of analogues for further structure–activity testing, late-
stage diversification will be the preferred strategy to capitalise on the work already achieved
while investigating the effects of modifications. Since we wish to probe the relationship between
structure and function in an already potent interaction, the modifications at this stage are not
intended to be too drastic: rather, to be relatively minor changes that could induce small but
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Figure 4.3: Side chain segments of related actin-binding natural products (numbering based on
the aplyronines). Left: stereochemistry in C23–C25 region equivalent to the aplyronines. Right:
altered stereochemistry in the C23–C25 region.
To this end, we could consider altering properties of the side chain region at a late stage by in-
corporation of revised fragments at the aldol coupling stage. For this we could seek inspiration
from actin-binding natural products with similar side chains terminating in the N-methyl-N-
vinylformamide moiety (Figure 4.3; see also Section 1.4.4). Compounds to the left of the dashed
line are those which have equivalent stereochemistry in the C23–C25 region to that of the aply-
ronines; compounds to the right have altered configuration in this region. An elegant publication
by Kigoshi and co-workers recently demonstrated that this stereochemistry has a strong effect
on the binding mode of these compounds, resulting in the macrocycle portion being oriented in
two different directions when in complex with actin.183 This difference explains why the group’s
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earlier aplyronine A–mycalolide B hybrid showed strong actin depolymerising ability, but sig-
nificantly decreased cytotoxicity relative to aplyronine A (see Figure 1.18, p. 18). Based on
these findings, the researchers synthesised a new hybrid containing the macrocycle part of aply-
ronine A and the side chain of swinholide A as a structurally simpler substitute that occupies the
same binding mode (Figure 4.4). This new hybrid retained picomolar cytotoxicity to HeLa-S3,
although the actin depolymerising activity was less potent, presumably due to the introduction
of the swinholide portion. These results lend support to the principle that simplified structures
















Figure 4.4: Kigoshi and co-workers’ aplyronine/swinholide hybrid183
Future modifications should follow this lead by adopting the simplified-hybrid model. For exam-
ple, we could consider similarly combining our simplified macrocycle with the swinholide side
chain, although this would involve developing some new chemistry to introduce the side chain
portion in our route. More straightforwardly, we could generate variants that more closely re-
semble the side chain of reidispongiolide A by using the equivalent aldol–dehydration–reduction
sequence from the total synthesis of this natural product.86 These would have the form of com-
pounds 176 and 177 (Figure 4.5). Although it would be preferable not to return to the C31
acetate-containing fragment from the aplyronine total synthesis due to its tendency to undergo
elimination under various conditions,91,92 if desired we could readily carry this out to produce
compounds 178 and 179 (Figure 4.5).
Additionally, a variety of changes could be made to the pendant amino acids at C7 and C29. In the
northern region, all evidence to date suggests that the trimethylserine moiety is very important
in promoting binding of tubulin to the actin–aplyronine complex; nevertheless, it may be that
some modifications are tolerated or even improve activity. Thus, a range of methylated serine
variants could be appended to any of the analogues already described (Figure 4.6). More so,
however, the range of modifications at C29 are of interest given our current investigations towards
extending this region for antibody conjugation. For this purpose it would be informative to test























Figure 4.5: Proposed second generation of analogues with altered side chains based on
reidispongiolide A and the aplyronines
is significant (Figure 4.6). The importance of the basic nitrogen at this position would also
be enlightening; this could be analysed by comparing a DMGly-functionalised substrate with
equivalents containing a non-basic nitrogen (e.g. from N-acetyl-N-methylglycine) or no nitrogen
(e.g. from isovaleric acid) at the same position.
4.4 Potential to streamline the overall synthesis
Much discussion in this dissertation has centred on “efficient” and “scalable” routes and reac-
tions, and mention has even been made of the developing steps for early process-scale synthesis.
Nevertheless, the synthesis of small quantities of analogues for exploratory biological testing and
the manufacture of commercial targets are two quite different concepts. To excerpt from Allred,
Manoni and Harran’s recent review on the manufacture of complex natural product-based drug
candidates by de novo synthesis,
the laboratory synthesis of complex natural products and the manufacture of small-
molecule drugs are chemistry compatriots that seldom meet. The former is typically
an academic pursuit in which emerging methods are tested and assembly tactics
are explored, whereas the latter are beautifully engineered exercises in brevity, effi-
ciency, and scale. The two operate on common principles, of course, but thereafter,
they focus on different goals with markedly different criteria for success.18
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Figure 4.6: Natural and modified amino acids for potential late-stage functionalisation of aply-
ronine analogues
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aplyronine analogues on small scales for biological testing, on the order of milligrams. Beyond
this, however, we have set our sights on generating structurally simplified candidates with the
potential for highly efficient manufacture in the future. Any manufacturing routes that might
eventuate are likely to contain some significant departures from our laboratory synthesis, and it
is left to those with relevant expertise to identify and enact these efficiencies. However, a priority
during this work has been to find reliable, highly stereoselective chemistry that would allow late-
stage modifications to produce a variety of analogues. Our synthesis has been highly effective
in this regard. Nevertheless, there remain a number of steps which could greatly improve the
efficiency of our route if they could be optimised for the current purposes. These have mainly













































































Scheme 4.3: Challenging synthetic steps which could benefit from further optimisation
Firstly, the alkylation step to introduce a phosphonate moiety into the northern fragment for
HWE coupling has continued to cause difficulties. The best results reported here represented
45−60% effective yield of the desired product 28 (Scheme 4.3, top), with lower yields attained
on larger scales. In future studies, it may be possible to redesign this disconnection. It is worth
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noting that SAR studies have indicated that removal of the C14 methyl group can be tolerated,
suggesting that future analogues could incorporate a simpler disubstituted olefin. This could
open up new opportunities for improving this sequence.78,79
Secondly, the Swern/Wittig protocol that installs the terminal N-methyl-N-vinylformamide into
the side chain fragment has been carried out in an optimised yield of 62% to date for the ana-
logue fragment discussed in this dissertation (Scheme 4.3, middle). This had been a challenging
transformation for Fink111 and the results achieved here did overcome the difficulties that still
remained. For instance, the need for constant vigilance in case of acetate elimination in subse-
quent steps was almost completely suppressed when using the methyl ether variant. However,
it would be advantageous to improve the overall yield and reliability of this step. The simplest
ways of achieving this might be to look for further inspiration in actin-binding macrolides with
conserved features, such as reidispongiolide A, which has the same structure bar the C32 methyl
group. A synthesis for the side chain fragment of reidispongiolide A has been reported,86 and
could be put to use in the design of new analogues (vide supra, Section 4.3). More adventurously,
we could consider substituting the N-vinylformamide for a different polar group entirely, such
as an alcohol, oxime or hydrazone, all of which were found to be tolerated in Kigoshi’s SAR
studies.70,76,78,79 Although this moiety is found in many actin-binding natural products, its level
of complexity may be somewhat incidental if what is needed is merely a hydrophilic group. If an
alternative can indeed be found without decreasing actin binding ability or overall cytotoxicity,
it could be a boon to the development of a much further simplified analogue, with the additional
benefit of making the NMR characterisation of intermediates more straightforward.
Thirdly, setting the desired stereochemistry at the C29 position presented a challenge which
slowed work at the final stages of the synthesis (Scheme 4.3, bottom). A lack of time and
reluctance to deplete valuable late-stage material meant that the best result achieved in this work
was only moderate in both yield (57%) and dr (2:1). Recommendations for immediate future
work are to investigate more reliable sources of the zinc borohydride reagent, if they can be
found. If not, less diastereoselective methods such as reduction with sodium borohydride could
be considered if the overall yield is higher. Provided the two epimers 158 and 159 can be sep-
arated, as early results suggest, the undesired compound could either be oxidised and recycled
as has previously been demonstrated in model studies,129 or Mitsunobu esterification could be
attempted.111 Reagent-controlled methods could also be investigated, although previous work
has ruled out the CBS reduction as a feasible option.111,131
If these challenging transformations can be accomplished more efficiently, either by re-evaluating
the methodology or the intended products, we will be able to realise even greater improvements
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to achieve a more practical aplyronine synthesis than those which have been described in this
work.
4.5 ADC development
Towards our ultimate goal of developing the aplyronine family of natural product-derived com-
pounds as novel cytotoxic payloads for antibody–drug conjugates, significant further work will
be needed to develop suitable linker species and reliable chemical methods for conjugation.
ADC linkers have been the subject of a rapidly growing chemical and biological literature. In
essence, we can consider linkers to have three main components: (1) part(s) for linkage to the
drug, (2) a spacer region which may affect the chemical and pharmacological properties of the
ADC, and (3) part(s) for linkage to natural or engineered conjugation sites on the antibody
(Figure 4.7). In the following sections, the conjugation chemistry at either end of the linker
species will be discussed.
mAb drug
spacer
Figure 4.7: Generalised schematic of the structure of an ADC linker
4.5.1 Development of a linker–payload species
In tandem with our investigations to improve the properties of aplyronine analogues for use
as ADC payloads, methods of linking these payloads to antibodies through functional handles
on the aplyronine scaffold are being explored. It will be necessary to identify optimal linker
attachment points, and to develop a method for linker conjugation that does not interfere with
the range of sensitive functionalities in the chosen analogue. The aplyronine–linker unit must
also be capable of undergoing conjugation to antibodies under bioorthogonal conditions.
Recently many interesting conjugation strategies for complex natural products accessible by total
synthesis have been proposed in the literature.30,47,184,185 For our objectives, a late-stage func-
tionalisation was desired in order to avoid the need for further structure–activity studies and
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re-synthesising many intermediates. Therefore methodologies such as a methyl extension strat-
egy proposed and validated specifically for polyketide natural products,186 although interesting
and perhaps applicable to our system, would not align with our plans at present.
Our initial efforts will focus on conjugating via the amino acid at the C29 position. This ap-
proach was validated by Williams with the synthesis of linker-modified aplyronine derivative
180,92,108 based around a non-cleavable maleimide conjugation strategy (Figure 4.8).36,187 The
conjugation site was justified on the basis that, in the crystal structure of the actin–aplyronine A
complex, the C29-DMAla appears to protrude into bulk solvent, leaving space to incorporate
linker-derived remnants in the active compound that would be released within the cell. Never-
theless, we could be more confident that conjugation would not impede the actin-binding prop-
erties of our payloads if a self-immolating linker was used. Given that the field of ADC research
has shifted strongly towards fully cleavable linkers, we now favour a cleavable linker strategy
that would tracelessly release our carefully designed analogue as a well-defined chemical unit.
Among other considerations, this simplifies the interpretation of biological results if the active
component released from an ADC can be unambiguously identified as the same entity resulting
























Figure 4.8: Aplyronine derivative synthesised by Williams for antibody conjugation via a non-
cleavable strategy108
Many possibilities for cleavable linker chemistry have been suggested in the literature. The
protocol that appears most appropriate for our purposes is a quaternary amine-based strategy,
described by researchers from Genentech188,189 and Seattle Genetics.190 This system allows ter-
tiary amine drugs to be converted to serum-stable para-aminobenzyl quaternary ammonium salts
(PABQs). The positively charged nitrogen helps improve the solubility profile of the conjugates,
decreasing the hydrophobicity of drug–linker units significantly. An enzyme-cleavable segment
connected to the PABQ promotes intracellular cleavage to regenerate the tertiary amine drug
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(Scheme 4.4).* Porter’s recent efforts to apply this strategy to the aplyronines have been centred
around the Genentech system, using a protease-cleavable valine-citrulline (Val–Cit) dipeptide to
set off the self-immolation of the PABQ unit.51,188,196 By this methodology, it should be possible
to introduce the linker molecule during an esterification step in the final stages of the analogue
synthesis. Importantly, physiological cleavage of this type of linker would lead to the release




















Scheme 4.4: Structure of the planned Val–Cit–PABQ linker and mechanism of intracellular
cleavage
In principle, as this strategy would cleanly release the desired drug entity, there is no fundamental
reason that the conjugation should be carried out at the C29 position in preference to C7. Further
studies will demonstrate whether one or the other is more viable. The advantages of linkage at
C29 include reacting at the less sterically hindered site and less need for monitoring of possible
overreaction in comparison with the C7/C9 diol. On the other hand, successful linkage at C7
would mean installing the linker at the very last step in the synthesis, and opens up the possibility
of conjugating species containing a C29-ketone moiety, such as 153 (Scheme 4.1).
The quaternary amine strategy will be the starting point for our investigations into antibody
conjugation; for completeness, two other possibilities are presented here.
Another possibility we considered was to use the oxygenated C13 position as a conjugation site.
However, this strategy has a number of drawbacks. Foremost, it has been proposed that together
with the C9 hydroxyl and C10 methyl groups, the C13 methyl ether forms an important anchoring
interaction with actin that positions the TMSer moiety to interact with tubulin. Substitution
might have been tolerated if a well-defined entity with no residual linker debris could be cleaved
in the cytosol; however, our route to reveal a C13 alcohol at a late stage proved problematic and
work has been discontinued at present. Full details of these investigations will be presented by
Porter.131
*More research may be needed in the near future to fully assess the properties and safety profile of the aza-
quinone methide side product191,192 given its similarity to quinone methides, which are known pan-assay interfer-
ence compounds (PAINs).193–195
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Alternatively, the N-vinylformamide terminus may provide an appropriate conjugation site, as
SAR studies showed that modification of this moiety to other polar functional groups did not give
rise to significant decreases in actin-binding activity. Attachment could occur via a C34-terminal
oxime linkage, as was used by Kigoshi and co-workers to introduce various groups containing
both hydrophobic and hydrophilic portions as biological probes without appreciable loss of actin
binding activity (e.g. 181, Figure 4.9).53,70,76,197 However, a limitation of this approach is that
oximes can be labile under physiological conditions, leading to spillage of the valuable cytotoxic
drug in circulation and consequently less clinical benefit and greater risk of off-target toxicity.
Accordingly, depending on the outcomes of investigations into second-generation analogues (see
Section 4.3), we could investigate more stable, enzyme-cleavable linkages through polar groups








































Figure 4.9: Photoaffinity-tagged aplyronine derivative synthesised by Kigoshi and co-workers
via a terminal oxime linkage53,197
4.5.2 Bioconjugation to form ADCs
Alongside developing a good understanding of the chemistry required to adjoin our analogues
to linkers, we will need to develop compatible bioconjugation chemistry for attachment to anti-
bodies. In addition, any information that can be gleaned about the pharmacological properties of
the resulting ADCs, such as solubility and potential to aggregate, must be taken into account.198
These considerations comprise the spacer and antibody-linkage parts of the linker unit.
As discussed in Chapter 1, maleimides have been extensively used to conjugate through native
cysteine residues accessible on the antibody surface. However, they are known to undergo retro-
Michael addition in circulation, leading to premature loss of the cytotoxic payload and associ-
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ated off-target toxicity. Attempts have been made to stabilise maleimide linkages by promoting
hydrolysis of the succinimide resulting from conjugation.199–201 Nevertheless, heterogeneous
ADCs with highly variable drug–antibody ratio (DAR) are generally obtained via these tradi-
tional methods. Recently, a variety of approaches have surfaced in attempts to overcome these
two key problems of plasma instability and heterogeneity. Antibody engineering can be used to
incorporate non-native amino acids at accessible sites for reaction under specified conditions.202
Alternatively, reduction of the four key interchain disulfides in an IgG generates precisely eight
free thiols which can act as nucleophiles in conjugation reactions, leading to more homogeneous
ADCs with more precise DAR and drug–linkers located at predictable sites. Spacer units are
also becoming more sophisticated, with options to include hydrophilic moieties for improved
solubility, or to use branched spacers.198,203 These can allow for multiple attachment either at
the drug or antibody end, for example for site-specific or bridging linkage strategies.
We intend to develop ADC constructs of the general form illustrated in Figure 4.10. These
will comprise payload–linker chemistry as discussed in Section 4.5.1 (vide supra), joined by
a hydrophilic spacer to the antibody-linkage site. The bioconjugation will be carried out site-




































Figure 4.10: General form of our intended ADCs
In collaboration with colleagues from Prof. David Spring’s research group, suitable techniques
for biomolecule conjugation that will be compatible with aplyronine payloads are currently
in development. These methods include interchain cysteine rebridging using divinylpyrim-
idines,204–206 sequence-dependent bioconjugation,207 and novel enzymatically-cleavable linker
methodologies.208 This will enable us to synthesise highly homogeneous, plasma-stable ADCs
with finely tuned pharmacokinetic properties. These constructs will be used to deliver cytotoxic




In Chapter 1, the vastly underexploited potential of marine natural products for medicinal appli-
cations was introduced. Species that thrive in the challenging oceanic environment have evolved
extremely bioactive small molecules to aid their survival, and many of these compounds can be
repurposed to aid in overcoming human diseases and medical conditions.
Meanwhile, despite great advances in modern medicine throughout the past century, our ap-
proach remains limited by the need to apply general treatments to specific diseases. This is true
both on the level of individual patients and heterogeneous cell populations within individuals.209
This thesis has formed part of a body of research that will help propel us towards better patient
outcomes through the development of targeted therapies.
It has been demonstrated herein that the aplyronines, a family of marine natural products which
were previously excluded from the search for medicinal treatments due to their extreme toxicity,
can re-surface not only as a viable but as a highly attractive candidate when that toxicity can be
harnessed effectively.
In this work, a function-oriented total synthesis of simplified analogues of the aplyronines has
been developed. The aim was to craft modified structures which would retain the exquisite
bioactivity of the natural products, but would represent more realistic commercial targets due to
their greater accessibility by means of synthesis.
In Chapter 2, the synthesis of three key fragments that would enable the construction of the
full molecules was discussed. Chapter 3 presented the coupling of these fragments and their
advancement towards the intended analogues.
This final chapter has described the completion of the first two members of this analogue library,
and plans for their imminent submission to biological testing. The outcomes thereof will serve
to confirm or disprove the validity of our SAR-informed simplifications. This will enable the
design of a new generation of aplyronine analogues, working towards optimised payloads for
delivery as part of a targeted therapeutic in the form of an antibody–drug conjugate.
The synthesis of analogue 153 was carried out in 6.5% yield and 23 steps LLS (38 steps total)
from Roche ester ethyl ketone 24. In terms of feasibility for a synthetic campaign on the larger
scale that would be needed in advance of clinical trials, this compares very favourably with
the Paterson second-generation total synthesis of aplyronine C, which required 29 steps LLS
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and was accomplished in 2.7% yield.92 This ultimately reflects the sheer level of complexity
of these delicate natural products, given the extensive efforts that were exerted to make the
natural product synthesis efficient and scalable, and the improvements that were made relative
to previous work. The industrial manufacture of marine natural product-inspired drug Halaven
(eribulin mesylate) by Eisai requires 30 steps LLS and 62 steps in total.18 Placed in this context,
our analogue synthesis could be eminently achievable. This seems particularly promising when
we consider that global supply for such a highly potent drug compound, anchored to an antibody
for targeted delivery, would be very low in comparison with a less biologically active equivalent.
With approximately 800 mg of macrocyclic intermediate 132 currently in hand, it should be
possible to generate a wide range of analogues in quantities amenable to the desired biological
testing (>1 mg).
Targeted therapies will form part of the wider field of personalised medicine, and will help shape
the future of clinical science. By causing drug treatments to act at the intended site within the
body, better overall patient outcomes and less resource wastage are among the many benefits that
can be achieved. This research has been a small part of a great movement towards improving
the standard of medical treatment available to the public, while reducing the resources required
to provide that treatment. Synthetic chemistry certainly has a role as an integral part of the






5.1.1 General experimental details
All experiments were performed under anhydrous conditions and under an inert atmosphere of
argon, except where stated or when water or aqueous solutions were used, using oven-dried
apparatus and employing standard techniques for handling air-sensitive materials.
Purification of reagents and solvents was carried out according to standard procedures.210 Ace-
tonitrile (MeCN), benzene (C6H6), dichloromethane (CH2Cl2), and dimethyl sulfoxide (DMSO)
were distilled from calcium hydride (CaH2) and stored under an argon atmosphere. Tetrahy-
drofuran (THF) and diethyl ether (Et2O) were distilled from benzophenone ketyl radical and
sodium or potassium wire, respectively, under an argon atmosphere. Solvents used in workup,
extraction, recrystallisation and column chromatography were distilled prior to use.
Triethylamine (Et3N), pyridine (py), diethyl ethylphosphonate and hexamethyldisilazane (HMDS)
were distilled from and stored over CaH2. 2,6-lutidine was distilled from CaH2 and stored neat
under argon. Diisopropylethylamine (i-Pr2NEt) was first distilled from ninhydrin, then dis-
tilled from and stored over CaH2. Titanium tetrachloride (TiCl4), titanium tetraisopropoxide
(Ti(Oi-Pr)4) and oxalyl chloride ((COCl)2) were distilled and stored at −20 °C under an argon
atmosphere. Acetaldehyde and propionaldehyde were distilled from calcium chloride (CaCl2)
immediately prior to use. Proton Sponge was recrystallised from methanol. DDQ was recrys-
tallised from chloroform. Barium hydroxide (Ba(OH)2) was dried under high vacuum at 130 °C
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and stored under argon. All other chemicals were used as received, except where noted other-
wise.
Sodium bicarbonate (NaHCO3), ammonium chloride (NH4Cl), sodium/potassium (Na+/K+) tar-
trate, brine (NaCl) and sodium thiosulfate (Na2S2O3) were used as saturated aqueous solutions,
unless otherwise stated in the text. Buffer solutions were prepared as directed from stock tablets
with deionised water.
Flash column chromatography was carried out on Merck Kieselgel 60 (230−400 mesh) silica gel
under a positive pressure of regulated compressed air. Merck Kieselgel F254 plates were used
for preparative thin layer chromatography. All solvent mixtures are reported as volume ratios.
Solvents were subsequently evaporated in vacuo.
Process-scale reactions were carried out in jacketed vessels under nitrogen atmosphere with ex-
ternal temperature control and internal temperature monitoring.
5.1.2 Analytical techniques
1H nuclear magnetic resonance (NMR) spectra were recorded using an internal deuterium lock at
ambient probe temperature (298 K) on the following instruments: Bruker Avance BB or Bruker
Avance TCI (500 MHz); and Bruker DPX400 (400 MHz). An internal reference of δH = 7.26
ppm was used for residual solvent protons in CDCl3. All 1H NMR data are represented as:
chemical shift (in ppm on the δ scale relative to δTMS = 0 ppm), integration, multiplicity (s =
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet, br = broad, obs
= obscured, app = apparent), coupling constant (J in Hz), and assignment. Coupling constants
were taken directly from the spectra and are uncorrected. Assignments were determined either on
the basis of unambiguous chemical shift or coupling pattern; 1H–1H COSY, HSQC, and HMBC
experiments; or by analogy to fully interpreted data for related compounds. Product strengths on
large-scale reactions were determined by quantitative 1H NMR analysis with 1,2,4,5-tetrachloro-
3-nitrobenzene as an internal standard.
Proton-decoupled 13C NMR spectra were recorded using an internal deuterium lock at ambient
probe temperature (298 K) on the following instruments: Bruker Avance BB or Bruker Avance
TCI (125 MHz); and Bruker DPX400 (100 MHz). An internal reference of δC = 77.0 ppm was
used for carbons in CDCl3. All chemical shift values are reported in ppm on the δ scale relative
to δTMS = 0 ppm.
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Infrared spectra were recorded on a Perkin–Elmer Spectrum One FT-IR spectrometer. Ab-
sorbance frequencies (ν) are reported in cm−1. Optical rotations were measured on an Anton
Paar MCP100 polarimeter or on a Perkin-Elmer 343 polarimeter at 589 nm and are reported as
follows: [α]20D at 20 °C, concentration (c in g dL
−1), and solvent. High resolution mass spec-
tra (HRMS) were recorded at the EPSRC Mass Spectrometry Service (Swansea, UK) or at the
departmental mass spectrometry service (University Chemical Laboratories, Cambridge) using
electron impact (EI), electrospray ionisation (ESI) or atmospheric solids analysis probe (ASAP)
techniques. The parent ion is quoted with the indicated cation: [M+H]+, [M+Na]+ or [M+NH4]+.
Analytical thin layer chromatography (TLC) was performed on Merck Kieselgel 60 F254 plates
coated with a 0.25 mm thickness of silica gel. Visualisation was accomplished by ultraviolet light
(254 nm) and potassium permanganate or phosphomolybic acid/cerium(IV) sulphate stains.




To a solution of benzyl alcohol (2.01 g, 18.6 mmol) in CH2Cl2 (22 mL) at −10 °C was added
tetrabutylammonium hydrogensulfate (69 mg, 0.203 mmol) followed by KOH (22 mL, 50%
w/v aq.) portionwise. Trichloroacetonitrile (2.10 mL, 20.9 mmol) was added dropwise over
30 min to the rapidly stirring biphasic mixture. The pale yellow reaction mixture was warmed
to rt and stirred overnight (16 h). The phases were separated and the aqueous layer extracted
with Et2O (3 × 20 mL). The combined organics were dried over Na2SO4 and concentrated in
vacuo. Crude product was purified by flash chromatography on alumina (1:10 EtOAc/PE) to
yield benzyl-2,2,2-trichloroacetimidate as a colourless oil (3.75 g, 80%).
Rf 0.79 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.39 (1H, br s, NH), 7.45–7.34 (5H,
m, ArH), 5.35 (2H, s, ArCH2O).






To a solution of KOH (78 mL, 50% w/v aq.) at −10 °C was added a solution of 4-methoxybenzyl
alcohol (9.19 g, 66.5 mmol) and tetrabutylammonium hydrogensulfate (229 mg, 0.674 mmol) in
CH2Cl2 (78 mL) dropwise via pipette. Trichloroacetonitrile (7.75 mL, 77.3 mmol) was added
dropwise over 10 min to the rapidly stirring biphasic mixture, ensuring the temperature remained
below −10 °C. The pale yellow reaction mixture was warmed to rt over 1 h, and stirred for a
further 1.5 h. The phases were separated and the aqueous layer extracted with Et2O (3 × 80 mL).
The combined organics were dried over MgSO4 and concentrated in vacuo. Purification by flash
chromatography on alumina (1:19 EtOAc/PE) gave 4-methoxybenzyl-2,2,2-trichloroacetimidate
84 as a colourless oil (15.3 g, 81%).
Rf 0.50 (1:9 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.36 (1H, br s, NH), 7.38 (2H, d, J =
8.7 Hz, ArH), 6.91 (2H, d, J = 8.7 Hz, ArH), 5.28 (2H, s, ArCH2O), 3.82 (3H, s, ArOMe).






To a stirred solution of paraformaldehyde (1.67 g, 55.6 mmol) in CHCl3 (150 mL) was added
N-methylformamide (2.95 mL, 50.5 mmol) and TMSCl (19.0 mL, 150 mmol). The mixture was
heated to reflux for 2 h then cooled to rt, filtered through Celite and concentrated in vacuo to
give crude 182 as a pale yellow oil. The crude material was used directly in the next reaction.
1H NMR (400 MHz, CDCl3) δH 8.27 (0.67H, s, NCHO), [8.04] (0.33H, s, NCHO*), 5.24
(1.33H, s, CH2Cl), [5.22] (0.67H, s, CH2Cl*), [3.05] (1H, s, NMe*), 2.95 (2H, s, NMe). Dis-
tinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and assignments







Crude N-chloromethyl-N-methylformamide (182) was added to a stirred solution of triphenylphos-
phine (14.3 g, 54.3 mmol) in Et2O (100 mL) and stirred at rt for 24 h. The resulting slurry was
filtered and washed with anhydrous Et2O (3 × 15 mL), then dried under high vacuum to give a
free-flowing yellow solid. The crude was recrystallised from CHCl3/Et2O to give 77 as white
crystals (8.94 g, 48% over 2 steps).
1H NMR (500 MHz, CDCl3) δH 8.17–7.64 (16H, m, NCHO, NCHO*, ArH), [6.60] (0.40H, d, J
= 2.4 Hz, NCH2P*), 6.22 (1.60H, d, J = 4.1 Hz, NCH2P), 3.18 (2.40H, s, NMe), [2.77] (0.60H,
s, NMe*); HRMS calc. for C21H21NOP [M – Cl]+ 334.1355, found 334.1355. Distinguishable
resonances of the minor rotamer (4:1 ratio) are given in brackets and assignments denoted with
an asterisk.





To a solution of diethyl ethylphosphonate (5.01 g, 30.2 mmol) in THF (40 mL) at −78 °C was
added n-BuLi (21 mL, 1.6 M in hexane, 33.6 mmol). The mixture was allowed to stir for 1 h, then
EtOAc (3.00 mL, 30.7 mmol, freshly distilled from CaH2) was added dropwise. After 2 h stirring
at −78 °C, the reaction was quenched with NH4Cl (70 mL) and warmed to rt. The layers were
separated and the aqueous extracted with EtOAc (5 × 50 mL). The combined organics were dried
over MgSO4 and concentrated in vacuo. Distillation under reduced pressure (0.4 Torr, 85−86°C)
gave phosphonate 90 as a colourless oil (3.03 g, 48%).
Rf 0.09 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 4.17–4.09 (4H, m, P(OCH2CH3)2),
3.20 (1H, dq, J = 25.6, 7.1 Hz, H12), 2.33 (3H, s, H14 × 3), 1.35 (3H, dd, J = 21.3, 7.1 Hz, Me14),
1.35–1.30 (6H, m, P(OCH2CH3)2).
These data are in agreement with those previously reported.216
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Tin(II) triflate (Sn(OTf)2)111
Tin granules (2.63 g, 22.2 mmol) were stirred under vacuum for 24 h, with occasional heating to
melt. The reaction flask was purged with argon, and TfOH (10.0 g, 66.6 mmol) was added into
the reaction flask via cannula. The reaction was stirred at 85 °C for 48 h. The resulting white
slurry was washed with Et2O without exposure to air until the supernatant appeared colourless,
and dried under vacuum with vigorous stirring for 16 h to give Sn(OTf)2 (3.79 g, 41%) as a very
pale grey powder, which was stored under an argon atmosphere.
Samarium diiodide (SmI2)
Method A:217 To samarium metal (23 mg, 150 μmol) and 1,2-diiodoethane (23 mg, 82 μmol)
was added THF (0.75 mL) and the suspension sonicated for 20 min at rt. The resulting dark
blue-green solution of SmI2 (ca. 0.1 M) was used immediately.
Method B:218 Iodine (407 mg, 1.60 mmol) was dissolved in THF (16 mL) and added to samar-
ium (267 mg, 1.78 mmol) via syringe. The mixture was allowed to stir at rt overnight (20 h),
resulting in a dark blue-green solution of SmI2 (ca. 0.1 M).
Isopropylmagnesium chloride (i-PrMgCl)
To magnesium turnings (3.79 g, 156 mmol) in THF (70 mL) was added a portion of i-PrCl
(1.30 mL, 14.2 mmol) and one bead of iodine (ca. 10 mg). The dark yellow reaction mixture
quickly turned colourless as the reaction initiated. The temperature was carefully controlled with
an ice bath as the remaining i-PrCl (11.5 mL, 126 mmol) was added dropwise over 1 h. The dark
grey solution of i-PrMgCl (ca. 2.0 M) was cooled to rt and used immediately.
Ethylmagnesium bromide (EtMgBr)
A portion of EtBr (1.00 mL, 13.4 mmol) was cautiously added to magnesium turnings (3.62 g,
149 mmol) in Et2O (45 mL). Within 1 min the reaction was seen to initiate, and turned pale grey
in colour. The remaining EtBr (9.00 mL, 121 mmol) was carefully added dropwise over 30 min.
The dark grey solution of EtMgBr (ca. 3.0 M) was cooled to rt and used immediately.
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Lithium hexamethyldisilazide (LiHMDS)
To a solution of HMDS (0.14 mL, 0.67 mmol) in THF (0.22 mL) at 0 °C was added n-BuLi
(0.38 mL, 1.6 M in hexane, 0.61 mmol). The mixture was stirred for 30 min at 0 °C, then used
immediately.
Cyclohexylboron chloride (Cy2BCl)
Cyclohexene (40 mL, 395 mmol, freshly distilled from CaH2) was dissolved in Et2O (250 mL)
and cooled to −10 °C. Monochloroborane methyl sulfide complex (ClBH2 · SMe2, 20.6 mL,
198 mmol) was added dropwise over 15 min, and the solution was stirred at 0 °C for 1 h, then
at rt for 1 h. The solvent was removed by distillation at ambient pressure (35 °C) under argon.
Distillation under reduced pressure (0.7 Torr, 92−94 °C) then gave Cy2BCl as a colourless liquid,
which was stored under argon at −20 °C.
Stryker’s reagent([CuH(PPh3)]6)176
To a solution of Cu(OAc)2 ·H2O (25.0 mg, 0.125 mmol) and PPh3 (65.0 mg, 0.248 mmol) in
toluene (4.66 mL) was added tetramethyldisiloxane (0.33 mL, 1.87 mmol). The mixture under-
went a colour change from aqua blue to brick red while stirring at rt for 16 h. The resulting
solution (0.025 M in copper, 0.37 M in hydride) was used directly in conjugate reduction reac-
tions or stored at −20 °C for up to 1 month.
Zinc borohydride (Zn(BH4)2)
Zinc(II) chloride (3.68 g, 27.0 mmol) was dried under high vacuum at 150 °C for 2 h then
suspended in Et2O (125 mL) and refluxed for 2 h. The solution was cooled and added to a
suspension of sodium borohydride (2.04 g, 54.0 mmol) in Et2O (30 mL). The reaction was
stirred at rt for 16 h, then the supernatant was decanted and stored under argon at −20 °C.
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Method A (Small scale):
PMBTCA (13.40 g, 47.4 mmol) was dissolved in CH2Cl2 (21 mL) and added to methyl (R)-3-
hydroxy-2-methylpropanoate (4.59 g, 38.8 mmol) in CH2Cl2 (34 mL) at 0 °C, followed by PPTS
(0.98 g, 3.9 mmol) in a single portion. The mixture was warmed to rt and allowed to stir for 16 h.
The mixture was cooled in an ice bath and quenched slowly with NaHCO3 (60 mL). The layers
were separated and the aqueous phase extracted with CH2Cl2 (3 × 30 mL). The organic phases
were combined, dried over MgSO4 and concentrated in vacuo. The resulting white slurry was
triturated with ice-cold PE and filtered through Celite. The filtrate was concentrated in vacuo and
purified by flash chromatography (1:10→ 1:8 EtOAc/PE) to give PMB ether 79 as a colourless
oil (8.15 g, 88%).
Method B (Large scale):
A solution of p-methoxybenzyl alcohol (140 g, 1.01 mol) in CH2Cl2 (1400 mL) was charged to
a 2 L jacketed vessel under N2 atmosphere. DBU (1.52 mL) was added in one portion, followed
by addition of trichloroacetonitrile (112 mL) over 30 min with internal temperature controlled
to 20 °C. The mixture was stirred for 30 min, during which a dark yellow colour developed. GC
analysis indicated full conversion to PMBTCA (84).
(R)-Roche ester 65 (103.6 g, 0.877 mol) was added as a solution in CH2Cl2 (200 mL), followed
by PPTS (21.2 g, 0.0843 mol), and stirring continued at 20 °C. Further portions of PPTS (3
× 10.6 g, 0.0421 mol) were added hourly until the reaction was judged to be complete by 1H
NMR analysis after 4 h. Solvent swap distillation replaced the CH2Cl2 solvent with n-heptane
(800 mL), which upon cooling to rt formed a clear solution along with an oily brown residue.
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The clear heptane fraction was concentrated in vacuo to a colourless oil (160.2 g, 80.0% w/w 79).
The residue was dissolved in CH2Cl2 (200 mL) and filtered through Celite, then through a plug
of silica, and concentrated in vacuo. The resulting crude material was triturated with heptane
to remove the trichloroacetamide, then subjected to automated gradient column chromatography
(7−60% EtOAc/heptane). The resultant product was combined with the heptane fraction to give
a colourless oil (202.5 g, 81.6% w/w, equivalent to 165.3 g 79), containing the desired PMB
ether in 79% corrected yield.
By the same procedure, starting from (S)-Roche ester 34 (50.6 g, 0.428 mol), the opposite enan-
tiomer (102.7 g, 84.2% w/w, equivalent to 86.5 g 81) was obtained as a colourless oil in 85%
corrected yield.
Rf 0.59 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.7 Hz, ArH), 6.87
(2H, d, J = 8.7 Hz, ArH), 4.47 (1H, d, J = 11.8 Hz, ArCHaHbO), 4.44 (1H, d, J = 11.8 Hz,
ArCHaHbO), 3.80 (3H, s, ArOMe), 3.69 (3H, s, COOMe), 3.63 (1H, dd, J = 9.2, 7.3 Hz, H33a),
3.46 (1H, dd, J = 9.2, 6.0 Hz, H33b), 2.77 (1H, dqd, J = 7.1, 7.1, 6.1 Hz, H32), 1.17 (3H, d, J =
7.1 Hz, Me32).















Method A (Small scale):
A solution of PMB ether 79 (8.06 g, 33.8 mmol) in THF (60 mL) was added to vacuum-dried
N,O-dimethylhydroxylamine hydrochloride (5.02 g, 51.4 mmol) and cooled to −30 °C. i-PrMgCl
(61 mL, 2.0 M in THF, 122 mmol) was added dropwise over 1 h, while keeping the internal
temperature below −20 °C. The reaction mixture was stirred at −15 °C for 1.5 h, then carefully
quenched with NH4Cl (120 mL), controlling the temperature with an ice bath. The mixture was
diluted with H2O (80 mL) and partitioned with Et2O (3 × 100 mL). The combined organic layers
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were dried over MgSO4, concentrated in vacuo, and purified by flash chromatography (1:2 →
1.5:1 EtOAc/PE) to give Weinreb amide 80 as a pale yellow oil (8.53 g, 94%).
Method B (Large scale):
Vacuum-dried N,O-dimethylhydroxylamine hydrochloride (101.5 g, 1.04 mol) was charged to a
3 L jacketed vessel under N2 atmosphere, and PMB ether 79 (165.3 g corr., 0.694 mol) in 2-
MeTHF (990 mL) was added. The solution was pre-cooled to −10 °C and i-PrMgCl (1040 mL,
2.0 M in THF, 2.08 mol) was added over 4 h, controlling the internal temperature to −10 °C
or below. After the addition was complete, the solution was stirred for 30 min, then quenched
slowly with NH4Cl (900 mL, 15% w/w aq). The layers were separated; the organics were washed
with brine (900 mL, 20% w/w aq) and the aqueous extracted with 2-MeTHF (300 mL). The
solvent was removed in vacuo, giving (R)-Weinreb amide 80 as a yellow oil (216.4 g, 82.4%
w/w, equivalent to 178.3 g) in 96% corrected yield.
The equivalent procedure in the opposite enantiomeric series starting from compound 81 (86.5 g
corr., 0.363 mol) gave the (S)-Weinreb amide 82 as a yellow oil (111.3 g, 86.1% w/w, equivalent
to 95.9 g) in 99% corrected yield.
Rf 0.11 (1:3 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.23 (2H, d, J = 8.4 Hz, ArH), 6.86
(2H, d, J = 8.4 Hz, ArH), 4.48 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.40 (1H, d, J = 11.6 Hz,
ArCHaHbO), 3.80 (3H, s, ArOMe), 3.70–3.66 (4H, m, N(OMe), H33a), 3.39 (1H, dd, J = 8.8, 5.9
Hz, H33b), 3.30–3.20 (1H, m, H32), 3.20 (3H, s, NMe), 1.10 (3H, d, J = 6.9 Hz, Me32).







Method A (Small scale):
To a vigorously stirred solution of (R)-Weinreb amide 80 (8.48 g, 31.7 mmol) in Et2O (80 mL) at
−5 °C was added EtMgBr (40 mL, 3.0 M in Et2O, 120 mmol) dropwise over 75 min, keeping the
internal temperature below 5 °C. The mixture was stirred at 0 °C for 1.5 h, then quenched very
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cautiously with NH4Cl (110 mL) and diluted with H2O (30 mL). The phases were separated, the
aqueous layer extracted with Et2O (2 × 80 mL) and the combined organics dried over MgSO4
and concentrated in vacuo. Flash chromatography (1:8 EtOAc/PE) gave a pale yellow oil, an
inseparable mixture of ketone 24 and byproduct 66 (6.96 g, 16:1 by 1H NMR, 87% calculated
yield of desired product).
Method B: Large scale
To a solution of (R)-Weinreb amide 80 (30.9 g corr., 0.116 mol) in 2-MeTHF (90 mL) in a
250 mL jacketed vessel under N2 atmosphere was added EtMgBr (102 mL, 3.4 M in 2-MeTHF,
0.347 mol) over 2 h, controlling the internal temperature of the reaction to −10 °C or lower.
The reaction was left to stir for 16 h, then quenched slowly with NH4Cl (90 mL, 15% w/w aq)
and gradually raised to rt. The aqueous layer was separated and the organics washed with brine
(90 mL, 20% w/w aq) and concentrated in vacuo. The resulting brown oil contained (R)-ethyl
ketone 24 (31.6 g, 78.7% w/w, equivalent to 24.9 g) in 91% corrected yield.
Rf 0.59 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.20 (2H, d, J = 8.7 Hz, ArH), 6.86
(2H, d, J = 8.7 Hz, ArH), 4.41 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.38 (1H, d, J = 11.7 Hz,
ArCHaHbO), 3.78 (3H, s, ArOMe), 3.58 (1H, dd, J = 9.1, 7.8 Hz, H33a), 3.42 (1H, dd, J = 9.1,
5.5 Hz, H33b), 2.85 (1H, dqd, J = 7.4, 7.4, 5.6 Hz, H32), 2.49 (2H, q, J = 7.3 Hz, H30 × 2), 1.05
(3H, d, J = 7.2 Hz, Me32), 1.03 (3H, t, J = 7.3 Hz, Me30); [α]20D −22.2 (c 1.02, CHCl3), lit. −22.5
(c 1.12, CHCl3).
These data are in agreement with those previously reported.221,222
5.4 Experimental procedures for Chapter 2






Sodium hydride (60% in mineral oil, 0.46 g, 11.4 mmol) was added portionwise to a solution
of 1,9-nonanediol (5.00 g, 31.2 mmol) in THF/DMSO (2:1, 93 mL) at 0 °C and stirred for 1 h.
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To the yellow solution was added TBAI (0.36 g, 0.97 mmol) followed by PMBCl (1.45 mL,
10.7 mmol) dropwise over 30 min. The mixture was warmed to rt and stirred for 70 h, then
quenched by addition of NH4Cl (90 mL). The phases were separated and the aqueous layer
extracted with EtOAc (3 × 50 mL). The combined organics were dried over Na2SO4 and con-
centrated in vacuo. Purification by flash chromatography (1:5 → 1:3 EtOAc/PE) gave alcohol
38 as an orange oil (2.17 g, 72% based on PMBCl).
Rf 0.28 (1:3 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.26 (2H, d, J = 8.5 Hz, ArH),
6.88 (2H, d, J = 8.6 Hz, ArH), 4.43 (2H, s, ArCH2O), 3.80 (3H, s, ArOMe), 3.63 (2H, t, J =
6.6 Hz, H23), 3.43 (2H, t, J = 6.6 Hz, H15), 1.65–1.48 (4H, m, H16, H22), 1.40–1.23 (11H, m,
H17 – 21, C23OH).






To a solution of oxalyl chloride (0.98 mL, 11.6 mmol) in CH2Cl2 (15 mL) at −78 °C was added
DMSO (1.10 mL, 15.5 mmol). The mixture was stirred for 1 h. A solution of alcohol 38 (2.16 g,
7.70 mmol) in CH2Cl2 (15 mL) was then added via cannula and the reaction mixture stirred
for a further 30 min. After addition of Et3N (3.2 mL, 23.1 mmol), the mixture was warmed to
rt and stirred for 3 h. Upon completion, the reaction was quenched with NH4Cl (18 mL). The
phases were separated and the aqueous layer extracted with CH2Cl2 (3 × 15 mL). The combined
organics were washed with NaHCO3 (30 mL), dried over MgSO4 and concentrated in vacuo.
Crude product was purified by flash chromatography (1:15→ 1:10 EtOAc/PE) to give aldehyde
39 as a pale yellow oil (1.62 g, 76%).
Rf 0.27 (1:8 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 9.76 (1H, t, J = 1.8 Hz, H23), 7.26
(2H, d, J = 8.6 Hz, ArH), 6.88 (2H, d, J = 8.6 Hz, ArH), 4.43 (2H, s, ArCH2O), 3.80 (3H, s,
ArOMe), 3.43 (2H, t, J = 6.6 Hz, H15), 2.41 (2H, td, J = 7.4, 1.8 Hz, H22), 1.67–1.52 (4H, m,
H16, H21), 1.39–1.24 (8H, m, H17 – 20); HRMS calc. for C17H30NO3 [M+NH4]+ 296.2222, found
296.2220.






To a solution of 1,9-nonanediol (12.0 g, 74.9 mmol) and imidazole (2.04 g, 68.1 mmol) in THF
(80 mL) at 0 °C was added a solution of TBSCl (3.77 g, 25.0 mmol) in THF (70 mL) dropwise
over 40 min. The mixture was slowly warmed to rt and allowed to stir for 65 h, then quenched
by addition of H2O. The phases were separated and the aqueous layer extracted with EtOAc
(3 × 100 mL). The combined organics were washed with H2O (50 mL), dried over Na2SO4
and concentrated in vacuo. Purification by flash chromatography (1:3 → 1:2 EtOAc/PE) gave
alcohol 183 as a colourless oil (5.69 g, 83%).
Rf 0.27 (1:6 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 3.64 (2H, t, J = 6.6 Hz, H23), 3.59
(2H, t, J = 6.6 Hz, H15), 1.61–1.45 (4H, m, H16, H22), 1.39–1.24 (10H, m, H17 – 21), 0.89 (9H,
s, SiC(CH3)3), 0.04 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 63.3, 63.0, 32.8, 32.8,
29.6, 29.3, 29.3, 26.0, 25.8, 25.7, 18.4, −5.3; HRMS calc. for C15H35O2Si [M+H]+ 275.2401,
found 275.2402.





To a solution of oxalyl chloride (2.39 mL, 28.2 mmol) in CH2Cl2 (50 mL) at −78 °C was added
DMSO (2.67 mL, 37.6 mmol). The mixture was stirred for 30 min, then a solution of alcohol
183 (5.16 g, 18.8 mmol) in CH2Cl2 (25 mL) was added via cannula and stirred for a further 1 h.
Addition of Et3N (7.86 mL, 56.4 mmol) dropwise at −78 °C caused the reaction mixture to seize.
After warming to rt with stirring and addition of CH2Cl2 (20 mL), the resulting yellow solution
was allowed to stir for 16 h. The reaction was quenched carefully with NH4Cl (40 mL). The
phases were separated and the aqueous layer extracted with CH2Cl2 (2 × 80 mL). The combined
organics were washed with NaHCO3 (50 mL), dried over MgSO4 and concentrated in vacuo.
The crude product was purified by flash chromatography (1:15 EtOAc/PE) to give aldehyde 49
as a colourless oil (4.68 g, 91%).
Rf 0.50 (1:8 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 9.76 (1H, t, J = 1.9 Hz, H23), 3.59
(2H, t, J = 6.6 Hz, H15), 2.41 (2H, td, J = 7.4, 1.9 Hz, H22), 1.68–1.57 (2H, m, H16), 1.55–
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1.43 (2H, m, H21), 1.37–1.24 (8H, m, H17 – 20), 0.89 (9H, s, SiC(CH3)3), 0.04 (6H, s, Si(CH3)2);
HRMS calc. for C15H33O2Si [M+H]+ 273.2244, found 273.2248.






To a solution of methyl (S)-3-hydroxy-2-methylpropanoate (1.19 g, 10.1 mmol) in Et2O (18 mL)
at 0 °C was added BnTCA (2.60 mL, 14.0 mmol) and TfOH (0.20 mL, 2.3 mmol). The mixture
was stirred at 0 °C for 20 min, then warmed to rt and stirred for a further 2 h. Upon completion
the yellow reaction mixture was cooled in an ice bath and NaHCO3 (36 mL) was carefully added.
The mixture was extracted with Et2O (3 × 20 mL) and the combined organics dried over MgSO4
and concentrated in vacuo to a yellow oil containing a large amount of white precipitate. The
crude mixture was triturated with ice-cold hexane and filtered through Celite. The filtrate was
concentrated in vacuo and purified by flash chromatography (1:50 → 1:20 EtOAc/PE) to give
benzyl ether 35 as a pale yellow oil (2.01 g, 96%).
Rf 0.44 (1:8 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.40–7.27 (5H, m, PhH), 4.52 (2H,
s, PhCH2O), 3.70 (3H, s, COOMe), 3.66 (1H, dd, J = 8.9, 7.3 Hz, H27a), 3.50 (1H, dd, J = 9.1,
5.9 Hz, H27b), 2.79 (1H, m, H26), 1.18 (3H, d, J = 7.1 Hz, Me26).









A solution of benzyl ether 35 (2.01 g, 9.7 mmol) in THF (19 mL) was added to vacuum-dried
N,O-dimethylhydroxylamine hydrochloride (1.51 g, 15.5 mmol) and cooled to −30 °C. i-PrMgCl
(14.5 mL, 2.0 M in THF, 29 mmol) was added dropwise over 15 min, keeping the internal
temperature below −25 °C. The reaction mixture was allowed to warm to −15 °C and stirred
for 30 min. A further aliquot of i-PrMgCl (4.8 mL, 9.6 mmol) was added over 20 min, before
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leaving the reaction to stir for 16 h at −10 °C. Once complete, the reaction was quenched by
careful addition of NH4Cl (30 mL), controlling the temperature with an ice bath. The mixture
was diluted with H2O (30 mL) and partitioned with Et2O (3 × 40 mL). The combined organic
layers were dried over MgSO4, concentrated in vacuo, and purified by flash chromatography (1:5
→ 1:3 EtOAc/PE) to give Weinreb amide 36 as a pale yellow oil (1.58 g, 69%).
Rf 0.65 (1:1 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.39–7.27 (5H, m, PhH), 4.56 (1H, d,
J = 12.1 Hz, PhCHaHbO), 4.48 (1H, d, J = 12.1 Hz, PhCHaHbO), 3.72 (1H, m, H27a), 3.70 (3H,
s, N(OMe)), 3.43 (1H, dd, J = 8.9, 5.9 Hz, H27b), 3.34–3.23 (1H, m, H26), 3.21 (3H, s, NMe),
1.12 (3H, d, J = 6.9 Hz, Me26).






To a vigorously stirred solution of Weinreb amide 36 (5.00 g, 21.1 mmol) in Et2O (53 mL) at
0 °C was added EtMgBr (21.5 mL, 3.0 M in Et2O, 64.5 mmol) dropwise over 75 min. The
mixture was stirred at 0 °C for 16 h, then quenched very carefully with NH4Cl (70 mL). The
mixture was diluted with H2O (20 mL), partitioned with Et2O (3 × 70 mL) and the combined
organics dried over MgSO4 and concentrated in vacuo. Purification by flash chromatography
(1:20 EtOAc/PE) afforded ketone 33 as a pale yellow oil (3.24 g, 75%).
Rf 0.68 (1:3 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.38–7.27 (5H, m, PhH), 4.50 (1H,
d, J = 12.0 Hz, PhCHaHbO), 4.46 (1H, d, J = 12.2 Hz, PhCHaHbO), 3.63 (1H, app t, J = 8.4 Hz,
H27a), 3.46 (1H, dd, J = 9.1, 5.5 Hz, H27b), 2.93–2.84 (1H, m, H26), 2.51 (2H, q, J = 7.2 Hz,
H24 × 2), 1.08 (3H, d, J = 7.2 Hz, Me26), 1.03 (3H, t, J = 7.2 Hz, Me24); [α]20D +22.7 (c 1.00,
CHCl3); IR (thin film) ν max (cm– 1) 2968, 2933, 2853, 2353, 1713, 1455, 1374, 1360, 1092,
1072, 1027, 975, 953, 735, 698; HRMS calc. for C13H19O2 [M+H]+ 207.1380, found 207.1379.










Method A: Titanium aldol
To a solution of TiCl4 (45 μL, 0.41 mmol) in CH2Cl2 (1 mL) at 0 °C was added Ti(Oi-Pr)4
(40 μL, 0.14 mmol). The mixture was stirred at 0 °C for 10 min, then at rt for 20 min. The
resulting colourless solution was added to a solution of ketone 33 (99.0 mg, 0.480 mmol, dried
azeotropically from C6H6 and stirred over CaH2 immediately prior to use) in CH2Cl2 (2.5 mL) at
−78 °C. Upon dropwise addition of i-Pr2NEt (95 μL, 0.55 mmol), the yellow solution underwent
a gradual colour change to bright red. The reaction mixture was allowed to enolise at −78 °C for
45 min, before addition of aldehyde 39 (201 mg, 0.722 mmol, dried azeotropically from C6H6
and stirred over CaH2 immediately prior to use) in CH2Cl2 (2.5 mL) via cannula. The mixture
was stirred at −78 °C for a further 2.5 h, then quenched with MeOH (1 mL), causing a colour
change back to yellow. After warming to rt, Na+/K+ tartrate (2 mL) was added and the biphasic
mixture was stirred rapidly overnight (16 h). The reaction mixture was diluted with CH2Cl2
(10 mL) and the organic phase washed sequentially with H2O (10 mL) then brine (5 mL). The
combined aqueous washings were then extracted with CH2Cl2 (20 mL). The combined organics
were dried over Na2SO4, concentrated in vacuo and purified by flash chromatography (1:6 →
1:3 EtOAc/PE) to give aldol adduct 47 as a colourless oil (183 mg, 78%, 5:1 dr).
Method B: Boron aldol
To a suspension of (+)-Ipc2BH (0.763 g, 2.67 mmol) in hexane (1.35 mL) at 0 °C was added
TfOH (0.235 mL, 2.65 mmol). The mixture was warmed to rt and stirred gently. Upon com-
pletion, the colourless upper layer (0.61 mL, ca. 1.2 M) was removed by syringe, diluted with
CH2Cl2 (0.3 mL) and cooled to −78 °C. i-Pr2NEt (250 μL, 1.44 mmol) was added, followed by
ketone 33 (103 mg, 0.499 mmol, dried azeotropically from C6H6 and stirred over CaH2 immedi-
ately prior to use) in CH2Cl2 (0.6 mL). The mixture was allowed to enolise at −78 °C for 15 min,
then at 0 °C for 2 h. It was then re-cooled to −78 °C and aldehyde 39 (402 mg, 1.44 mmol, dried
azeotropically from C6H6 and stirred over CaH2 immediately prior to use) in CH2Cl2 (0.6 mL)
was added. The reaction mixture was stirred at −60 °C for 2 h, then at −20 °C for 14 h, after
which it was quenched by addition of MeOH (2 mL), pH 7 buffer (2 mL) and dropwise H2O2
(1 mL, 30% w/w aqueous) at 0 °C. After warming to rt, the mixture was stirred for 1 h, then ex-
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tracted with CH2Cl2 (3 × 8 mL). The combined organics were dried over Na2SO4, concentrated
in vacuo, and purified by flash chromatography (1:4→ 1:3 EtOAc/PE) to give aldol adduct 47
as a pale yellow oil (191 mg, 79%, 3:1 dr).
Rf 0.34 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.36–7.24 (7H, m, ArH, PhH), 6.88
(2H, d, J = 8.7 Hz, ArH), 4.47 (1H, d, J = 11.7 Hz, PhCHaHbO), 4.46–4.42 (3H, m, PhCHaHbO, ArCH2O),
4.01–3.96 (1H, m, H23), 3.80 (3H, s, ArOMe), 3.64 (1H, app t, J = 9.0 Hz, H27a), 3.46 (1H, dd,
J = 8.7, 4.8 Hz, H27b), 3.43 (2H, t, J = 6.7 Hz, H15 × 2), 3.17 (1H, dqd, J = 9.3, 7.0, 4.9 Hz,
H26), 2.84 (1H, v br s, C23OH), 2.74 (1H, qd, J = 7.1, 2.7 Hz, H24), 1.59 (2H, app quint, J =
7.0 Hz, H16 × 2), 1.49–1.42 (1H, m, H22a), 1.40–1.19 (11H, m, H17 – 21, H22b), 1.07 (3H, d, J =
7.1 Hz, Me24), 1.02 (3H, d, J = 6.9 Hz, Me26); 13C NMR (125 MHz, CDCl3) δC 218.0, 159.0,
137.5, 130.7, 129.1, 128.3, 127.7, 127.6, 113.6, 73.4, 73.1, 72.4, 70.6, 70.1, 55.1, 50.8, 44.8,
33.6, 29.7, 29.5, 29.5, 29.3, 26.1, 26.1, 13.5, 8.8; [α]20D +3.0 (c 1.01, CHCl3); IR (thin film) ν max
(cm– 1) 3480, 2933, 2853, 1705, 1611, 1586, 1510, 1455, 1364, 1302, 1247, 1207, 1173, 1034,








To a solution of TiCl4 (45 μL, 0.41 mmol) in CH2Cl2 (1 mL) at 0 °C was added Ti(Oi-Pr)4
(40 μL, 0.14 mmol). The mixture was stirred at 0 °C for 10 min, then at rt for 20 min. The
resulting colourless solution was added to a solution of ketone 33 (100 mg, 0.485 mmol, dried
azeotropically from C6H6 and stirred over CaH2 immediately prior to use) in CH2Cl2 (2.5 mL)
at −78 °C. Upon dropwise addition of i-Pr2NEt (95 μL, 0.55 mmol), the yellow solution changed
colour to bright red. The reaction mixture was stirred at −78 °C for 35 min to allow to enolise,
before addition of aldehyde 49 (200 mg, 0.734 mmol, dried azeotropically from C6H6 and stirred
over CaH2 immediately prior to use) in CH2Cl2 (2.5 mL) slowly via cannula. The mixture was
stirred at −78 °C for a further 1.5 h, then quenched with MeOH (1 mL), causing a colour change
back to yellow. After warming to rt, Na+/K+ tartrate (2 mL) was added and the biphasic mixture
was stirred rapidly for 30 min. The reaction mixture was diluted with CH2Cl2 (10 mL) and H2O
(10 mL) and the organic phase was washed with H2O (10 mL). The combined aqueous fractions
were then extracted with CH2Cl2 (3 × 10 mL). The combined organic phases were dried over
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Na2SO4, concentrated in vacuo and purified by flash chromatography (1:10→ 1:6 EtOAc/PE)
to give aldol adduct 184 as a colourless oil (161 mg, 70%, 5:1 dr).
Rf 0.48 (1:4 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.37–7.24 (5H, m, PhH), 4.48 (1H,
d, J = 11.7 Hz, PhCHaHbO), 4.44 (1H, d, J = 11.7 Hz, PhCHaHbO), 4.03–3.95 (1H, m, H23),
3.64 (1H, app t, J = 8.9 Hz, H27a), 3.59 (2H, t, J = 6.6 Hz, H15 × 2), 3.46 (1H, dd, J = 8.6, 4.8
Hz, H27b), 3.17 (1H, dqd, J = 8.8, 7.2, 4.9 Hz, H26), 2.84 (1H, br s, C23OH), 2.74 (1H, qd, J =
7.0, 2.6 Hz, H24), 1.59–1.40 (4H, m, H16 × 2, H22 × 2),ArH 1.36–1.19 (10H, m, H17 – 21), 1.07
(3H, d, J = 7.1 Hz, Me26), 1.02 (3H, d, J = 6.9 Hz, Me24), 0.89 (9H, s, SiC(CH3)3), 0.05 (6H,
s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 218.2, 137.5, 128.4, 127.8, 127.7, 73.5, 73.2,
70.6, 63.3, 50.8, 44.9, 33.6, 32.9, 29.6, 29.5, 29.4, 26.1, 26.0, 25.8, 18.4, 13.6, 8.8, −5.3; [α]20D
−3.2 (c 0.99, CHCl3); IR (thin film) ν max (cm– 1) 3484, 2929, 2853, 1703, 1457, 1385, 1372,
1362, 1253, 1096, 1029, 1005, 989, 834, 815, 777, 733, 700, 664; HRMS calc. for C28H51O4Si









To a solution of TiCl4 (1.37 mL, 12.5 mmol) in CH2Cl2 (50 mL) at 0 °C was added Ti(Oi-Pr)4
(1.23 mL, 4.17 mmol). The mixture was stirred at 0 °C for 10 min, then at rt for 30 min. The
resulting colourless solution was added dropwise to a solution of ketone 25 (3.52 g, 14.9 mmol,
stirred over CaH2 immediately before use) in CH2Cl2 (150 mL) at −78 °C, during which the so-
lution gradually turned through yellow to light orange. Dropwise addition of i-Pr2NEt (2.85 mL,
16.4 mmol) caused a further colour change to dark red. The reaction mixture was stirred at
−78 °C for 30 min to allow full enolisation. Aldehyde 49 (4.46 g, 16.4 mmol, stirred over CaH2
immediately before use) in CH2Cl2 (100 mL) was then added via cannula down the side of the
reaction flask over 10 min. Shortly thereafter the solution was observed to return to a light orange
colour. The mixture was stirred at −78 °C for a further 40 min. Upon completion the reaction
was quenched with NaHCO3/Na+/K+ tartrate (1:1, 90 mL) and warmed to rt. The biphasic mix-
ture was stirred vigorously for 2 h and then left to stand overnight. The layers were separated
and the organic phase washed with brine (100 mL). The combined aqueous fractions were then
extracted with EtOAc (2 × 100 mL). The organics were dried over Na2SO4 and concentrated in
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vacuo. Purification by flash chromatography (1:10→ 1:5 EtOAc/PE) afforded aldol adduct 54
as a colourless oil (6.42 g, 85%, 18:1 dr).
Rf 0.26 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.18 (2H, d, J = 8.7 Hz, ArH), 6.85
(2H, d, J = 8.7 Hz, ArH), 4.39 (1H, d, J = 11.4 Hz, ArCHaHbO), 4.36 (1H, d, J = 11.5 Hz,
ArCHaHbO), 4.00–3.95 (1H, m, H23), 3.79 (3H, s, ArOMe), 3.61 (1H, app t, J = 8.7 Hz, H27a),
3.59 (2H, t, J = 6.7 Hz, H15 × 2), 3.42 (1H, dd, J = 8.7, 4.7 Hz, H27b), 3.15 (1H, dqd, J = 9.3,
6.9, 4.9 Hz, H26), 2.88 (1H, d, J = 3.9 Hz, C23OH), 2.72 (1H, qd, J = 7.1, 2.7 Hz, H24), 1.50 (2H,
app quint, J = 6.8 Hz, H16 × 2), 1.47–1.34 (2H, m, H22 × 2), 1.34–1.18 (10H, m, H17 – 21), 1.05
(3H, d, J = 7.1 Hz, Me24), 1.00 (3H, d, J = 6.9 Hz, Me26), 0.89 (9H, s, SiC(CH3)3), 0.04 (6H, s,
Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 218.1, 159.3, 129.6, 129.3, 113.8, 73.1, 72.9, 70.6,
63.3, 55.2, 50.9, 44.8, 33.6, 32.9, 29.6, 29.6, 29.4, 26.2, 25.9, 25.8, 18.3, 13.6, 8.8, −5.3; [α]20D
−2.0 (c 0.10, CHCl3); IR (thin film) ν max (cm– 1) 3500, 2929, 2853, 1709, 1615, 1514, 1461,
















Alcohol 55 (19 mg, 48 μmol) was dissolved in THF (1 mL) and cooled to 0 °C. Imidazole (4 mg,
58 μmol) and TBSCl (11 mg, 72 μmol) were added, and the mixture was stirred at rt for 16 h. The
reaction was quenched with H2O (2 mL), diluted with Et2O, and the aqueous layer extracted with
Et2O (3 × 2 mL). The combined organics were washed with H2O (4 mL), dried over MgSO4,
and concentrated in vacuo. Purification by flash chromatography (1:5 EtOAc/PE) yielded TBS
ether 54 as a colourless oil (24 mg, 98%).
















To alcohol 56 (202 mg, 520 μmol) in CH2Cl2 (5 mL) at 0 °C was added PMBTCA (120 μL,
578 μmol) and PPTS (14 mg, 56 μmol). The mixture was warmed to rt and stirred for 21 h.
Upon completion, the reaction was quenched by addition of NaHCO3 (5 mL). The layers were
separated and the aqueous extracted with CH2Cl2 (3 × 5 mL). The combined organics were dried
over Na2SO4 and concentrated in vacuo, then purified by flash chromatography (1:3 EtOAc/PE)
to give PMB ether 54 as a colourless oil (169 mg, 64%).
All characterisation data matched those given above for 54.

























To a solution of alcohol 54 (10.1 mg, 19.8 μmol) and (S)-α-methoxy-α-trifluoromethylphenylacetic
acid (13.9 mg, 59.4 μmol) in CH2Cl2 (1 mL) was added DCC (60 μL, 1.0 M in CH2Cl2,
60.0 μmol) followed by DMAP (8.4 mg, 68.8 μmol). The reaction was stirred at rt for 19 h,
then filtered and concentrated. Flash chromatography (1:30 → 1:20 EtOAc/PE) gave the (S)-
MTPA ester 57 as a colourless oil (10.6 mg, 74%).
Rf 0.65 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.58–7.53 (2H, m, PhH), 7.40–7.36
(3H, m, PhH), 7.19 (2H, d, J = 8.6 Hz, PMB ArH), 6.85 (2H, d, J = 8.7 Hz, PMB ArH), 5.44
(1H, app dt, J = 7.6, 5.2 Hz, H23), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.33 (1H, d, J = 11.6
Hz, ArCHaHbO), 3.79 (3H, s, ArOMe), 3.59 (2H, t, J = 6.7 Hz, H15 × 2), 3.56 (1H, dd, J = 8.9,
8.2 Hz, H27a), 3.52 (3H, s, OMe), 3.39 (1H, dd, J = 9.0, 5.4 Hz, H27b), 3.08–2.99 (1H, m, H26),
2.93 (1H, dq, J = 7.1, 6.7 Hz, H24), 1.60–1.53 (1H, m, H22a), 1.53–1.43 (3H, m, H16 × 2,H22b),
1.31–1.10 (10H, m, H17 – 21), 1.09 (3H, d, J = 7.2 Hz, Me24), 1.03 (3H, d, J = 7.0 Hz, Me26),
0.89 (9H, s, SiC(CH3)3), 0.05 (6H, s, Si(CH3)2).
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The analogous procedure gave the (R)-MTPA ester 58 in 47% yield.
Rf 0.65 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.59–7.52 (2H, m, PhH), 7.41–7.35
(3H, m, PhH), 7.19 (2H, d, J = 8.7 Hz, PMB ArH), 6.85 (2H, d, J = 8.7 Hz, PMB ArH), 5.42
(1H, app q, J = 6.1 Hz, H23), 4.38 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.34 (1H, d, J = 11.6
Hz, ArCHaHbO), 3.79 (3H, s, ArOMe), 3.58 (2H, t, J = 6.7 Hz, H15 × 2), 3.56–3.51 (4H, m,
OMe, H27a), 3.36 (1H, dd, J = 9.0, 5.4 Hz, H27b), 3.00–2.92 (1H, m, H26), 2.90 (1H, dq, J = 7.3,
6.9 Hz, H24), 1.62–1.52 (2H, m, H22 × 2), 1.48 (2H, app quint, J = 7.1 Hz, H16 × 2), 1.31–1.12
(10H, m, H17 – 21), 1.02 (3H, d, J = 7.2 Hz, Me24), 0.97 (3H, d, J = 7.0 Hz, Me26), 0.89 (9H, s,










Freshly prepared SmI2 (18.7 mL, ca. 0.1 M in THF, 1.87 mmol) was added dropwise to a so-
lution of propionaldehyde (8.1 mL, 112 mmol, distilled from CaCl2 immediately prior to use)
in THF (120 mL) at 0 °C. The blue-green colour of SmI2 faded upon addition to give a golden
yellow solution, which was stirred at 0 °C for 15 min then cooled to −20 °C. Ketone 54 (9.34 g,
18.3 mmol) was dissolved in THF (70 mL) and added to the reaction mixture via cannula. The
reaction was kept at −20 °C for 1 h, then quenched with NaHCO3 (100 mL) and warmed to rt.
The aqueous fraction was extracted with Et2O (3 × 100 mL). The combined organics were dried
over Na2SO4, concentrated in vacuo, and purified by flash chromatography (1:15 EtOAc/PE) to
give alcohol 59 as a pale yellow oil (9.91 g, 95%, >20:1 dr).
Rf 0.48 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.6 Hz, ArH), 6.87
(2H, d, J = 8.6 Hz, ArH), 5.27 (1H, ddd, J = 8.7, 5.0, 1.5 Hz, H23), 4.43 (1H, d, J = 11.6 Hz,
ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe), 3.59 (2H, t, J = 6.6
Hz, H15 × 2), 3.55 (1H, dd, J = 9.2, 5.1 Hz, H27a), 3.43 (1H, dd, J = 9.2, 5.8 Hz, H27b), 3.35 (1H,
d, J = 5.7 Hz, C25OH), 3.10 (1H, ddd, J = 8.9, 5.7, 3.5 Hz, H25), 2.33 (2H, q, J = 7.6 Hz, H2 ′ × 2),
2.05–1.98 (1H, m, H26), 1.76 (1H, dqd, J = 8.5, 6.9, 1.3 Hz, H24), 1.72–1.63 (1H, m, H22a), 1.50
(2H, app quint, J = 6.9 Hz, H16 × 2), 1.45–1.36 (1H, m, H22b), 1.34–1.20 (10H, m, H17 – 21), 1.14
(3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J = 7.0 Hz, Me26), 0.89 (9H, s, SiC(CH3)3), 0.87 (3H,
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d, J = 6.9 Hz, Me24), 0.04 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 175.3, 159.1,
130.4, 129.1, 113.7, 76.3, 73.7, 72.9, 71.7, 63.3, 55.2, 40.2, 34.7, 32.8, 32.6, 29.5, 29.4, 29.3,
27.8, 26.0, 26.0, 25.7, 18.3, 16.3, 10.1, 9.3, −5.3; [α]20D −3.5 (c 1.00, CHCl3); IR (thin film) ν
max (cm– 1) 3504, 2929, 2849, 1728, 1711, 1617, 1514, 1463, 1364, 1247, 1203, 1096, 1039,










Proton Sponge (9.30 g, 43.4 mmol) and Me3O ·BF4 (4.28 g, 28.9 mmol) were charged to a
flask in an argon-filled glove box, then a solution of alcohol 59 (8.17 g, 14.4 mmol) in CH2Cl2
(300 mL) was added at rt. The reaction was stirred for 3 h, during which time it gradually turned
yellow, then bright orange. The mixture was then quenched by addition of NH4Cl (150 mL)
and stirred overnight. The aqueous layer was extracted with CH2Cl2 (3 × 100 mL), then the
combined organics were washed with citric acid (2 × 200 mL, 10% w/v aq.), dried over MgSO4,
and concentrated in vacuo. Purification by flash chromatography (1:20 EtOAc/PE) provided the
methyl ether 61 as a colourless oil (7.42 g, 89%, 99% brsm).
Rf 0.48 (1:8 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.7 Hz, ArH), 6.86
(2H, d, J = 8.7 Hz, ArH), 5.18 (1H, app td, J = 7.4, 2.0 Hz, H23), 4.43 (1H, d, J = 11.5 Hz,
ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe), 3.59 (2H, t, J = 6.7
Hz, H15 × 2), 3.53 (1H, dd, J = 9.2, 4.9 Hz, H27a), 3.38 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.1,
7.3 Hz, H27b), 2.87 (1H, dd, J = 8.5, 3.6 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.12–2.04
(1H, m, H26), 1.78 (1H, dqd, J = 8.9, 7.0, 2.0 Hz, H24), 1.66–1.58 (1H, m, H22a), 1.49 (2H, app
quint, J = 7.0 Hz, H16 × 2), 1.46–1.39 (1H, m, H22b), 1.33–1.19 (10H, m, H17 – 21), 1.14 (3H, t, J
= 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J = 7.1 Hz, Me26), 0.92–0.88 (12H, m, Me24, SiC(CH3)3), 0.04
(6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 174.1, 159.0, 130.8, 129.0, 113.7, 85.9,
73.2, 72.7, 71.6, 63.3, 61.3, 55.2, 38.8, 35.9, 32.9, 32.7, 29.5, 29.5, 29.4, 28.0, 26.0, 25.8, 25.7,
18.4, 16.3, 10.6, 9.4, −5.3; [α]20D −4.4 (c 0.79, CHCl3); IR (thin film) ν max (cm
– 1) 2932, 2858,
1732, 1614, 1513, 1463, 1247, 1193, 1090, 1038, 834, 776; HRMS calc. for C33H64NO6Si











TBS ether 61 (2.03 g, 3.49 mmol) was dissolved in THF (50 mL) and cooled to 0 °C. HCl
(30 mL, 1.0 M aq.) was added, then the reaction was stirred at rt. After 1 h the reaction was
quenched by careful addition of NaHCO3 (80 mL) with cooling in an ice bath. The resulting
mixture was then diluted with H2O (100 mL) and Et2O (50 mL) and extracted with Et2O (3 ×
100 mL). The combined organics were dried over Na2SO4, concentrated in vacuo, and purified
by flash chromatography (1:3 EtOAc/PE) to give alcohol 62 as a colourless oil (1.62 g, 99%).
Rf 0.15 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.5 Hz, ArH), 6.86
(2H, d, J = 8.5 Hz, ArH), 5.18 (1H, app td, J = 7.0, 1.6 Hz, H23), 4.42 (1H, d, J = 11.6 Hz,
ArCHaHbO), 4.39 (1H, d, J = 11.5 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe), 3.62 (2H, t, J = 6.6
Hz, H15 × 2), 3.53 (1H, dd, J = 9.2, 4.8 Hz, H27a), 3.37 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.0,
7.4 Hz, H27b), 2.86 (1H, dd, J = 8.5, 3.5 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.12–2.04
(1H, m, H26), 1.78 (1H, dqd, J = 8.6, 7.1, 1.6 Hz, H24), 1.69–1.59 (1H, m, H22a), 1.55 (2H, app
quint, J = 6.9 Hz, H16 × 2), 1.47–1.39 (1H, m, H22b), 1.39–1.19 (10H, m, H17 – 21), 1.14 (3H, t,
J = 7.6 Hz, H3 ′ × 3), 1.05 (3H, d, J = 7.0 Hz, Me26), 0.90 (3H, d, J = 7.0 Hz, Me24); 13C NMR
(125 MHz, CDCl3) δC 174.1, 159.0, 130.8, 129.0, 113.7, 85.9, 73.1, 72.7, 71.6, 63.0, 61.4, 55.2,
38.8, 35.9, 32.7, 32.7, 29.4, 29.3, 29.2, 28.0, 25.6, 25.6, 16.3, 10.6, 9.4; [α]20D −8.0 (c 0.10,
CHCl3); IR (thin film) ν max (cm– 1) 3452, 2972, 2933, 2857, 1730, 1613, 1588, 1514, 1463,













To a solution of alcohol 62 (38.5 mg, 82.5 μmol) in CH2Cl2 (1.5 mL) was added NaHCO3
(47.5 mg, 565 μmol). The mixture was cooled in an ice bath, and DMP (71.4 mg, 168 μmol)
was added in one portion. The reaction was stirred at room temperature for 1 h, then quenched
with NaHCO3 (0.3 mL) and NaS2O3 (0.8 mL) and stirred for 1 h. The layers were separated and
the aqueous extracted with CH2Cl2 (3 × 1 mL). The combined organics were dried over MgSO4
and concentrated in vacuo, then purified by flash chromatography (1:5→ 1:4 EtOAc/PE) to give
aldehyde 29 as a colourless oil (38.5 mg, 100%).
Swern method:
Oxalyl chloride (381 μL, 4.50 mmol) and CH2Cl2 (40 mL) were charged to a flask and cooled
to −78 °C. DMSO (426 μL, 6.00 mmol) was added dropwise, and the mixture was stirred for
30 min. A solution of alcohol 62 (1.41 g, 3.03 mmol) in CH2Cl2 (20 mL) was added and stirring
continued for 20 min. After addition of Et3N (1.25 mL, 9.00 mmol), the reaction was warmed
to rt and stirred for 1.5 h. Addition of NH4Cl (60 mL) to quench was followed by extraction
with Et2O (3 × 50 mL). The combined organics were washed with HCl (100 mL, 0.5 M aq.),
brine (100 mL), and NaHCO3(100 mL), then dried over MgSO4 and concentrated in vacuo. The
product could be used crude or purified by flash chromatography (1:8 EtOAc/PE) to yield the
aldehyde 29 as a colourless oil (1.32 g, 94%).
Rf 0.45 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 9.75 (1H, t, J = 1.8 Hz, H15), 7.24 (2H,
d, J = 8.6 Hz, ArH), 6.86 (2H, d, J = 8.7 Hz, ArH), 5.17 (1H, app td, J = 7.0, 1.9 Hz, H23), 4.43
(1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe),
3.53 (1H, dd, J = 9.2, 4.9 Hz, H27a), 3.38 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.1, 7.4 Hz, H27b),
2.86 (1H, dd, J = 8.5, 3.5 Hz, H25), 2.40 (2H, td, J = 7.4, 1.8 Hz, H16 × 2), 2.31 (2H, q, J = 7.6
Hz, H2 ′ × 2), 2.12–2.04 (1H, m, H26), 1.78 (1H, dqd, J = 8.9, 7.0, 1.9 Hz, H24), 1.66–1.58 (3H,
m, H17 × 2, H22a), 1.47–1.38 (1H, m, H22b), 1.33–1.20 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz,
H3 ′ × 3), 1.05 (3H, d, J = 7.0 Hz, Me26), 0.90 (3H, d, J = 7.0 Hz, Me24); 13C NMR (125 MHz,
CDCl3) δC 202.9, 174.1, 159.0, 130.8, 129.0, 113.7, 85.9, 73.1, 72.7, 71.6, 61.4, 55.3, 43.9,
38.8, 35.9, 32.7, 29.3, 29.2, 29.0, 28.0, 25.6, 22.0, 16.3, 10.6, 9.4; [α]20D −5.6 (c 0.65, CHCl3);
IR (thin film) ν max (cm– 1) 2936, 2858, 1726, 1614, 1511, 1461, 1364, 1247, 1195, 1088, 1038,
822; HRMS calc. for C27H48O6N [M+NH4]+ 482.3476, found 482.3471.
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Method A: Tin aldol
Sn(OTf)2 (459 mg, 1.10 mmol) was washed with Et2O (3 × 3 mL), then dried under vacuum
and dissolved in CH2Cl2 (1 mL) and cooled to −78 °C. Et3N (165 μL, 1.18 mmol) was added,
followed by a pre-cooled solution of ketone 25 (203 mg, 0.859 mmol, dried azeotropically from
C6H6 and stirred over CaH2 immediately prior to use) in CH2Cl2 (1.25 mL) at −78 °C. The
reaction mixture was allowed to enolise at −78 °C for 3 h. Acetaldehyde (140 μL, 2.49 mmol,
distilled from CaCl2 immediately prior to use) was dissolved in CH2Cl2 (1 mL) and added to
the reaction mixture. After stirring for 3.5 h at −78 °C, the reaction was quenched by addition
of pH 7 buffer (3 mL) and warmed to rt. Na+/K+ tartrate (3 mL) was added, and the biphasic
mixture was stirred vigorously overnight. It was then filtered through Celite and diluted with
CH2Cl2. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL), and the combined organics
were washed with brine (15 mL), dried over Na2SO4, and concentrated in vacuo. Purification
by flash chromatography (1:2 EtOAc/PE) gave aldol adduct 63 as a colourless oil (71 mg, 30%,
3.5:1 dr).
Method B: Titanium aldol
To a solution of TiCl4 (218 μL, 1.99 mmol) in CH2Cl2 (5.6 mL) at 0 °C was added Ti(Oi-Pr)4
(196 μL, 0.66 mmol). The mixture was stirred at 0 °C for 10 min, then at rt for 20 min. The
resulting colourless solution was added to a solution of 25 (562 mg, 2.38 mmol, dried azeotropi-
cally from C6H6 and stirred over CaH2 immediately prior to use) in CH2Cl2 (13 mL) at −78 °C.
Upon dropwise addition of i-Pr2NEt (450 μL, 2.58 mmol), the yellow solution changed colour
to dark red. The reaction mixture was allowed to enolise at −78 °C for 30 min. Acetaldehyde
(1.00 mL, 17.8 mmol, distilled from CaCl2 immediately prior to use) was dissolved in CH2Cl2
(10 mL) and added to the reaction mixture slowly via syringe, causing a colour change to light
orange. The mixture was stirred at −78 °C for a further 45 min, then quenched with MeOH
(8 mL). After warming to rt, Na+/K+ tartrate (20 mL) was added and the biphasic mixture was
stirred rapidly for 30 min and left to stand overnight. The layers were separated and the organic
phase washed with H2O (25 mL). The aqueous fractions were then extracted with CH2Cl2 (2 ×
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25 mL). The combined organics were dried over Na2SO4, concentrated in vacuo and purified by
flash chromatography (1:2 EtOAc/PE) to give aldol adduct 63 as a colourless oil (545 mg, 82%,
14:1 dr).
Rf 0.18 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.19 (2H, d, J = 8.7 Hz, ArH), 6.87
(2H, d, J = 8.7 Hz, ArH), 4.41 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.36 (1H, d, J = 11.5 Hz,
ArCHaHbO), 4.18 (1H, qdd, J = 6.5, 4.2, 3.2 Hz, H29), 3.80 (3H, s, ArOMe), 3.61 (1H, app t,
J = 9.0 Hz, H33a), 3.42 (1H, dd, J = 8.7, 4.8 Hz, H33b), 3.15 (1H, dqd, J = 9.2, 6.9, 4.8 Hz,
H32), 2.93 (1H, d, J = 4.2 Hz, C29OH), 2.73 (1H, qd, J = 7.1, 3.1 Hz, H30), 1.12 (3H, d, J =
6.5 Hz, H28 × 3), 1.08 (3H, d, J = 7.2 Hz, Me30), 1.00 (3H, d, J = 7.0 Hz, Me32); [α]20D +14.0
(c 0.10, CHCl3); IR (thin film) ν max (cm– 1) 3460, 2972, 2937, 1707, 1611, 1586, 1512, 1459,
1372, 1300, 1247, 1173, 1092, 1033, 997, 910, 820; HRMS calc. for C16H28NO4 [M+NH4]+
298.2013, found 298.2015.







To a solution of TiCl4 (1.19 mL, 10.9 mmol) in CH2Cl2 (30 mL) at 0 °C was added Ti(Oi-Pr)4
(1.07 mL, 3.63 mmol). The mixture was stirred at 0 °C for 10 min, then at rt for 20 min. The
resulting colourless solution was added dropwise over 20 min to a solution of ketone 24 (2.86 g,
12.1 mmol, dried azeotropically from C6H6 and stirred over CaH2 immediately prior to use) in
CH2Cl2 (65 mL) at −78 °C. To the yellow solution was added i-Pr2NEt (2.48 mL, 14.2 mmol)
dropwise over 15 min, and the reaction mixture was allowed to enolise at −78 °C for 30 min.
Acetaldehyde (6.20 mL, 110 mmol, distilled from CaCl2 immediately prior to use) was dissolved
in CH2Cl2 (70 mL) and added to the reaction mixture via syringe over 20 min, causing the deep
red solution to gradually turn pale orange. The mixture was stirred at −78 °C for a further
15 min, then quenched with MeOH (30 mL). After warming to rt, Na+/K+ tartrate (110 mL)
was added and the biphasic mixture was stirred vigorously overnight. The layers were separated
and aqueous phase extracted with CH2Cl2 (3 × 70 mL). The combined organics were dried over
Na2SO4, concentrated in vacuo and purified by flash chromatography (1:2 EtOAc/PE) to give
aldol adduct 69 as a colourless oil (2.85 g, 84%, 16:1 dr).
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Rf 0.24 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.19 (2H, d, J = 8.7 Hz, ArH), 6.87
(2H, d, J = 8.7 Hz, ArH), 4.41 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.36 (1H, d, J = 11.5 Hz,
ArCHaHbO), 4.18 (1H, qdd, J = 6.5, 4.2, 3.2 Hz, H29), 3.80 (3H, s, ArOMe), 3.61 (1H, app t, J
= 9.0 Hz, H33a), 3.42 (1H, dd, J = 8.7, 4.8 Hz, H33b), 3.15 (1H, dqd, J = 9.2, 6.9, 4.8 Hz, H32),
2.93 (1H, d, J = 4.2 Hz, C29OH), 2.73 (1H, qd, J = 7.1, 3.1 Hz, H30), 1.12 (3H, d, J = 6.5 Hz,
H28 × 3), 1.08 (3H, d, J = 7.2 Hz, Me30), 1.00 (3H, d, J = 7.0 Hz, Me32); [α]20D −12.6 (c 1.02,
CHCl3).









Freshly prepared SmI2 (1.02 mL, ca. 0.1 M in THF, 0.102 mmol) was added dropwise to a
solution of propionaldehyde (0.22 mL, 3.06 mmol, distilled from CaCl2 immediately prior to
use) in THF (1.5 mL) at 0 °C. The blue-green colour of SmI2 faded upon addition to give a
murky yellow solution, which was stirred at 0 °C for 10 min then cooled to −20 °C. Ketone 63
(143 mg, 0.510 mmol, 14:1 dr) was dissolved in THF (2.5 mL) and added to the reaction mixture
via cannula, causing a colour change to bright yellow. The reaction was stirred at −20 °C for 1 h
15 min, then quenched with NaHCO3 (5 mL) and warmed to rt. The aqueous layer was extracted
with EtOAc (2 × 5 mL), and the combined organics were washed with brine (10 mL), dried over
Na2SO4, and concentrated in vacuo. Purification by flash chromatography (1:5 EtOAc/PE) gave
alcohol ent-71 as a pale yellow oil (146 mg, 84%, 14:1 dr).
Rf 0.43 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.6 Hz, ArH), 6.87
(2H, d, J = 8.6 Hz, ArH), 5.40 (1H, qd, J = 6.6, 2.0 Hz, H29), 4.43 (1H, d, J = 11.7 Hz,
ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe), 3.52 (1H, dd, J =
9.3, 4.8 Hz, H33a), 3.49 (1H, dd, J = 9.3, 5.1 Hz, H33b), 3.21–3.15 (2H, m, H31, C31OH), 2.30
(2H, q, J = 7.6 Hz, H2 ′ × 2), 2.02–1.94 (1H, m, H32), 1.69–1.61 (1H, m, H30), 1.23 (3H, d, J =
6.6 Hz, H28 × 3), 1.12 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.08 (3H, d, J = 7.1 Hz, Me32), 0.89 (3H, d, J
= 7.0 Hz, Me30); [α]20D −1.9 (c 1.00, CHCl3).










To a solution of propionaldehyde (4.50 mL, 62.1 mmol, freshly distilled from CaCl2 immediately
before use) in THF (60 mL) at 0 °C was added freshly prepared SmI2 (10.3 mL, ca. 0.1 M in
THF, 1.03 mmol) dropwise over 15 min. The resulting golden yellow solution was cooled to
−20 °C and ketone 69 (2.88 g, 10.3 mmol) was added dropwise in THF (30 mL). After 1 h
the reaction was quenched by addition of NaHCO3 (80 mL). The layers were separated and the
aqueous was extracted with Et2O (3 × 70 mL). The combined organics were washed with brine
(50 mL), dried over Na2SO4, and concentrated in vacuo. Flash chromatography (1:5 EtOAc/PE)
yielded alcohol 71 (3.40 g, 98%) as a pale yellow oil.
Rf 0.39 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.7 Hz, ArH), 6.87
(2H, d, J = 8.7 Hz, ArH), 5.40 (1H, qd, J = 6.5, 2.0 Hz, H29), 4.43 (1H, d, J = 11.6 Hz,
ArCHaHbO), 4.39 (1H, d, J = 11.7 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe), 3.52 (1H, dd, J =
9.3, 4.8 Hz, H33a), 3.49 (1H, dd, J = 9.3, 5.1 Hz, H33b), 3.21–3.15 (2H, m, H31, C31OH), 2.30
(2H, q, J = 7.4 Hz, H2 ′ × 2), 2.02–1.94 (1H, m, H32), 1.70–1.60 (1H, m, H30), 1.22 (3H, d, J =
6.6 Hz, H28 × 3), 1.12 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.08 (3H, d, J = 7.1 Hz, Me32), 0.89 (3H, d,
J = 6.9 Hz, Me30); 13C NMR (125 MHz, CDCl3) δC 174.6, 159.2, 130.3, 129.2, 113.8, 76.6,
73.0, 71.8, 70.0, 55.3, 41.6, 34.7, 27.9, 18.2, 16.2, 10.2, 9.2; [α]20D +2.6 (c 1.81, CHCl3); IR
(thin film) ν max (cm– 1) 3508, 2976, 2937, 2905, 2878, 1730, 1613, 1512, 1463, 1370, 1300,
1276, 1249, 1203, 1174, 1082, 1035, 1007, 983, 819; HRMS calc. for C19H30O5Na [M+Na]+
361.1985, found 361.1987.











To alcohol 71 (3.77 g, 11.1 mmol) in CH2Cl2 (110 mL) at −78 °C were added dropwise sequen-
tially 2,6-lutidine (3.90 mL, 33.5 mmol) and TESOTf (3.80 mL, 16.8 mmol). After stirring for
1.5 h at −78 °C, the reaction was quenched with NH4Cl (90 mL) and allowed to warm to rt. The
aqueous layer was extracted with EtOAc (3 × 70 mL), dried over MgSO4, and concentrated in
vacuo. Purification by flash chromatography (1:20 EtOAc/PE) gave silyl ether 72 as a colourless
oil (4.73 g, 94%).
Rf 0.53 (1:8 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.25 (2H, d, J = 8.7 Hz, ArH), 6.87
(2H, d, J = 8.7 Hz, ArH), 5.06 (1H, qd, J = 6.3, 3.3 Hz, H29), 4.41 (2H, s, OCH2Ar), 3.56 (1H,
dd, J = 9.5, 4.9 Hz, H33a), 3.54 (1H, dd, J = 7.6, 3.2 Hz, H31), 3.25 (1H, dd, J = 9.1, 8.0 Hz,
H33b), 2.28 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.07–1.99 (1H, m, H32), 1.67 (1H, dqd, J = 7.1, 7.1, 3.3
Hz, H30), 1.21 (3H, d, J = 6.5 Hz, H28 × 3), 1.12 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.01 (3H, d, J = 7.0
Hz, Me32), 0.93 (9H, obs t, J = 8.0 Hz, Si(CH2CH3)3), 0.92 (3H, obs d, J = 8.3 Hz, Me30), 0.59
(6H, q, J = 8.0 Hz, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC 173.9, 159.0, 130.8, 129.0,
113.6, 76.8, 72.6, 71.6, 70.6, 55.2, 42.7, 36.6, 28.0, 18.7, 16.0, 10.7, 9.1, 7.0, 5.3; [α]20D +2.60
(c 1.00, CHCl3); IR (thin film) ν max (cm– 1) 2955, 2913, 2877, 1733, 1613, 1587, 1513, 1462,
1423, 1373, 1302, 1247, 1194, 1171, 1094, 1040, 1010, 821, 738; HRMS calc. for C25H45O5Si
[M+H]+ 453.3031, found 453.3024.









To a flask containing Me3O ·BF4 (4.80 g, 32.5 mmol) and Proton Sponge (6.97 g, 32.5 mmol)
was added a solution of alcohol 71 (2.20 g, 6.5 mmol) in CH2Cl2 (110 mL). The reaction was
stirred at rt for 4 h, then quenched with NH4Cl (90 mL) and stirred for a further 30 min. The
biphasic mixture was filtered through Celite, then the layers were separated and the aqueous
extracted with EtOAc (3 × 70 mL). The organics were dried over MgSO4 and concentrated in
vacuo. Flash chromatography (1:12 EtOAc/PE) gave the methyl ether 73 as a pale yellow oil
(2.06 g, 90%, 94% brsm). The byproduct 74 was also isolated as a bright pink oil (33 mg, 2.3%).
Rf 0.59 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.23 (2H, d, J = 8.8 Hz, ArH), 6.85
(2H, d, J = 8.8 Hz, ArH), 5.22 (1H, qd, J = 6.5, 2.4 Hz, H29), 4.41 (1H, d, J = 11.2 Hz,
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ArCHaHbO), 4.38 (1H, d, J = 11.8 Hz, ArCHaHbO), 3.78 (3H, s, ArOMe), 3.53 (1H, dd, J =
9.2, 5.0 Hz, H33a), 3.35 (3H, s, C31OMe), 3.29 (1H, dd, J = 9.2, 7.6 Hz, H33b), 2.88 (1H, dd, J
= 8.9, 3.3 Hz, H31), 2.29 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.11–2.03 (1H, m, H32), 1.69 (1H, dqd,
J = 9.3, 7.0, 2.3 Hz, H30), 1.20 (3H, d, J = 6.6 Hz, H28 × 3), 1.13 (3H, t, J = 7.6 Hz, H3 ′ × 3),
1.06 (3H, d, J = 7.1 Hz, Me32), 0.92 (3H, d, J = 7.1 Hz, Me30); 13C NMR (125 MHz, CDCl3)
δC 173.8, 158.9, 130.7, 128.9, 113.6, 85.9, 72.6, 71.3, 69.6, 61.3, 55.1, 40.8, 35.8, 27.9, 18.2,
16.2, 10.3, 9.2; [α]20D +2.3 (c 0.98, CHCl3); IR (thin film) ν max (cm
– 1) 2974, 2937, 1731, 1613,
1513, 1462, 1367, 1302, 1246, 1195, 1172, 1083, 1036, 1011, 819; HRMS calc. for C20H36O5N









Diol 74 was isolated as a byproduct from the methylation of 71 (vide supra).
Rf 0.23 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 5.38 (1H, qd, J = 6.6, 1.8 Hz, H29),
3.83 (1H, ddd, J = 11.0, 2.8, 2.8 Hz, H33a), 3.71 (1H, d, J = 5.2 Hz, C31OH), 3.56 (1H, ddd, J
= 11.1, 6.4, 4.8 Hz, H33b), 3.19 (1H, ddd, J = 8.9, 4.8, 4.0 Hz, H31), 3.05 (1H, br s, C33OH),
2.32 (2H, q, J = 7.6 Hz, H2 ′ × 2), 1.84–1.73 (2H, m, H30, H32), 1.25 (3H, d, J = 6.5 Hz, H28 × 3),
1.12 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.09 (3H, d, J = 7.1 Hz, Me32), 0.88 (3H, d, J = 7.1 Hz,
Me30); 13C NMR (125 MHz, CDCl3) δC 175.2, 77.9, 70.1, 64.7, 41.6, 35.4, 27.8, 18.2, 15.6,
9.9, 9.2; [α]20D +3.0 (c 1.02, CHCl3); IR (thin film) ν max (cm
– 1) 3388, 2976, 2941, 2881, 1712,
1462, 1426, 1377, 1346, 1325, 1280, 1208, 1161, 1076, 1029, 1012, 976; HRMS calc. for









To a biphasic mixture containing PMB ether 73 (1.00 g, 2.84 mmol) in CH2Cl2 (30 mL) and
pH 7 buffer (15 mL) at 0 °C was added DDQ (1.29 g, 5.68 mmol) in one portion. The reaction
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was warmed to rt and stirred rapidly for 1 h, during which time a colour change from dark
green to bright red was observed. NaHCO3 (20 mL) and H2O (20 mL) were added to quench the
reaction, and the quenching mixture was stirred vigorously for 30 min. The layers were separated
and the organic layer was washed with brine (30 mL). The combined aqueous fractions were then
extracted with EtOAc (2 × 100 mL). The organics were dried over Na2SO4 and concentrated in
vacuo. Flash chromatography (1:2 EtOAc/PE) allowed the isolation of alcohol 185 as a yellow
oil (611 mg, 93%).
Rf 0.32 (1:2 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 5.22 (1H, qd, J = 6.4, 2.5 Hz, H29),
3.78 (1H, dd, J = 11.1, 3.7 Hz, H33a), 3.53 (1H, dd, J = 11.1, 4.5 Hz, H33b), 3.40 (3H, s,
C31OMe), 2.96 (1H, dd, J = 8.9, 3.3 Hz, H31), 2.67 (1H, br s, C33OH), 2.30 (2H, q, J = 7.6 Hz,
H2 ′ × 2), 1.91–1.83 (1H, m, H32) 1.76 (1H, dqd, J = 9.5, 7.0, 2.6 Hz, H30), 1.22 (3H, d, J = 6.5
Hz, H28 × 3), 1.13 (3H, d, J = 7.2 Hz, Me32), 1.12 (3H, t, J = 7.7 Hz, H3 ′ × 3), 0.90 (3H, d, J =
7.1 Hz, Me30); 13C NMR (125 MHz, CDCl3) δC 173.9, 88.6, 69.6, 64.5, 61.7, 41.3, 36.0, 28.0,
18.3, 16.0, 10.3, 9.2; [α]20D −8.8 (c 1.00, CHCl3); IR (thin film) ν max (cm
– 1) 3425, 2977, 2938,
2881, 2829, 1731, 1462, 1376, 1276, 1194, 1158, 1123, 1083, 1032, 966, 936, 870, 807; HRMS







Ester 185 (600 mg, 2.58 mmol) was dissolved in CH2Cl2 (26 mL) and cooled to −78 °C. DIBAL
(10.5 mL, 10.5 mmol, 1.0 M in hexane) was added cautiously, and the reaction was stirred at
−78 °C for 45 min. The mixture was quenched with Na+/K+ tartrate (20 mL) and H2O (20 mL)
and stirred at rt for 2 h. The aqueous layer was then extracted with CH2Cl2 (4 × 40 mL),
and the combined organics dried over Na2SO4 and concentrated in vacuo. Purification by flash
chromatography (1:1 EtOAc/PE) gave diol 75 as a colourless oil (431 mg, 95%).
Rf 0.20 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 4.16 (1H, qd, J = 6.5, 1.6 Hz, H29),
3.68 (1H, dd, J = 10.8, 4.4 Hz, H33a), 3.64 (1H, dd, J = 10.8, 4.9 Hz, H33b), 3.52 (3H, s,
C31OMe), 3.16 (1H, dd, J = 7.6, 4.3 Hz, H31), 3.07 (1H, br s, C29OH), 2.54 (1H, br s, C33OH),
1.99–1.91 (1H, m, H32), 1.65 (1H, dqd, J = 7.1, 4.3, 1.7 Hz, H30), 1.13 (3H, d, J = 6.5 Hz,
H28 × 3), 1.00 (3H, d, J = 7.3 Hz, Me30), 0.94 (3H, d, J = 7.1 Hz, Me32); 13C NMR (125 MHz,
CDCl3) δC 90.7, 66.5, 65.3, 61.9, 39.7, 37.6, 20.7, 14.9, 11.0; [α]20D +8.3 (c 1.00, CHCl3); IR
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(thin film) ν max (cm– 1) 3392, 2968, 2932, 2833, 1456, 1413, 1371, 1193, 1157, 1076, 1032,







Oxalyl chloride (52 μL, 0.615 mmol) was charged to a flask with CH2Cl2 (2.6 mL) and cooled
to −78 °C. DMSO (90 μL, 1.23 mmol) was added, and the solution was stirred for 15 min. A
solution of diol 75 (33.2 mg, 0.188 mmol) in CH2Cl2 (1.4 mL) was added dropwise. After a
further 15 min, Et3N (340 μL, 2.43 mmol) was added, and stirring was continued at −78 °C
for 30 min, then at −40 °C for 10 min. The reaction mixture was then quenched with NH4Cl
(3 mL), warmed to rt, and extracted with CH2Cl2 (3 × 3 mL). The combined organics were
washed sequentially with HCl (5 mL, 0.5 M), H2O (5 mL), NaHCO3 (5 mL), and brine (5 mL),
and then dried over MgSO4 and concentrated in vacuo to afford 76 as a pale yellow oil. The
crude material was carried through directly to the next step without further purification.
Rf 0.42 (1:2 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 9.76 (1H, d, J = 1.6 Hz, H33), 3.74
(1H, dd, J = 8.6, 3.5 Hz, H31), 3.36 (3H, s, C31OMe), 2.89 (1H, dq, J = 7.7, 7.2 Hz, H30), 2.69–








To a solution of HMDS (0.14 mL, 0.67 mmol) in THF (0.22 mL) was added n-BuLi (0.38 mL,
0.38 mmol, 1.6 M in hexane) dropwise at 0 °C. This mixture was stirred for 30 min to form
a 1.0 M solution of LiHMDS. Meanwhile, phosphonium salt 77 (115 mg, 0.311 mmol) was
suspended in THF (2 mL) and cooled to −78 °C. The LiHMDS solution (0.29 mL, 0.29 mmol)
was added, then the mixture was warmed to 0 °C, stirred for 30 min, and re-cooled to −78 °C.
Aldehyde 76 (ca 32 mg, crude material, ≤ 0.188 mmol) was stirred over CaH2 in THF (3 mL)
for 45 min, then was added via cannula to the ylid solution. The mixture was stirred at at −78 °C
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for 1 h, then quenched with NH4Cl (3 mL) and warmed to rt. The aqueous layer was extracted
with Et2O (3 × 5 mL) and the combined organics dried over MgSO4 and concentrated in vacuo.
Purification by flash chromatography (1:1 EtOAc/PE) gave the N-methyl-N-vinylformamide 78
as a colourless oil (9.2 mg, 21% from 75, 8:1 Z/E).
Rf 0.24 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.16 (0.87H, s, NCHO), [8.05] (0.13H,
s, NCHO*), [6.24] (0.13H, d, J = 9.4 Hz, H34*), 5.97 (0.87H, d, J = 8.7 Hz, H34), 5.32 (0.87H,
dd, J = 10.8, 8.7 Hz, H33), [5.27] (0.13H, dd, J = 10.3, 9.5 Hz, H33*), 3.37 (3H, s, C31OMe),
3.26 (1H, dd, J = 9.1, 3.0 Hz, H31), [3.15] (0.39H, s, NMe*), 3.00 (2.61H, s, NMe), 2.79–2.62
(2H, m, H30, H32), 2.19 (3H, s, Me28), 1.15 (3H, d, J = 6.9 Hz, Me32), [0.93] (0.39H, d, J = 7.0
Hz, Me30*), 0.90 (2.61H, d, J = 7.1 Hz, Me30).
Distinguishable resonances of the minor rotamer (ca 2:1 ratio) are given in brackets and marked
with an asterisk.







A crystal of I2 (3.3 mg, 0.013 mmol) was dissolved in CH2Cl2 (0.5 mL) under argon and added
to a solution of enamide 78 (9.0 mg, 0.039 mmol, 8:1 Z/E) in CH2Cl2 (2 mL) at rt. The reaction
was stirred in the dark for 68 h, then quenched by addition of Na2S2O3 (2.5 mL) and stirred for
30 min. The mixture was extracted with CH2Cl2 (3 × 3 mL), dried over MgSO4 and concentrated
in vacuo. Flash chromatography (1:1 EtOAc/PE) gave the isomeric enamide 32 as a colourless
oil (6.7 mg, 74%, >20:1 E/Z).
Rf 0.17 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.29 (0.67H, s, NCHO), [8.07] (0.33H,
s, NCHO*), [7.13] (0.33H, d, J = 14.7 Hz, H34*), 6.46 (0.67H, d, J = 14.2 Hz, H34), [5.13]
(0.33H, dd, J = 14.6, 9.3 Hz, H33*), 5.11 (0.67H, dd, J = 14.1, 9.1 Hz, H33), 3.38 (3H, s,
C31OMe), 3.29 (1H, dd, J = 9.2, 2.5 Hz, H31), [3.07] (1H, s, NMe*), 3.04 (2H, s, NMe), 2.76–
2.65 (1H, m, H30), [2.44] (0.33H, dqd, J = 9.3, 6.9, 2.4 Hz, H32*), 2.39 (0.67H, dqd, J = 9.3,
6.9, 2.5 Hz, H32), 2.20 (2H, s, Me28), [2.18] (1H, s, Me28*), 1.16 (3H, d, J = 7.0 Hz, Me32), 0.96
(2H, d, J = 6.9 Hz, Me30), [0.94] (1H, d, J = 6.7 Hz, Me30*).
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Distinguishable resonances of the minor rotamer (ca 2:1 ratio) are given in brackets and marked
with an asterisk.
These data are in agreement with those previously reported.129









PMB ether 86 (75.8 mg, 0.148 mmol) was dissolved in CH2Cl2 (2 mL) and pH 9.2 buffer
(0.5 mL) and stirred vigorously at 0 °C. After addition of DDQ (43.7 mg, 0.192 mmol), the
mixture was warmed to rt, stirred for 30 min, then quenched with NaHCO3 (2.5 mL) and H2O
(2 mL). The aqueous layer was extracted with CH2Cl2 (4 × 10 mL), and the combined organics
washed with brine (40 mL), dried over Na2SO4, and concentrated in vacuo. Purification by flash
chromatography (1:2 EtOAc/PE) gave alcohol 186 as a colourless oil (37.8 mg, 65%).
Rf 0.48 (1:1 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.35 (2H, d, J = 8.7 Hz, ArH), 7.26
(1H, dd, J = 15.4, 10.8 Hz, H3), 6.88 (2H, d, J = 8.7 Hz, ArH), 6.29 (1H, dd, J = 15.2, 10.9 Hz,
H4), 6.13 (1H, dt, J = 14.7, 7.3 Hz, H5), 5.83 (1H, d, J = 15.4 Hz, H2), 5.74 (1H, s, ArCHO2),
4.02 (1H, dd, J = 8.4, 6.8 Hz, H7), 3.96 (1H, dd, J = 10.0, 2.3 Hz, H9), 3.80 (3H, s, ArOMe), 3.74
(3H, s, CO2Me), 3.73–3.60 (2H, m, H11 × 2), 3.02 (1H, dd, J = 15.3, 7.6 Hz, H6a), 2.63–2.53
(2H, m, H6b, C11OH), 2.07–2.00 (1H, m, H10), 1.61–1.52 (1H, m, H8), 1.26 (3H, d, J = 7.0 Hz,
Me10), 0.82 (3H, d, J = 7.0 Hz, Me8).










To a solution of alcohol 186 (37.8 mg, 0.0968 mmol) in Et2O/MeCN (1:1, 3 mL) at 0 °C were
added PPh3 (100 mg, 0.383 mmol), imidazole (32.0 mg, 0.468 mmol), and iodine (99.7 mg,
0.392 mmol, portionwise). The reaction was stirred at 0 °C for 30 min, then at rt for 1.5 h,
whereupon it was quenched with NaHCO3 (3 mL). The layers were separated and the aqueous
extracted with Et2O (3 × 5 mL). The organics were then washed with brine (10 mL), dried
over MgSO4, and concentrated in vacuo. The crude was purified by flash chromatography (1:4
EtOAc/PE) to yield iodide 187 as a colourless oil (39.5 mg, 82%).
Rf 0.69 (1:2 EtOAc/PE); 1H NMR (400 MHz, CDCl3) δH 7.39 (2H, d, J = 8.7 Hz, ArH), 7.27
(1H, dd, J = 15.4, 10.8 Hz, H3), 6.89 (2H, d, J = 8.8 Hz, ArH), 6.30 (1H, dd, J = 15.2, 11.0 Hz,
H4), 6.15 (1H, dt, J = 14.7, 7.3 Hz, H5), 5.84 (1H, d, J = 15.4 Hz, H2), 5.71 (1H, s, ArCHO2),
4.01 (1H, dd, J = 8.5, 6.7 Hz, H7), 3.80 (3H, s, ArOMe), 3.77 (1H, dd, J = 9.7, 2.2 Hz, H9), 3.74
(3H, s, CO2Me), 3.55 (1H, dd, J = 9.5, 5.1 Hz, H11a), 3.38 (1H, dd, J = 9.4, 2.5 Hz, H11b), 3.02
(1H, ddd, J = 15.4, 7.7, 7.7 Hz, H6a), 2.58 (1H, ddd, J = 14.4, 7.2, 7.2 Hz, H6b), 1.62–1.54 (1H,
m, H8), 1.48–1.40 (1H, m, H10), 1.23 (3H, d, J = 6.9 Hz, Me10), 0.90 (3H, d, J = 6.6 Hz, Me8).









To methyl ester 187 (39.5 mg, 0.0789 mmol) in CH2Cl2 (2 mL) at −78 °C was added DIBAL
(0.64 mL, 0.64 mmol, 1.0 M in hexane). After stirring for 1.5 h, the reaction was quenched with
Na+/K+ tartrate (2.5 mL) and stirred vigorously while warming to rt. The mixture was diluted
with H2O (5 mL) and Et2O (5 mL) and stirred for a further 1 h. The aqueous layer was extracted
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with Et2O (3 × 8 mL). The combined organics were dried over Na2SO4, concentrated in vacuo,
and purified by flash chromatography (1:2 EtOAc/PE) giving product 188 as a pale yellow oil
(26.7 mg, 72%).
Rf 0.25 (1:2 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.40 (2H, d, J = 8.6 Hz, ArH), 6.89
(2H, d, J = 8.8 Hz, ArH), 6.24 (1H, dd, J = 15.0, 10.5 Hz, H3), 6.17 (1H, dd, J = 14.8, 10.5
Hz, H4), 5.78 (1H, dt, J = 14.9, 5.9 Hz, H2), 5.72 (1H, dt, J = 14.8, 7.1 Hz, H5), 5.72 (1H, s,
ArCHO2), 4.18 (2H, dd, J = 5.6, 5.6 Hz, H1 × 2), 3.95 (1H, dd, J = 7.7, 7.7 Hz, H7), 3.80 (3H, s,
ArOMe), 3.77 (1H, dd, J = 9.6, 2.2 Hz, H9), 3.54 (1H, dd, J = 9.4, 5.1 Hz, H11a), 3.38 (1H, dd,
J = 9.5, 2.6 Hz, H11b), 2.89 (1H, ddd, J = 14.7, 7.4, 7.4 Hz, H6a), 2.56 (1H, ddd, J = 14.8, 7.4,
7.4 Hz, H6b), 1.60 (1H, qd, J = 7.0, 1.3 Hz, H8), 1.48–1.42 (1H, m, H10), 1.29 (1H, t, J = 5.9 Hz,
C1OH), 1.22 (3H, d, J = 7.0 Hz, Me10), 0.90 (3H, d, J = 6.6 Hz, Me8).









Alcohol 188 (26.7 mg, 0.0565 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to −78 °C.
To the solution were added 2,6-lutidine (20 μL, 0.085 mmol) and TBSOTf (20 μL, 0.17 mmol).
After 1 h, the reaction was quenched with NH4Cl (2 mL) and allowed to warm to rt while
stirring briskly. The aqueous layer was extracted with CH2Cl2 (3 × 2 mL), dried over MgSO4
and concentrated in vacuo. Flash chromatography (1:20 EtOAc/PE) yielded a colourless oil,
TBS ether 87 (30.4 mg, 92%).
Rf 0.70 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.41 (2H, d, J = 8.7 Hz, ArH), 6.89
(2H, d, J = 8.8 Hz, ArH), 6.25–6.12 (2H, m, H4, H5), 5.72 (1H, s, ArCHO2), 5.72–5.63 (2H,
m, H2, H3), 4.21 (2H, d, J = 5.6 Hz, H1 × 2), 3.95 (1H, dd, J = 7.7, 7.7 Hz, H7), 3.80 (3H, s,
ArOMe), 3.77 (1H, dd, J = 9.7, 2.2 Hz, H9), 3.54 (1H, dd, J = 9.5, 5.1 Hz, H11a), 3.39 (1H, dd,
J = 9.5, 2.6 Hz, H11b), 2.86 (1H, ddd, J = 14.5, 7.3, 7.3 Hz, H6a), 2.57 (1H, ddd, J = 14.9, 7.5,
7.5 Hz, H6b), 1.61 (1H, qd, J = 6.9, 1.4 Hz, H8), 1.49–1.41 (1H, m, H10), 1.22 (3H, d, J = 7.0
Hz, Me10), 0.92 (9H, s, SiC(CH3)3), 0.90 (3H, d, J = 6.6 Hz, Me8), 0.08 (6H, s, Si(CH3)2).
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Sodium hydride (271 mg, 60% dispersion in mineral oil, 6.78 mmol) was suspended in THF
(8 mL) and cooled to 0 °C. A solution of phosphonate 90 (1.03 g, 4.95 mmol) in THF (4 mL)
was added dropwise and stirred for 40 min, forming a white slurry. Maintaining the reaction
at 0 °C, n-BuLi (3.61 mL, 1.6 M in hexane, 5.78 mmol) was added dropwise, giving rise to a
cloudy yellow solution which was allowed to stir for 30 min then cooled to −78 °C.
The dianion solution was added slowly via cannula to a solution of iodide 87 (565 mg, 0.963 mmol)
and HMPA (0.50 mL, 2.9 mmol) in THF (3 mL) at −78 °C. The reaction was stirred at this tem-
perature for 2 h, then warmed to −30 °C and allowed to gradually warm to −10 °C over 1 h.
The dark yellow reaction mixture was then quenched with NH4Cl (10 mL), warmed to rt, and
extracted with Et2O (3 × 10 mL). The organic extracts were combined and dried over MgSO4,
concentrated in vacuo, and purified by flash chromatography (1:2 EtOAc/PE) to give a 4:1 in-
separable mixture of phosphonate 20 and the undesired regioisomer 91 (488 mg, 76%) as a pale
yellow oil.
Rf 0.25 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.39 (2H, d, J = 8.5 Hz, ArH), 6.86
(2H, d, J = 8.5 Hz, ArH), 6.24–6.09 (2H, m, H3, H4), 5.73–5.61 (3H, m, H2, H5, ArCHO2),
4.20 (2H, d, J = 5.0 Hz, H1 × 2), 4.14–4.01 (4H, m, P(OCH2CH3)2), 3.92 (1H, dd, J = 7.5, 7.5
Hz, H7), 3.79 (3H, s, ArOMe), 3.65 (1H, dd, J = 10.0, 1.9 Hz, H9), 3.18 (1H, dq, J = 24.8,
7.2 Hz, H14), 2.94–2.79 (2H, m, H6a, H12a), 2.78–2.65 (1H, m, H12b), 2.59–2.48 (1H, m, H6b),
2.11–2.00 (1H, m, H11a), 1.71–1.63 (1H, m, H8), 1.63–1.56 (1H, m, H10), 1.34–1.23 (10H, m,
H11b, Me14, P(OCH2CH3)2), 1.17 (3H, d, J = 6.9 Hz, Me10), 0.91 (9H, s, SiC(CH3)3), 0.81 (3H,
dd, J = 6.7, 1.7 Hz, Me8), 0.07 (6H, s, Si(CH3)2).
These data are in agreement with those previously reported.118
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To a rapidly stirred solution of PMB ether 96 (1.07 g, 1.73 mmol) in CH2Cl2 (20 mL) and pH 7
buffer (10 mL) at 0 °C was added DDQ (650 mg, 2.86 mmol). The mixture was allowed to warm
to rt, and a colour change from dark green to red was observed over 1 h. NaHCO3 (20 mL)
was added to quench the reaction, and the solution was diluted with H2O (30 mL) and CH2Cl2
(20 mL) and stirred for a further 30 min. The aqueous layer was then extracted with EtOAc (3
× 20 mL), dried over Na2SO4, and concentrated in vacuo. Purification by flash chromatography
(1:8 EtOAc/PE) gave the alcohol 189 as a pale yellow oil (839 mg, 97%).
Rf 0.52 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.26 (1H, obs dd, H3), 6.21 (1H, dd,
J = 15.3, 10.1 Hz, H4), 6.15 (1H, ddd, J = 15.2, 7.0, 6.9 Hz, H5), 5.80 (1H, d, J = 15.4 Hz, H2),
3.80–3.74 (2H, m, H9, H11a), 3.75 (3H, s, COOMe), 3.71 (1H, ddd, J = 6.3, 6.3, 3.9 Hz, H7),
3.56 (1H, ddd, J = 12.0, 6.2, 6.2 Hz, H11b), 2.60 (1H, dd, J = 6.4, 5.2 Hz, C11OH), 2.37–2.22
(2H, m, H6 × 2), 1.87–1.79 (1H, m, H8), 1.79–1.71 (1H, m, H10), 1.00 (3H, d, J = 7.7 Hz, Me10),
0.98 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.89 (3H, d, J =
7.0 Hz, Me8), 0.65 (6H, q, J = 8.1 Hz, Si(CH2CH3)3), 0.60 (6H, q, J = 8.0 Hz, Si(CH2CH3)3).








To a solution of alcohol 189 (839 mg, 1.68 mmol) in MeCN/Et2O (1:1, 30 mL) at 0 °C was
added PPh3 (791 mg, 3.02 mmol), imidazole (229 mg, 3.36 mmol) and, in small portions, iodine
(765 mg, 3.02 mmol). After stirring for 30 min at this temperature, the reaction was warmed to
rt for 2 h, then quenched with NaHCO3 (30 mL). The layers were separated and the aqueous ex-
tracted with Et2O (3 × 20 mL). The combined organics were dried over MgSO4, concentrated in
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vacuo, and purified via flash chromatography (1:15 EtOAc/PE) to yield iodide 98 as a colourless
oil (906 mg, 89%).
Rf 0.76 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.27 (1H, dd, J = 15.4, 10.2 Hz, H3),
6.22 (1H, dd, J = 15.3, 10.1 Hz, H4), 6.16 (1H, ddd, J = 15.2, 6.8, 6.2 Hz, H5), 5.81 (1H, d, J =
15.4 Hz, H2), 3.75 (3H, s, COOMe), 3.70 (1H, ddd, J = 6.1, 5.9, 4.5 Hz, H7), 3.66 (1H, app t, J =
4.4 Hz, H9), 3.29 (1H, dd, J = 9.9, 4.3 Hz, H11a), 3.00 (1H, dd, J = 9.8, 8.8 Hz, H11b), 2.32–2.27
(2H, m, H6 × 2), 1.88–1.79 (1H, m, H10), 1.73–1.65 (1H, m, H8), 1.05 (3H, d, J = 6.8 Hz, Me10),
0.97 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.96 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.85 (3H, d, J =
7.0 Hz, Me8), 0.63 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.60 (6H, q, J = 8.1 Hz, Si(CH2CH3)3).







Ester 98 (906 mg, 1.48 mmol) was dissolved in CH2Cl2 (30 mL) and cooled to −78 °C. After
dropwise addition of DIBAL (4.45 mL, 1.0 M in hexane, 4.45 mmol), the reaction was stirred
for 1.5 h, then quenched with Na+/K+ tartrate (30 mL) and stirred vigorously for 30 min. The
quenching mixture was diluted with H2O (50 mL) and CH2Cl2 (50 mL), and the aqueous layer
extracted with CH2Cl2 (3 × 60 mL). The combined organic fractions were dried over Na2SO4
and concentrated in vacuo. The crude was subjected to flash chromatography (1:10 EtOAc/PE),
giving alcohol 190 as a colourless oil (833 mg, 96%).
Rf 0.33 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 6.23 (1H, dd, J = 15.2, 10.4 Hz, H3),
6.08 (1H, dd, J = 15.1, 10.4 Hz, H4), 5.79–5.69 (2H, m, H2, H5), 4.18 (2H, app t, J = 5.9 Hz,
H1 × 2), 3.69–3.63 (2H, m, H7, H9), 3.32 (1H, dd, J = 9.9, 4.0 Hz, H11a), 2.99 (1H, app t, J =
9.4 Hz, H11b), 2.21 (2H, br t, J = 6.1 Hz, H6 × 2), 1.88–1.79 (1H, m, H10), 1.73–1.64 (1H, m,
H8), 1.27 (1H, t, J = 5.9 Hz, C1OH), 1.05 (3H, d, J = 6.8 Hz, Me10), 0.97 (9H, t, J = 7.9 Hz,
Si(CH2CH3)3), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.85 (3H, d, J = 7.0 Hz, Me8), 0.63 (6H,
q, J = 7.4 Hz, Si(CH2CH3)3), 0.60 (6H, q, J = 7.5 Hz, Si(CH2CH3)3).









Imidazole (139 mg, 2.04 mmol) and TBSCl (359 mg, 2.38 mmol) were added sequentially to a
stirred solution of alcohol 190 (992 mg, 1.70 mmol) in CH2Cl2 (35 mL) at rt. The mixture was
stirred for 5 h, then quenched by addition of NH4Cl (30 mL). The aqueous layer was extracted
with CH2Cl2 (3 × 20 mL), and the combined organics were dried over MgSO4 and concentrated
in vacuo. Flash chromatography (1:30 EtOAc/PE) gave TBS ether 99 as a colourless oil (1.16 g,
98%).
Rf 0.51 (1:20 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 6.19 (1H, dd, J = 15.1, 10.6 Hz,
H3), 6.06 (1H, dd, J = 15.1, 10.6 Hz, H4), 5.70–5.62 (2H, m, H2, H5), 4.21 (2H, d, J = 5.0 Hz,
H1 × 2), 3.68–3.63 (2H, m, H7, H9), 3.33 (1H, dd, J = 9.8, 3.9 Hz, H11a), 2.98 (1H, app t, J = 9.5
Hz, H11b), 2.19 (2H, br t, J = 6.2 Hz, H6 × 2), 1.89–1.79 (1H, m, H10), 1.73–1.65 (1H, m, H8),
1.05 (3H, d, J = 6.7 Hz, Me10), 0.97 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.96 (9H, t, J = 8.0 Hz,
Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.85 (3H, d, J = 7.0 Hz, Me8), 0.63 (6H, q, J = 7.7 Hz,
Si(CH2CH3)3), 0.60 (6H, q, J = 7.7 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2).





















Sodium hydride (60 mg, 60% in mineral oil, 1.50 mmol) was dissolved in THF (1 mL) and
cooled to 0 °C. Phosphonate linker 90 (269 mg, 1.29 mmol) was added dropwise as a solution in
THF (1 mL). H2 evolution was initially observed as the grey slurry was stirred for 45 min at 0 °C,
then the mixture seized and was re-suspended in THF (0.5 mL). To the monoanion suspension
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was then added n-BuLi (0.82 mL, 1.58 M in hexane, 1.29 mmol) dropwise, and the resulting
bright yellow solution was stirred for a further 45 min at 0 °C.
Iodide 99 (130 mg, 0.186 mmol) was dried azeotropically with C6H6 then dissolved in THF
(1 mL) and HMPA (80 μL, 0.460 mmol). This solution was cooled to 0 °C, and the pre-cooled
dianion solution was added dropwise over 5 min. After stirring for 1.5 h at 0 °C, the reaction was
quenched with NH4Cl (5 mL). The layers were separated and the aqueous extracted with Et2O
(3 × 5 mL). The combined organic fractions were dried over MgSO4 and concentrated in vacuo.
Flash chromatography (1:2 EtOAc/PE) gave a colourless oil containing the desired phosphonate
28 as an inconsequential mixture of diastereomers at the C14 position, along with the inseparable
branched regioisomer 100 (93.5 mg, 65% combined yield, 3.8:1 28/100).
Rf 0.67 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 6.18 (1H, dd, J = 15.1, 10.5 Hz, H3),
6.04 (1H, dd, J = 14.9, 10.6 Hz, H4), 5.72–5.60 (2H, m, H2, H5), 4.20 (2H, d, J = 5.2 Hz, H1 × 2),
4.16–4.07 (4H, m, P(OCH2CH3)2), 3.67–3.56 (1H, m, H7), 3.56–3.50 (1H, m, H9), 3.22 (0.4H,
dq, J = 21.4, 7.1 Hz, H14), 3.21 (0.4H, dq, J = 21.4, 7.1 Hz, H14†), 2.87 (0.4H, ddd, J = 17.5, 9.9,
5.1 Hz, H12a†), 2.77–2.59 (0.8H, m, H12a, H12b), 2.46 (0.4H, ddd, J = 17.5, 9.7, 6.0 Hz, H12b†),
[2.35] (0.6H, s, Me3 ′*), 2.23–2.10 (2H, m, H6 × 2), [1.88–1.81] (0.2H, m, H11a*), 1.79–1.61 (2H,
m, H8, H11a, H11b*), 1.57–1.47 (1H, m, H10), 1.42–1.30 (9.2H, m, Me14, H11b, P(OCH2CH3)2),
0.99–0.90 (18.6H, m, Si(CH2CH3)3 × 2, Me1 ′*), 0.91 (9H, s, SiC(CH3)3), 0.88 (3H, d, J = 7.0
Hz, Me10), 0.86 (2.4H, d, J = 6.6 Hz, Me8), [0.72] (0.6H, d, J = 7.0 Hz, Me8*), 0.65–0.54 (12H,
m, Si(CH2CH3)3 × 2), 0.07 (6H, s, Si(CH3)2).
Distinguishable resonances of the minor regioisomer are given in brackets and marked with an
asterisk (*). The diastereomeric ratio of the product at C14 is approximately 1:1, and distinguish-
able resonances of the two diastereomers are noted with a dagger (†).
These data are in agreement with those previously reported.92
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5.5 Experimental procedures for Chapter 3










To a slurry of anhydrous Ba(OH)2 (16.1 mg, 0.0940 mmol) in THF (0.5 mL) was added phos-
phonate 90 (10.0 mg, 0.0480 mmol) in THF (1 mL). After stirring for 1 h at rt, a solution of
aldehyde 29 (10.3 mg, 0.0222 mmol) in THF/H2O (40:1, 1 mL) was added and stirring was
continued for 6.5 h. The reaction was quenched with NH4Cl (2.5 mL), extracted with Et2O (3
× 3 mL) and dried over MgSO4. After concentrating in vacuo, the crude was purified by flash
chromatography (1:10 EtOAc/PE) to give the coupled product 109 as a colourless oil (10.5 mg,
91%).
Rf 0.46 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.6 Hz, ArH), 6.86
(2H, d, J = 8.7 Hz, ArH), 6.62 (1H, td, J = 7.3, 1.1 Hz, H15), 5.18 (1H, td, J = 7.0, 1.9 Hz,
H23), 4.43 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 3.80 (3H,
s, ArOMe) 3.53 (1H, dd, J = 9.2, 4.9 Hz, H27a), 3.38 (3H, s, C25OMe) 3.32 (1H, dd, J = 9.1, 7.4
Hz, H27b), 2.86 (1H, dd, J = 8.5, 3.5 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.30 (3H, s,
Me12), 2.22 (2H, app q, J = 7.4 Hz, H16 × 2), 2.11–2.05 (1H, m, H26), 1.78 (1H, dqd, J = 7.2, 7.2,
1.8 Hz, H24), 1.76 (3H, s, Me14), 1.69–1.58 (1H, m, H22a), 1.49–1.39 (3H, m, H22b, H17 × 2),
1.35–1.20 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.05 (3H, d, J = 7.0 Hz, Me26),
0.90 (3H, d, J = 7.1 Hz, Me24); 13C NMR (125 MHz, CDCl3) δC 199.9, 174.1, 159.0, 143.9,
137.6, 130.8, 129.0, 113.7, 85.9, 73.1, 72.7, 71.6, 61.4, 55.2, 38.8, 35.9, 32.7, 29.4, 29.3, 29.3,
29.1, 28.6, 28.0, 25.7, 25.4, 16.3, 11.1, 10.6, 9.4; [α]20D −6.4 (c 0.659, CHCl3); IR (thin film)
ν max (cm– 1) 2927, 2855, 1730, 1668, 1614, 1514, 1462, 1366, 1302, 1276, 1247, 1193, 1087,
















A solution of phosphonate 20 (471 mg, 4:1 ratio of regioisomers, 0.565 mmol) in THF (6 mL)
was charged to a flask containing barium hydroxide (145 mg, 0.846 mmol) and stirred at rt for
2 h. Aldehyde 29 (297 mg, 0.639 mmol) was added as a solution in THF/H2O (4 mL, 40:1).
The reaction was left to stir for 68 h, then was quenched with NH4Cl (10 mL). The aqueous
fraction was extracted with Et2O (3 × 8 mL) and the combined organics were washed with brine
(20 mL), dried over MgSO4, and concentrated in vacuo. The crude was purified by careful flash
chromatography (1:15→ 1:8 EtOAc/PE) to yield enone 104 as a colourless oil (460 mg, 83%,
>20:1 E/Z).
Rf 0.57 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.38 (2H, d, J = 8.7 Hz, PMP ArH),
7.24 (2H, d, J = 8.7 Hz, PMB ArH), 6.86 (2H, d, J = 8.7 Hz, PMP ArH), 6.85 (2H, d, J = 8.8
Hz, PMB ArH), 6.54 (1H, td, J = 7.3, 1.0 Hz, H15), 6.21 (1H, dd, J = 14.8, 10.5 Hz, H3), 6.14
(1H, dd, J = 14.8, 10.6 Hz, H4), 5.69 (1H, s, ArCHO2), 5.68 (1H, dt, J = 14.8, 5.2 Hz, H2), 5.66
(1H, obs dt, H5), 5.18 (1H, td, J = 7.9, 1.9 Hz, H23), 4.43 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39
(1H, d, J = 11.6 Hz, ArCHaHbO), 4.20 (2H, d, J = 5.1 Hz, H1 × 2), 3.92 (1H, dd, J = 7.7, 7.7
Hz, H7), 3.80 (3H, s, ArOMe), 3.78 (3H, s, ArOMe), 3.67 (1H, dd, J = 9.9, 1.9 Hz, H9), 3.52
(1H, dd, J = 9.2, 4.9 Hz, H27a), 3.38 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.1, 7.4 Hz, H27b), 2.87
(1H, dd, J = 8.4, 3.5 Hz, H25), 2.84 (1H, ddd, J = 14.5, 7.2, 7.2 Hz, H6a), 2.69 (2H, t, J = 8.0 Hz,
H12 × 2), 2.54 (1H, ddd, J = 14.8, 7.5, 7.5 Hz, H6b), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.14 (2H,
app q, J = 7.3 Hz, H16 × 2), 2.11–2.05 (1H, m, H26), 2.05–1.98 (1H, m, H11a), 1.78 (1H, dqd, J =
8.9, 7.1, 1.8 Hz, H24), 1.73 (3H, s, Me14), 1.73–1.65 (1H, m, H10), 1.65–1.57 (2H, m, H8, H22a),
1.53–1.39 (2H, m, H11b, H22b), 1.39–1.32 (2H, m, H17 × 2), 1.32–1.20 (8H, m, H18 – 21), 1.18
(3H, d, J = 6.9 Hz, Me8), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J = 7.0 Hz, Me26),
0.91 (9H, s, SiC(CH3)3), 0.90 (3H, obs d, Me24), 0.83 (3H, d, J = 6.9 Hz, Me10), 0.07 (6H, s,
Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 202.5, 174.1, 159.8, 159.0, 142.5, 136.9, 132.2,
131.8, 131.3, 130.9, 129.8, 129.5, 129.0, 127.3, 113.7, 113.5, 94.9, 85.9, 79.8, 79.2, 73.1, 72.8,
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71.6, 63.5, 61.4, 55.3, 55.3, 38.9, 35.9, 35.3, 34.0, 33.9, 32.7, 31.4, 29.5, 29.4, 29.3, 29.1, 29.0,
28.6, 28.1, 26.0, 25.7, 18.4, 16.3, 14.6, 13.0, 11.4, 10.7, 9.4, −5.2; [α]20D +2.4 (c 1.01, CHCl3);
IR (thin film) ν max (cm– 1) 2928, 2856, 1730, 1666, 1615, 1515, 1462, 1380, 1302, 1248, 1194,























To a solution of enone 104 (34.8 mg, 0.0356 mmol) in THF (2.5 mL) at −5 °C was added Me-
CBS catalyst (R)-112 (47 μL, 1.0 M in toluene, 0.047 mmol) and borane dimethylsulfide (4 μL,
0.042 mmol). The mixture was stirred at this temperature for 40 min, then quenched by dropwise
addition of MeOH (1 mL). Stirring continued for a further 20 min as the solution warmed to rt,
then the solvent was then removed in vacuo. The crude material was re-dissolved in MeOH
(1 mL) and concentrated in vacuo three times, then was purified by flash chromatography (1:3
EtOAc/PE) to give alcohol 116 as a colourless oil (28.4 mg, 81%, >20:1 dr).
Rf 0.30 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.38 (2H, d, J = 8.8 Hz, PMP ArH),
7.24 (2H, d, J = 8.6 Hz, PMB ArH), 6.87 (2H, d, J = 8.7 Hz, PMP ArH), 6.86 (2H, d, J = 8.6 Hz,
PMB ArH), 6.21 (1H, dd, J = 14.9, 10.5 Hz, H3), 6.13 (1H, dd, J = 14.9, 10.6 Hz, H4), 5.72–5.62
(2H, m, H2, H5), 5.68 (1H, s, ArCHO2), 5.33 (1H, t, J = 6.8 Hz, H15), 5.18 (1H, td, J = 7.0, 1.9
Hz, H23), 4.43 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.20
(2H, d, J = 5.1 Hz, H1 × 2), 3.96–3.92 (1H, m, H13), 3.92 (1H, dd, J = 7.7, 7.7 Hz, H7), 3.80 (3H,
s, ArOMe), 3.79 (3H, s, ArOMe), 3.64 (1H, dd, J = 10.3, 1.9 Hz, H9), 3.53 (1H, dd, J = 9.2, 4.9
Hz, H27a), 3.38 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.2, 7.4 Hz, H27b), 2.86 (1H, dd, J = 8.5, 3.6
Hz, H25), 2.83 (1H, ddd, J = 14.7, 7.3, 7.3 Hz, H6a), 2.53 (1H, ddd, J = 14.7, 7.4, 7.4 Hz, H6b),
2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.12–2.04 (1H, m, H26), 2.03–1.89 (2H, m, H16 × 2), 1.78 (1H,
dqd, J = 8.9, 7.2, 2.0 Hz, H24), 1.75–1.67 (2H, m, H10, H11a), 1.66–1.56 (3H, m, H8, H12a, H22a),
1.55 (3H, s, Me14), 1.53–1.48 (1H, m, H12b), 1.48–1.39 (2H, m, H22b, C13OH), 1.35–1.20 (10H,
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m, H17 – 21), 1.17 (3H, d, J = 7.0 Hz, Me8), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J =
7.1 Hz, Me26), 1.06–1.00 (1H, m, H11b), 0.91 (9H, s, SiC(CH3)3), 0.90 (3H, obs d, Me24), 0.82
(3H, d, J = 6.8 Hz, Me10), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 174.1,
159.7, 159.0, 136.6, 132.1, 131.8, 131.2, 130.8, 129.8, 129.6, 129.0, 127.4, 127.3, 113.7, 113.5,
94.8, 85.9, 79.8, 78.6, 78.5, 73.1, 72.7, 71.6, 63.5, 61.4, 55.3, 55.2, 38.8, 35.9, 33.9, 33.7, 32.7,
31.3, 31.2, 29.5, 29.4, 29.3, 29.3, 28.8, 28.0, 27.5, 25.9, 25.7, 18.4, 16.3, 14.2, 13.0, 10.8, 10.6,
9.4, −5.2; [α]20D +8.0 (c 1.01, CHCl3); IR (thin film) ν max (cm
– 1) 3403, 2929, 2855, 1731,
1615, 1515, 1463, 1379, 1364, 1302, 1248, 1194, 1171, 1096, 1037, 991, 969, 835, 777; HRMS















To a flask containing proton sponge (27.0 mg, 0.126 mmol) and Meerwein salt (15.5 mg, 0.105 mmol)
was added a solution of alcohol 116 (20.4 mg, 0.0208 mmol) in CH2Cl2 (2 mL). The reaction
mixture gradually turned yellow while stirring at rt. After 1.5 h no further reaction progress was
observed, and the reaction was quenched with NH4Cl (3 mL) and stirred until the mixture re-
turned to colourless. The reaction mixture was then extracted with CH2Cl2 (2 × 3 mL), washed
with citric acid (5 mL, 10% w/v), and dried over MgSO4. After concentrating in vacuo, the crude
was purified by flash chromatography (1:8 EtOAc/PE) to give methyl ether 118 as a colourless,
viscous oil (18.5 mg, 89%).
Rf 0.35 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.38 (2H, d, J = 8.7 Hz, PMP ArH),
7.24 (2H, d, J = 8.7 Hz, PMB ArH), 6.86 (4H, d, J = 8.2 Hz, ArH), 6.21 (1H, dd, J = 14.9, 10.5
Hz, H3), 6.12 (1H, dd, J = 14.7, 10.6 Hz, H4), 5.68 (1H, dt, J = 14.9, 5.2 Hz, H2), 5.67 (1H, s,
ArCHO2), 5.66 (1H, obs dt, H5), 5.29 (1H, t, J = 7.1 Hz, H15), 5.19 (1H, td, J = 7.0, 1.8 Hz,
H23), 4.43 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.20 (2H,
d, J = 5.3 Hz, H1 × 2), 3.91 (1H, dd, J = 7.6, 7.6 Hz, H7), 3.80 (3H, s, ArOMe), 3.79 (3H, s,
ArOMe), 3.63 (1H, dd, J = 10.0, 1.9 Hz, H9), 3.53 (1H, dd, J = 9.2, 4.8 Hz, H27a), 3.38 (3H,
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s, C25OMe), 3.36 (1H, t, J = 7.0 Hz, H13), 3.32 (1H, dd, J = 9.1, 7.5 Hz, H27b), 3.14 (3H, s,
C13OMe), 2.87 (1H, dd, J = 8.5, 3.5 Hz, H25), 2.82 (1H, ddd, J = 14.6, 7.3, 7.3 Hz, H6a), 2.52
(1H, ddd, J = 14.7, 7.4, 7.4 Hz, H6b), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.12–2.06 (1H, m, H26),
2.06–1.98 (1H, m, H16a), 1.98–1.90 (1H, m, H16b), 1.78 (1H, dqd, J = 8.8, 7.0, 1.8 Hz, H24),
1.74–1.66 (1H, m, H10), 1.66–1.60 (2H, m, H11a, H22a), 1.60–1.51 (3H, m, H8, H12 × 2), 1.45
(3H, s, Me14), 1.45–1.39 (1H, m, H22b), 1.36–1.29 (2H, m, H17 × 2), 1.29–1.20 (8H, m, H18 – 21),
1.16 (3H, d, J = 7.1 Hz, Me8), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J = 7.0 Hz, Me26),
1.06–0.99 (1H, m, H11b), 0.91 (9H, s, SiC(CH3)3), 0.90 (3H, obs d, Me24), 0.80 (3H, d, J =
6.8 Hz, Me10), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 174.1, 159.7, 159.0,
133.5, 132.1, 131.9, 131.2, 130.8, 129.8, 129.8, 129.6, 129.0, 127.3, 113.7, 113.5, 94.8, 88.1,
85.9, 79.8, 78.3, 73.1, 72.7, 71.6, 63.5, 61.4, 55.5, 55.3, 55.2, 38.8, 35.9, 33.9, 33.6, 32.7, 31.3,
29.6, 29.6, 29.5, 29.4, 29.3, 28.6, 28.0, 27.5, 26.0, 25.8, 18.4, 16.3, 14.1, 13.0, 10.6, 10.0, 9.4,
−5.2; [α]20D +5.6 (c 0.804, CHCl3); IR (thin film) ν max (cm
– 1) 2928, 2855, 1732, 1615, 1515,
1463, 1379, 1364, 1302, 1247, 1193, 1171, 1092, 1036, 991, 967, 834, 777; HRMS calc. for













Ester 118 (15.7 mg, 0.0158 mmol) was dissolved in CH2Cl2 (1 mL) and cooled to −78 °C.
DIBAL (70 μL, 0.070 mmol, 1.0 M in hexane) was added and the reaction was stirred for 1.5 h,
then was quenched by addition of Na+/K+ tartrate (1 mL), warmed to rt and stirred for 30 min.
The mixture was extracted with CH2Cl2 (3 × 1 mL), dried over Na2SO4, and concentrated in
vacuo. Flash chromatography (1:5 EtOAc/PE) gave alcohol 122 as a colourless oil (14.6 mg,
99%).
Rf 0.43 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.38 (2H, d, J = 8.7 Hz, PMP ArH),
7.26 (2H, d, J = 8.6 Hz, PMB ArH), 6.88 (2H, d, J = 8.7 Hz, PMP ArH), 6.87 (2H, d, J = 8.7
Hz, PMB ArH), 6.21 (1H, dd, J = 14.9, 10.5 Hz, H3), 6.12 (1H, dd, J = 14.8, 10.6 Hz, H4),
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5.72–5.62 (2H, m, H2, H5), 5.67 (1H, s, ArCHO2), 5.29 (1H, t, J = 6.8 Hz, H15), 4.44 (2H, s,
ArCH2O), 4.20 (2H, d, J = 5.2 Hz, H1 × 2), 3.91 (1H, dd, J = 7.9, 7.9 Hz, H7), 3.90 (1H, dd, J =
7.3, 7.3 Hz, H23), 3.81 (3H, s, ArOMe), 3.80 (3H, s, ArOMe), 3.63 (1H, dd, J = 9.9, 1.8 Hz, H9),
3.52 (1H, dd, J = 8.8, 5.3 Hz, H27a), 3.49–3.45 (2H, m, H27b, C23OH), 3.44 (3H, s, C25OMe),
3.36 (1H, t, J = 7.2 Hz, H13), 3.18 (1H, dd, J = 8.9, 2.9 Hz, H25), 3.14 (3H, s, C13OMe), 2.82
(1H, ddd, J = 14.5, 7.2, 7.2 Hz, H6a), 2.52 (1H, ddd, J = 14.7, 7.3, 7.3 Hz, H6b), 2.10–2.00
(2H, m, H16a, H26), 2.00-1.90 (1H, m, H16b), 1.76–1.61 (3H, m, H10, H11a, H24), 1.61–1.47 (4H,
m, H8, H12 × 2, H22a), 1.45 (3H, s, Me14), 1.41–1.20 (11H, m, H17 – 21, H22b), 1.16 (3H, d, J =
6.9 Hz, Me8), 1.07–0.99 (1H, m, H11b), 1.03 (3H, d, J = 7.1 Hz, Me24), 0.94 (3H, d, J = 7.0
Hz, Me26), 0.91 (9H, s, SiC(CH3)3), 0.80 (3H, d, J = 6.8 Hz, Me10), 0.07 (6H, s, Si(CH3)2);
13C NMR (125 MHz, CDCl3) δC 159.7, 159.1, 133.4, 132.1, 131.9, 131.2, 130.7, 129.9, 129.8,
129.6, 129.2, 127.3, 113.7, 113.5, 94.8, 89.1, 88.1, 79.8, 78.3, 72.8, 72.0, 70.6, 63.5, 61.7, 55.5,
55.3, 55.3, 37.1, 36.7, 34.7, 33.9, 33.6, 31.3, 29.8, 29.6, 29.5, 29.4, 29.3, 28.6, 27.5, 26.2, 26.0,
18.4, 15.0, 14.1, 13.0, 11.4, 10.0, −5.2; [α]20D +4.7 (c 0.47, CHCl3); IR (thin film) ν max (cm
– 1)
3674, 2957, 2928, 2856, 1615, 1516, 1463, 1380, 1303, 1249, 1172, 1097, 1038, 991, 836, 778;













To a rapidly stirred biphasic solution of silyl ether 122 (40.8 mg, 0.0435 mmol) in CH2Cl2 (2 mL)
and aqueous pH 9.2 buffer (0.5 mL) at 0 °C was added DDQ (12.0 mg, 0.0529 mmol). After
20 min, the reaction was quenched with NaHCO3 (2.5 mL) and warmed to rt. After extraction
with CH2Cl2 (3 × 5 mL) and washing with brine/H2O (1:3, 20 mL), the organics were dried over
MgSO4 and concentrated in vacuo. The crude was purified by flash chromatography (1:4→ 1:2
EtOAc/hexane) to give the aldehyde 128 as a pale yellow oil (21.3 mg, 60%, 89% brsm).
Rf 0.24 (1:2 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 9.54 (1H, d, J = 8.0 Hz, H1), 7.36
(2H, d, J = 8.7 Hz, PMP ArH), 7.25 (2H, d, J = 8.6 Hz, PMB ArH), 7.09 (1H, dd, J = 15.3,
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10.7 Hz, H3), 6.88 (2H, d, J = 8.7 Hz, PMP ArH), 6.87 (2H, d, J = 8.8 Hz, PMB ArH), 6.42
(1H, dd, J = 15.1, 10.7 Hz, H4), 6.30 (1H, dt, J = 15.2, 7.1 Hz, H5), 6.10 (1H, dd, J = 15.3,
8.0 Hz, H2), 5.67 (1H, s, ArCHO2), 5.29 (1H, t, J = 7.1 Hz, H15), 4.43 (2H, s, ArCH2O), 4.02
(1H, dd, J = 9.3, 6.0 Hz, H7), 3.90 (1H, dd, J = 6.3, 6.3 Hz, H23), 3.80 (3H, s, ArOMe), 3.79
(3H, s, ArOMe), 3.63 (1H, dd, J = 9.9, 2.0 Hz, H9), 3.51 (1H, dd, J = 8.9, 5.3 Hz, H27a), 3.49
(1H, br s, C23OH), 3.47 (1H, dd, J = 8.9, 3.6 Hz, H27b), 3.44 (3H, s, C25OMe), 3.36 (1H, t, J
= 7.0 Hz, H13), 3.18 (1H, dd, J = 8.9, 2.9 Hz, H25), 3.14 (3H, s, C13OMe), 3.07 (1H, dt, J =
15.7, 7.8 Hz, H6a), 2.53 (1H, dt, J = 14.2, 7.1 Hz, H6b), 2.09–2.00 (2H, m, H16a, H26), 2.00–1.90
(1H, m, H16b), 1.77–1.60 (3H, m, H10, H11a, H24), 1.59–1.47 (4H, m, H8, H12 × 2, H22a), 1.45
(3H, s, Me14), 1.42–1.22 (11H, m, H17 – 21, H22b), 1.19 (3H, d, J = 7.0 Hz, Me8), 1.07–0.99 (1H,
m, H11b), 1.03 (3H, d, J = 7.2 Hz, Me24), 0.94 (3H, d, J = 7.0 Hz, Me26), 0.80 (3H, d, J = 6.8
Hz, Me10); 13C NMR (125 MHz, CDCl3) δC 193.8 (C1), 159.8 (Ar C), 159.1 (Ar C), 152.0
(C3), 142.3 (C5), 133.4 (C14), 131.5 (Ar C), 130.7 (C2), 130.6 (C4), 130.6 (Ar C), 129.9 (C15),
129.2 (Ar C), 127.2 (Ar C), 113.7 (Ar C), 113.5 (Ar C), 94.9 (ArCHO2), 89.0 (C25), 88.1 (C13),
79.1 (C7), 78.4 (C9), 72.7 (ArCH2O), 72.0 (C27), 70.6 (C23), 61.7 (OMe25), 55.5 (OMe13), 55.3
(ArOMe), 55.2 (ArOMe), 37.0 (C24), 36.7 (C26), 34.7 (C22), 34.4 (C6), 33.5 (C10), 32.0 (C8),
29.8, 29.5, 29.5, 29.4, 29.3 (C12, C17 – 20), 28.6 (C11), 27.5 (C16), 26.2 (C21), 14.9 (Me26), 14.1
(Me10), 13.0 (Me8), 11.4 (Me24), 10.0 (Me14); [α]20D +11.0 (c 0.97, CHCl3); IR (thin film) ν max
(cm– 1) 3513, 2961, 2931, 2858, 1683, 1642, 1615, 1516, 1462, 1303, 1249, 1172, 1114, 1092,














Aldehyde 128 (21.3 mg, 0.0259 mmol) was dissolved in t-BuOH (1 mL) and 2-methyl-2-butene
(0.5 mL). A solution of NaH2PO4 · 2 H2O (175 mg, 1.12 mmol) and NaClO2 (91 mg, 80% tech-
nical grade, 0.80 mmol) in H2O (1 mL) was added, and the mixture was stirred rapidly at rt for
20 h. After dilution with brine (3 mL) and extraction with EtOAc (3 × 3 mL), the organics were
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dried over Na2SO4 and concentrated in vacuo. The crude was purified by flash chromatography
(50:1 EtOAc/AcOH) to yield the seco-acid 131 as a pale yellow oil (21.5 mg, 99%).
Rf 0.41 (50:50:1 EtOAc/PE/AcOH); 1H NMR (500 MHz, CDCl3) δH 7.36 (2H, d, J = 8.7 Hz,
PMP ArH), 7.33 (1H, dd, J = 15.3, 10.9 Hz, H3), 7.25 (2H, d, J = 8.6 Hz, PMB ArH), 6.88 (2H,
d, J = 8.7 Hz, PMP ArH), 6.87 (2H, d, J = 8.9 Hz, PMB ArH), 6.30 (1H, dd, J = 15.1, 11.0 Hz,
H4), 6.19 (1H, dt, J = 14.6, 7.3 Hz, H5), 5.81 (1H, d, J = 15.3 Hz, H2), 5.66 (1H, s, ArCHO2),
5.29 (1H, t, J = 6.9 Hz, H15), 4.43 (2H, s, ArCH2O), 3.99 (1H, dd, J = 8.2, 6.8 Hz, H7), 3.91
(1H, dd, J = 6.2, 6.2 Hz, H23), 3.80 (3H, s, ArOMe), 3.79 (3H, s, ArOMe), 3.62 (1H, dd, J =
10.0, 1.4 Hz, H9), 3.52 (1H, dd, J = 8.8, 5.3 Hz, H27a), 3.47 (1H, dd, J = 8.8, 3.6 Hz, H27b), 3.44
(3H, s, C25OMe), 3.36 (1H, t, J = 7.1 Hz, H13), 3.18 (1H, dd, J = 8.9, 2.7 Hz, H25), 3.13 (3H,
s, C13OMe), 3.00 (1H, ddd, J = 15.2, 7.6, 7.6 Hz, H6a), 2.54 (1H, ddd, J = 14.2, 7.1, 7.1 Hz,
H6b), 2.10–2.00 (2H, m, H16a, H26), 2.00–1.90 (1H, m, H16b), 1.76–1.59 (3H, m, H10, H11a, H24),
1.59–1.47 (4H, m, H8, H12 × 2, H22a), 1.45 (3H, s, Me14), 1.40–1.22 (11H, m, H17 – 21, H22b),
1.18 (3H, d, J = 6.9 Hz, Me8), 1.07–1.00 (1H, m, H11b), 1.03 (3H, d, J = 7.1 Hz, Me24), 0.94
(3H, d, J = 7.0 Hz, Me26), 0.80 (3H, d, J = 6.8 Hz, Me10); 13C NMR (125 MHz, CDCl3) δC
171.6 (C1), 159.7 (Ar C), 159.1 (Ar C), 146.5 (C3), 141.0 (C5), 133.4 (C14), 131.5 (Ar C), 130.6
(Ar C), 130.3 (C4), 129.9 (C15), 129.2 (Ar C), 127.2 (Ar C), 119.3 (C2), 113.7 (Ar C), 113.5 (Ar
C), 94.8 (ArCHO2), 89.0 (C25), 88.1 (C13), 79.1 (C7), 78.4 (C9), 72.7 (ArCH2O), 72.0 (C27),
70.7 (C23), 61.7 (OMe25), 55.4 (OMe13), 55.3 (ArOMe), 55.2 (ArOMe), 37.0 (C24), 36.6 (C26),
34.6 (C22), 34.3 (C6), 33.6 (C10), 31.8 (C8), 29.8, 29.5, 29.5, 29.4, 29.3 (C12, C18 – 21), 28.6 (C11),
27.5 (C16), 26.2 (C17), 14.9 (Me26), 14.1 (Me10), 13.0 (Me8), 11.4 (Me24), 10.0 (Me14); [α]20D
+10.5 (c 1.00, CHCl3); IR (thin film) ν max (cm– 1) 3481, 2965, 2932, 2854, 1709, 1644, 1615,
1516, 1462, 1381, 1302, 1248, 1172, 1089, 1035, 1001, 828; HRMS calc. for C50H76O100Na














Seco-acid 131 (21.5 mg, 0.0257 mmol) was dried azeotropically with C6H6 and dried under
high vacuum for 16 h, then was dissolved in THF (2.5 mL) at rt. Et3N (40 μL, 0.287 mmol) and
2,4,6-trichlorobenzoyl chloride (30 μL, 0.192 mmol) were added, and the solution was stirred for
1 h 15 min, during which time a pale orange colour developed and a white precipitate formed.
The mixture was then diluted with toluene (4 mL). A solution of DMAP (42 mg, 0.344 mmol)
was made up in toluene (6 mL), and to this was added the mixed anhydride solution via syringe
pump over 4.5 h. After the addition was complete, stirring continued at rt for a further 12 h.
The reaction mixture was then filtered through a plug of silica and concentrated in vacuo. Flash
chromatography (1:4 EtOAc/hexane) afforded the macrolactone 133 as a colourless oil (9.9 mg,
47%).
Rf 0.29 (1:4 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.42 (2H, d, J = 8.7 Hz, PMP ArH),
7.30 (1H, dd, J = 15.2, 10.8 Hz, H3), 7.24 (2H, d, J = 8.6 Hz, PMB ArH), 6.89 (2H, d, J = 8.8
Hz, PMP ArH), 6.87 (2H, d, J = 8.6 Hz, PMB ArH), 6.31 (1H, dd, J = 14.7, 11.3 Hz, H4), 6.13
(1H, ddd, J = 15.0, 9.6, 5.5 Hz, H5), 5.87 (1H, d, J = 15.3 Hz, H2), 5.81 (1H, s, ArCHO2), 5.32
(1H, app dt, J = 10.2, 2.8 Hz, H23), 5.29 (1H, t, J = 6.8 Hz, H15), 4.43 (1H, d, J = 11.6 Hz,
ArCHaHbO), 4.39 (1H, d, J = 11.6 Hz, ArCHaHbO), 4.01 (1H, dd, J = 8.4, 5.4 Hz, H7), 3.80
(3H, s, ArOMe), 3.80 (3H, s, ArOMe), 3.71 (1H, dd, J = 8.4, 1.9 Hz, H9), 3.53 (1H, dd, J =
9.1, 4.6 Hz, H27a), 3.44 (3H, s, C25OMe), 3.35–3.30 (2H, m, H13, H27b), 3.14 (3H, s, C13OMe),
3.02 (1H, app dt, J = 14.4, 9.3 Hz, H6a), 2.92 (1H, dd, J = 8.0, 3.8 Hz, H25), 2.64 (1H, app dt,
J = 14.6, 4.8 Hz, H6b), 2.14–2.06 (1H, m, H26), 2.06–1.97 (2H, m, H16 × 2), 1.83–1.75 (1H, m,
H24), 1.75–1.61 (3H, m, H8, H10, H22a), 1.56–1.52 (2H, m, H12 × 2), 1.50 (3H, s, Me14), 1.47–
1.40 (1H, m, H22b), 1.39–1.22 (11H, m, H11a, H17 – 21), 1.20 (3H, d, J = 6.9 Hz, Me8), 1.06 (3H,
d, J = 7.0 Hz, Me26), 0.92 (3H, d, J = 7.1 Hz, Me24), 0.90–0.82 (1H, m, H11b), 0.82 (3H, d,
J = 6.9 Hz, Me10); 13C NMR (125 MHz, CDCl3) δC 167.0, 159.9, 159.0, 144.1, 139.2, 133.5,
131.7, 131.0, 130.8, 129.8, 129.1, 127.4, 120.8, 113.7, 113.6, 96.3, 88.0, 85.7, 78.9, 77.7, 73.9,
72.7, 71.6, 61.1, 55.6, 55.3, 55.2, 40.4, 36.3, 36.0, 35.1, 33.4, 30.7, 30.6, 29.0, 28.7, 28.6, 28.4,
27.9, 27.2, 25.1, 16.2, 14.5, 14.3, 11.3, 10.4; [α]20D −58.4 (c 0.45, CHCl3); IR (thin film) ν max
(cm– 1) 2929, 2854, 1709, 1641, 1614, 1514, 1457, 1302, 1247, 1171, 1137, 1111, 1094, 1035,
999, 825, 755; HRMS calc. for C50H75O9 [M+H]+ 819.5411, found 819.5397.
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A solution of phosphonate 28 (1.48 g, 3:1 mixture with regioisomer 100, 1.43 mmol) in THF
(38 mL) was added to Ba(OH)2 (392 mg, 2.29 mmol) at rt and stirred for 1.5 h. Aldehyde 29
(750 mg, 1.61 mmol) was added as a solution in THF/H2O (40:1, 12 mL), and the reaction was
left to stir under argon. After 68 h, NH4Cl (30 mL) was added. The aqueous layer was extracted
with Et2O (3 × 30 mL), dried over MgSO4, and concentrated in vacuo. Flash chromatography
gave enone 103 as a colourless oil (1.42 g, 91%).
Rf 0.80 (1:3 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.6 Hz, ArH), 6.86
(2H, d, J = 8.7 Hz, ArH), 6.59 (1H, td, J = 7.3, 1.0 Hz, H15), 6.18 (1H, dd, J = 15.1, 10.5 Hz,
H3), 6.04 (1H, dd, J = 15.1, 10.5 Hz, H4), 5.68 (1H, dt, J = 15.1, 7.2 Hz, H5), 5.64 (1H, dt, J =
15.1, 5.4 Hz, H2), 5.18 (1H, td, J = 7.0, 1.8 Hz, H23), 4.43 (1H, d, J = 11.6 Hz, OCHaHbAr),
4.39 (1H, d, J = 11.6 Hz, OCHaHbAr), 4.20 (2H, d, J = 5.2 Hz, H1 × 2), 3.80 (3H, s, ArOMe),
3.63 (1H, app q, J = 5.4 Hz, H7), 3.56–3.51 (2H, m, H9, H27a), 3.38 (3H, s, C25OMe), 3.32 (1H,
dd, J = 9.1, 7.4 Hz, H27b), 2.87 (1H, dd, J = 8.5, 3.5 Hz, H25), 2.73 (1H, ddd, J = 15.7, 10.2, 5.4
Hz, H12a), 2.56 (1H, ddd, J = 15.9, 9.8, 6.1 Hz, H12b), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.21
(2H, app q, J = 7.4 Hz, H16 × 2), 2.18–2.13 (2H, m, H6 × 2), 2.12–2.04 (1H, m, H26), 1.82–1.68
(3H, m, H8, H11a, H24), 1.76 (3H, s, Me14), 1.67–1.59 (1H, m, H22a), 1.58–1.50 (1H, m, H10),
1.48–1.36 (4H, m, H11b, H17 × 2, H22b), 1.35–1.20 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz,
H3 ′ × 3), 1.06 (3H, d, J = 7.0 Hz, Me26), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.93 (9H, t, J =
8.0 Hz, Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.91 (3H, obs d, Me10), 0.90 (3H, obs d, Me24),
0.86 (3H, d, J = 7.0 Hz, Me8), 0.60 (6H, q, J = 8.1 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 8.1 Hz,
Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 202.1, 174.1, 159.0,
142.1, 137.1, 131.5, 131.4, 130.9, 130.3, 130.3, 129.0, 113.7, 85.9, 77.5, 74.5, 73.1, 72.8, 71.6,
63.7, 61.4, 55.2, 41.8, 38.9, 38.2, 36.0, 35.9, 35.4, 32.8, 29.5, 29.5, 29.4, 29.1, 28.7, 28.0, 26.9,
26.0, 25.8, 18.4, 16.3, 16.3, 11.4, 10.6, 10.5, 9.4, 7.2, 7.0, 5.6, 5.3, −5.2; [α]20D −2.6 (c 1.01,
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CHCl3); IR (thin film) ν max (cm– 1) 2952, 2931, 2876, 2857, 1732, 1670, 1614, 1513, 1461,
1378, 1247, 1192, 1083, 1040, 1005, 990, 835, 775, 738, 725; HRMS calc. for C62H118O9Si3N




















To a solution of enone 103 (1.49 g, 1.37 mmol) in THF (27 mL) at −10 °C was added Me-CBS
catalyst (R)-112 (1.65 mL, 1.65 mmol, 1.0 M in toluene), followed by BH3 · SMe2 (144 μL,
1.52 mmol). After 45 min, the reaction was quenched by addition of MeOH (20 mL). Bubbles of
gas evolved as the mixture was stirred and warmed to rt. The volatiles were evaporated in vacuo.
The crude material was re-suspended in MeOH (20 mL) and concentrated again in vacuo. This
process was repeated twice further. The resulting crude was purified by flash chromatography
(1:9 EtOAc/PE), yielding alcohol 115 as a colourless oil (1.47 g, 99%, >20:1 dr).
Rf 0.46 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.8 Hz, ArH), 6.86
(2H, d, J = 8.7 Hz, ArH), 6.18 (1H, ddt, J = 15.1, 10.6, 1.4 Hz, H3), 6.04 (1H, dd, J = 15.0, 10.4
Hz, H4), 5.68 (1H, dt, J = 15.0, 7.5 Hz, H5), 5.64 (1H, dt, J = 15.2, 5.3 Hz, H2), 5.36 (1H, t, J
= 7.1 Hz, H15), 5.18 (1H, td, J = 7.0, 2.0 Hz, H23), 4.43 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39
(1H, d, J = 11.5 Hz, ArCHaHbO), 4.20 (2H, dd, J = 5.4, 1.1 Hz, H1 × 2), 3.94 (1H, td, J = 6.8, 3.0
Hz, H13), 3.80 (3H, s, ArOMe), 3.60 (1H, ddd, J = 7.0, 5.0, 4.2 Hz, H7), 3.53 (1H, dd, J = 9.2,
4.8 Hz, H27a), 3.50 (1H, dd, J = 5.1, 3.5 Hz, H9), 3.38 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.1,
7.4 Hz, H27b), 2.86 (1H, dd, J = 8.5, 3.6 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.20–2.12
(2H, m, H6 × 2), 2.12–2.05 (1H, m, H26), 2.05–1.93 (2H, m, H16 × 2), 1.78 (1H, dqd, J = 8.5,
7.1, 2.0 Hz, H24), 1.73 (1H, dqd, J = 6.7, 5.2, 5.2 Hz, H8), 1.67–1.59 (2H, m, H12a, H22a), 1.58
(3H, br s, Me14), 1.55–1.48 (1H, m, H10), 1.47–1.37 (4H, m, H12b, H22b, H11 × 2), 1.35–1.30
(2H, m, H17 × 2), 1.30–1.20 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J =
7.0 Hz, Me26), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.94 (9H, t, J = 8.0 Hz, Si(CH2CH3)3),
0.91 (9H, s, SiC(CH3)3), 0.90 (3H, d, J = 7.0 Hz, Me24), 0.89 (3H, d, J = 5.9 Hz, Me10), 0.85
(3H, d, J = 7.0 Hz, Me8), 0.60 (6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 8.0 Hz,
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Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 174.1, 159.0, 136.7,
131.6, 131.4, 130.8, 130.3, 130.3, 129.0, 127.5, 113.7, 85.9, 78.7, 77.6, 74.6, 73.1, 72.7, 71.6,
63.7, 61.3, 55.2, 41.7, 38.8, 38.5, 35.9, 35.9, 33.0, 32.7, 29.5, 29.5, 29.4, 29.3, 28.0, 27.8, 27.5,
25.9, 25.7, 18.4, 16.3, 16.2, 10.8, 10.6, 10.3, 9.4, 7.1, 7.0, 5.6, 5.2, −5.2; [α]20D +1.9 (c 1.01,
CHCl3); IR (thin film) ν max (cm– 1) 2952, 2930, 2876, 2856, 1733, 1614, 1514, 1462, 1378,
1362, 1248, 1193, 1084, 1041, 1005, 990, 835, 776, 737, 725; HRMS calc. for C62H120O9Si3N
[M+NH4]+ 1106.8265, found 1106.8257.





































To a solution of alcohol 115 (3.9 mg, 3.58 μmol) and (S)-α-methoxy-α-trifluoromethylphenylacetic
acid (4.6 mg, 19.6 μmol) in CH2Cl2 (0.2 mL) was added DCC (8.0 mg, 38.8 μmol) followed by
DMAP (6.5 mg, 53.2 μmol). The reaction was stirred at rt for 24 h, then filtered and concentrated.
The crude was re-suspended in Et2O (1 mL), filtered, and concentrated. Flash chromatography
(1:20 EtOAc/PE) gave the (S)-MTPA ester 141 as a colourless oil (4.2 mg, 90%).
Rf 0.53 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.51–7.46 (2H, m, PhH), 7.41–7.33
(3H, m, PhH), 7.24 (2H, d, J = 8.7 Hz, PMB ArH), 6.86 (2H, d, J = 8.7 Hz, PMB ArH), 6.18
(1H, dd, J = 14.9, 10.4 Hz, H3), 6.04 (1H, dd, J = 15.1, 10.5 Hz, H4), 5.71–5.61 (2H, m, H2, H5),
5.57 (1H, t, J = 6.7 Hz, H15), 5.36 (1H, t, J = 7.3 Hz, H23), 5.18 (1H, br t, J = 7.0 Hz, H13),
4.43 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.20 (2H, d, J
= 5.1 Hz, H1 × 2), 3.80 (3H, s, ArOMe), 3.59–3.55 (1H, m, H7), 3.53 (1H, dd, J = 9.2, 4.8 Hz,
H27a), 3.52 (3H, s, OMe), 3.46 (1H, dd, J = 5.1, 3.4 Hz, H9), 3.38 (3H, s, C25OMe), 3.32 (1H,
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dd, J = 9.1, 7.5 Hz, H27b), 2.87 (1H, dd, J = 8.6, 3.7 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2),
2.20–2.11 (2H, m, H6 × 2), 2.11–2.05 (1H, m, H26), 2.05–2.01 (1H, m, H16a), 2.01–1.97 (1H, m,
H16b), 1.81–1.74 (1H, m, H24), 1.74–1.68 (1H, m, H22a), 1.68–1.60 (2H, m, H8, H12a), 1.58 (3H,
s, Me14), 1.57–1.51 (1H, m, H22b), 1.51–1.43 (1H, m, H10), 1.43–1.38 (1H, m, H12b), 1.36–1.28
(3H, m, H11a, H17 × 2), 1.28–1.18 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H,
d, J = 7.0 Hz, Me26), 0.95–0.91 (1H, obs m, H11b), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.94
(9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.90 (3H, obs d, Me24), 0.86 (3H, d,
J = 6.6 Hz, Me10), 0.83 (3H, d, J = 7.0 Hz, Me8), 0.58 (6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.56
(6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2).
The analogous procedure gave the (R)-MTPA ester 142 in ca 90% yield.
Rf 0.53 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.51–7.46 (2H, m, PhH), 7.41–7.33
(3H, m, PhH), 7.24 (2H, d, J = 8.8 Hz, PMB ArH), 6.86 (2H, d, J = 8.7 Hz, PMB ArH), 6.18 (1H,
dd, J = 15.1, 10.5 Hz, H3), 6.04 (1H, dd, J = 15.2, 10.6 Hz, H4), 5.70–5.61 (2H, m, H2, H5), 5.50
(1H, t, J = 6.8 Hz, H15), 5.30 (1H, t, J = 7.3 Hz, H23), 5.18 (1H, br t, J = 7.0 Hz, H13), 4.43 (1H,
d, J = 11.6 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.20 (2H, d, J = 5.3 Hz,
H1 × 2), 3.80 (3H, s, ArOMe), 3.60–3.55 (1H, m, H7), 3.55 (3H, s, OMe), 3.53 (1H, dd, J = 9.2,
4.8 Hz, H27a), 3.49 (1H, dd, J = 4.9, 3.5 Hz, H9), 3.38 (3H, s, C25OMe), 3.32 (1H, dd, J = 9.1,
7.5 Hz, H27b), 2.87 (1H, dd, J = 8.5, 3.6 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.20–2.12
(2H, m, H6 × 2), 2.11–2.04 (1H, m, H26), 2.03–1.95 (1H, m, H16a), 1.98–1.90 (1H, m, H16b),
1.82–1.72 (1H, m, H24), 1.72–1.65 (1H, m, H8), 1.65–1.56 (2H, m, H12a, H22a), 1.53–1.47 (1H,
m, H10), 1.41 (3H, s, Me14), 1.47–1.42 (1H, m, H12b), 1.42–1.35 (2H, m, H11a, H22b), 1.33–1.27
(2H, m, H17 × 2), 1.28–1.19 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J =
7.0 Hz, Me26), 1.00–0.94 (1H, obs m, H11b), 0.94 (18H, t, J = 8.4 Hz, Si(CH2CH3)3 × 2), 0.91
(9H, s, SiC(CH3)3), 0.90 (3H, obs d, Me24), 0.88 (3H, d, J = 6.5 Hz, Me10), 0.84 (3H, d, J = 7.0















In an argon-filled glove box, Me3O ·BF4 (601 mg, 4.07 mmol) and Proton Sponge (1.16 g,
5.41 mmol) were weighed into a flask. A solution of alcohol 115 (1.45 g, 1.33 mmol) in CH2Cl2
(68 mL) was added via cannula at rt. The mixture turned from colourless to bright yellow while
stirring at rt for 2 h. After quenching with NH4Cl (68 mL), the yellow colour gradually faded
during a further 1.5 h stirring. The layers were separated and the aqueous extracted with CH2Cl2
(3 × 30 mL). The combined organics were washed with citric acid (80 mL, 10% w/v aq.), dried
over MgSO4, and concentrated in vacuo. Flash chromatography (1:15 EtOAc/PE) gave product
117 as a pale yellow oil (1.37 g, 93%, 98% brsm).
Rf 0.59 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.24 (2H, d, J = 8.6 Hz, ArH), 6.86
(2H, d, J = 8.7 Hz, ArH), 6.18 (1H, dd, J = 15.1, 10.5 Hz, H3), 6.03 (1H, dd, J = 15.1, 10.5 Hz,
H4), 5.68 (1H, dt, J = 14.8, 7.4 Hz, H5), 5.64 (1H, dt, J = 14.9, 5.2 Hz, H2), 5.31 (1H, t, J = 6.5
Hz, H15), 5.18 (1H, td, J = 7.0, 1.8 Hz, H23), 4.43 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 (1H,
d, J = 11.6 Hz, ArCHaHbO), 4.20 (2H, d, J = 5.1 Hz, H1), 3.80 (3H, s, ArOMe), 3.59 (1H, dt, J
= 6.9, 4.7 Hz, H7), 3.53 (1H, dd, J = 9.2, 4.8 Hz, H27a), 3.48 (1H, dd, J = 4.6, 3.7 Hz, H9), 3.38
(3H, s, C25OMe), 3.34 (1H, t, J = 7.4 Hz, H13), 3.32 (1H, dd, J = 9.3, 7.4 Hz, H27b), 3.14 (3H,
s, C13OMe), 2.87 (1H, dd, J = 8.5, 3.6 Hz, H25), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.20–2.12
(2H, m, H6 × 2), 2.12–2.03 (2H, m, H16a, H26), 2.03–1.94 (1H, m, H16b), 1.78 (1H, dqd, J = 8.5,
7.0, 2.0 Hz, H24), 1.73 (1H, app sex, J = 6.0 Hz, H8), 1.67–1.57 (1H, m, H22a), 1.54–1.39 (4H,
m, H10, H12 × 2, H22b), 1.49 (3H, s, Me14), 1.39–1.31 (3H, m, H11a, H17 × 2), 1.31–1.19 (8H, m,
H18 – 21), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J = 7.0 Hz, Me26), 0.96–0.90 (1H, m,
H11b), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.91 (9H,
s, SiC(CH3)3), 0.90 (3H, obs d, Me24), 0.87 (3H, d, J = 6.9 Hz, Me10), 0.85 (3H, d, J = 7.2 Hz,
Me8), 0.59 (6H, q, J = 8.2 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 8.3 Hz, Si(CH2CH3)3), 0.07 (6H,
s, Si(CH3)2); 13C NMR (125 MHz, CDCl3) δC 174.1 (C1 ′), 159.0 (Ar C), 133.8 (C14), 131.7
(C5), 131.3 (C4), 130.9 (Ar C), 130.3 (C3), 130.3 (C2), 129.6 (C15), 129.0 (Ar C), 113.7 (Ar C),
88.3 (C13), 85.9 (C25), 77.6 (C9), 74.7 (C7), 73.1 (C23), 72.8 (ArCH2O), 71.6 (C27), 63.7 (C1),
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61.4 (OMe25), 55.5 (OMe13), 55.2 (ArOMe), 41.7 (C8), 38.9 (C24), 38.6 (C10), 35.9 (C26), 35.8
(C6), 32.8 (C22), 31.8 (C12), 29.6, 29.6, 29.5, 29.4 (C17 – 20), 28.0 (C11), 27.9 (C2 ′), 27.6 (C16),
26.0 (TBS), 25.8 (C21), 18.4 (TBS), 16.3 (Me26), 16.1 (Me10), 10.6 (Me24), 10.3 (Me8), 10.1
(Me14), 9.4 (C3 ′), 7.2, 7.0, 5.6, 5.2 (TES × 4), −5.2 (TBS); [α]20D +1.5 (c 0.89, CHCl3); IR (thin
film) ν max (cm– 1) 2952, 2926, 2876, 2855, 1734, 1615, 1514, 1462, 1378, 1362, 1248, 1192,












To a solution of propionate ester 117 (1.36 g, 1.23 mmol) in CH2Cl2 (25 mL) at −78 °C was
added DIBAL (2.48 mL, 2.48 mmol, 1.0 M in hexane) dropwise. After stirring for 1 h, the
reaction was quenched with Na+/K+ tartrate/H2O (1:1, 25 mL) and stirred for 2 h at rt. The
mixture was diluted with CH2Cl2 (25 mL) and H2O (25 mL), then extracted with CH2Cl2 (3 ×
25 mL). The combined organics were dried over Na2SO4, concentrated in vacuo, and purified by
flash chromatography (1:14 EtOAc/PE) to give alcohol 121 as a colourless oil (1.26 g, 98%).
Rf 0.40 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.26 (2H, d, J = 8.7 Hz, ArH), 6.87
(2H, d, J = 8.7 Hz, ArH), 6.18 (1H, dd, J = 15.1, 10.5 Hz, H3), 6.03 (1H, dd, J = 15.1, 10.5
Hz, H4), 5.68 (1H, dt, J = 15.1, 7.2 Hz, H5), 5.63 (1H, dt, J = 15.1, 5.3 Hz, H2), 5.31 (1H,
t, J = 7.1 Hz, H15), 4.43 (2H, s, ArCH2O), 4.20 (2H, d, J = 5.3 Hz, H1 × 2), 3.90 (1H, app t,
J = 6.3 Hz, H23), 3.80 (3H, s, ArOMe), 3.59 (1H, dt, J = 6.6, 4.7 Hz, H7), 3.52 (1H, dd, J =
8.8, 5.3 Hz, H27a), 3.50–3.45 (3H, m, H9, H27b, C23OH), 3.44 (3H, s, C25OMe), 3.34 (1H, t,
J = 6.8 Hz, H13), 3.18 (1H, dd, J = 8.9, 2.8 Hz, H25), 3.14 (3H, s, C13OMe), 2.20–2.10 (2H,
m, H6 × 2), 2.10–1.95 (3H, m, H16 × 2, H26), 1.78–1.65 (2H, m, H8, H24), 1.58–1.43 (4H, m,
H10, H12 × 2, H22a), 1.49 (3H, s, Me14), 1.42–1.33 (3H, m, H11a, H17 × 2), 1.33–1.20 (9H, m,
H18 – 21, H22b), 1.03 (3H, d, J = 7.2 Hz, Me24), 0.95–0.92 (4H, obs m, H11b, Me26), 0.95 (9H, t, J
= 7.9 Hz, Si(CH2CH3)3), 0.94 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.87
(3H, d, J = 7.6 Hz, Me10), 0.85 (3H, d, J = 7.1 Hz, Me8), 0.59 (6H, q, J = 8.2 Hz, Si(CH2CH3)3),
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0.58 (6H, q, J = 8.4 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2); 13C NMR (125 MHz, CDCl3)
δC 159.1, 133.7, 131.7, 131.3, 130.6, 130.3, 130.2, 129.6, 129.1, 113.7, 89.0, 88.2, 77.6, 74.7,
72.7, 72.0, 70.6, 63.7, 61.7, 55.5, 55.2, 41.6, 38.6, 37.1, 36.7, 35.8, 34.7, 31.7, 29.8, 29.6, 29.5,
29.4, 27.9, 28.5, 26.2, 25.9, 18.4, 16.0, 14.9, 11.4, 10.2, 10.0, 7.1, 7.0, 5.6, 5.2, −5.2; [α]20D −1.8
(c 1.01, CHCl3); IR (thin film) ν max (cm– 1) 3507, 2952, 2928, 2876, 2853, 1613, 1514, 1460,
1413, 1377, 1359, 1300, 1246, 1169, 1084, 1042, 1006, 990, 965, 834, 776, 739, 725, 675;













Silyl ether 117 (9.0 mg, 8.2 μmol) was dissolved in CH2Cl2 (0.6 mL) and pH 7 buffer (0.2 mL)
and cooled to 0 °C. The mixture was stirred rapidly as a solution of DDQ (2.0 mg, 8.8 μmol) in
CH2Cl2 (0.2 mL) was added dropwise. After 20 min, the reaction was quenched with NaHCO3
(1 mL), allowed to warm to rt, and extracted with CH2Cl2 (3 × 3 mL). The organics were dried
over MgSO4 and concentrated in vacuo. Purification by flash chromatography (1:8 EtOAc/PE)
gave aldehyde 124 as a colourless oil (4.9 mg, 61%, 79% brsm).
Rf 0.42 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 9.55 (1H, d, J = 8.0 Hz, H1), 7.24
(2H, d, J = 8.7 Hz, ArH), 7.08 (1H, dd, J = 15.3, 10.0 Hz, H3), 6.86 (2H, d, J = 8.7 Hz, ArH),
6.37–6.27 (2H, m, H4, H5), 6.08 (1H, dd, J = 15.3, 8.0 Hz, H2), 5.31 (1H, t, J = 6.8 Hz, H15),
5.18 (1H, td, J = 7.0, 1.8 Hz, H23), 4.43 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 (1H, d, J =
11.6 Hz, ArCHaHbO), 3.80 (3H, s, ArOMe), 3.67 (1H, ddd, J = 7.4, 4.9, 3.9 Hz, H7), 3.53 (1H,
dd, J = 9.2, 4.8 Hz, H27a), 3.50 (1H, app t, J = 4.0 Hz, H9), 3.38 (3H, s, C25OMe), 3.36–3.20
(2H, m, H13, H27b), 3.14 (3H, s, C13OMe), 2.87 (1H, dd, J = 8.5, 3.5 Hz, H25), 2.36–2.25 (2H,
m, H6 × 2), 2.31 (2H, q, J = 7.6 Hz, H2 ′ × 2), 2.12–2.02 (2H, m, H16a, H26), 1.99 (1H, dddd, J
= 14.4, 14.4, 7.1, 7.1 Hz, H16b), 1.81–1.72 (2H, m, H8, H24), 1.66–1.56 (1H, m, H22a), 1.56–
1.48 (2H, m, H10, H12a), 1.50 (3H, s, Me14), 1.48–1.38 (2H, m, H12b, H22b), 1.38–1.31 (3H, m,
H11a, H17 × 2), 1.31–1.20 (8H, m, H18 – 21), 1.14 (3H, t, J = 7.6 Hz, H3 ′ × 3), 1.06 (3H, d, J =
7.0 Hz, Me26), 0.97–0.93 (1H, obs m, H11b), 0.96 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.95 (9H,
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t, J = 7.9 Hz, Si(CH2CH3)3), 0.90 (3H, d, J = 7.1 Hz, Me24), 0.88 (3H, d, J = 6.5 Hz, Me10),
0.87 (3H, d, J = 6.8 Hz, Me8), 0.60 (6H, q, J = 8.1 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 8.1 Hz,
Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC 194.0 (C1), 174.1 (C1 ′), 159.0 (Ar C), 152.5
(C3), 144.8 (C5), 133.8 (C14), 130.9 (Ar C), 130.3 (C4), 130.2 (C2), 129.6 (C15), 129.0 (Ar C),
113.7 (Ar C), 88.2 (C13), 85.9 (C25), 77.4 (C9), 74.4 (C7), 73.1 (C23), 72.8 (ArCH2O), 71.6
(C27), 61.4 (OMe25), 55.5 (OMe13), 55.3 (ArOMe), 41.6 (C8), 38.9 (C10), 38.8 (C24), 36.4 (C6),
35.9 (C26), 32.8 (C22), 31.9 (C12), 29.7, 29.6, 29.4, 29.4 (C17 – 20), 28.3 (C11), 28.0 (C2 ′), 27.6
(C16), 25.8 (C21), 16.3 (Me26), 15.9 (Me10), 10.6 (Me24), 10.1 (Me14), 10.0 (Me8), 9.4 (C3 ′), 7.2,
7.0, 5.6, 5.2 (TES × 4); [α]20D −28.7 (c 0.017, CHCl3); IR (thin film) ν max (cm
– 1) 2952, 2921,
2853, 2873, 1730, 1687, 1639, 1514, 1461, 1376, 1263, 1193, 1157, 1090, 1013, 803, 737, 706;










Dienyl silyl ether 121 (1.08 g, 1.03 mmol) was dissolved in CH2Cl2 (56 mL) and pH 9.2 buffer
(14 mL) and cooled to 0 °C. DDQ (256 mg, 1.13 mmol) was added in one portion. The reaction
was stirred for 10 min, then immediately quenched with NaHCO3 (70 mL) and stirred vigorously
while warming to rt. The mixture was extracted with CH2Cl2 (3 × 40 mL), dried over Na2SO4
and concentrated in vacuo. Product isolation by flash chromatography (1:6 EtOAc/PE) gave the
aldehyde 127 as a colourless oil (589 mg, 62%, 81% brsm).
Rf 0.23 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 9.54 (1H, d, J = 8.0 Hz, H1), 7.25
(2H, d, J = 8.2 Hz, ArH), 7.07 (1H, dd, J = 15.3, 10.0 Hz, H3), 6.87 (2H, d, J = 8.7 Hz, ArH),
6.37–6.26 (2H, m, H4, H5), 6.08 (1H, dd, J = 15.3, 8.0 Hz, H2), 5.31 (1H, t, J = 6.8 Hz, H15),
4.43 (2H, s, ArCH2O), 3.89 (1H, app t, J = 6.4 Hz, H23), 3.80 (3H, s, ArOMe), 3.66 (1H, dt, J
= 7.4, 4.3 Hz, H7), 3.51 (1H, dd, J = 8.9, 5.4 Hz, H27a), 3.50–3.45 (3H, m, H9, H27b, C23OH),
3.44 (3H, s, C25OMe), 3.33 (1H, t, J = 7.0 Hz, H13), 3.18 (1H, dd, J = 8.9, 2.9 Hz, H25), 3.14
(3H, s, C13OMe), 2.36–2.24 (2H, m, H6 × 2), 2.11–2.01 (2H, m, H16a, H26), 2.01–1.94 (1H, m,
H16b), 1.75 (1H, dqd, J = 6.9, 6.9, 4.9 Hz, H8), 1.69 (1H, br q, J = 7.0 Hz, H24), 1.58–1.42 (4H,
m, H10, H12 × 2, H22a), 1.49 (3H, s, Me14), 1.42–1.18 (12H, m, H11a, H17 – 21, H22b), 1.03 (3H, d,
166
J = 7.2 Hz, Me24), 0.97–0.92 (4H, obs m, H11b, Me26), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3),
0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.88 (3H, d, J = 6.8 Hz, Me10), 0.87 (3H, d, J = 6.8
Hz, Me8), 0.59 (6H, q, J = 8.1 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 8.2 Hz, Si(CH2CH3)3);
13C NMR (125 MHz, CDCl3) δC 193.9, 159.1, 152.5, 144.8, 133.7, 130.6, 130.3, 130.2, 129.6,
129.2, 113.7, 89.0, 88.2, 77.4, 74.3, 72.7, 72.0, 70.6, 61.7, 55.5, 55.2, 41.5, 38.9, 37.1, 36.7,
36.4, 34.7, 31.8, 29.8, 29.6, 29.5, 29.4, 28.3, 27.5, 26.2, 15.9, 14.9, 11.4, 10.1, 10.0, 7.1, 6.9,
5.6, 5.1; [α]20D −2.4 (c 1.01, CHCl3); IR (thin film) ν max (cm
– 1) 3486, 2952, 2931, 2876, 2853,
1685, 1640, 1613, 1514, 1459, 1416, 1378, 1367, 1302, 1247, 1171, 1159, 1087, 1038, 1009,












Aldehyde 127 (281 mg, 0.302 mmol) was dissolved in t-BuOH (2 mL) and 2-methyl-2-butene
(2 mL), and a solution of NaClO2 (1.02 g, 80% technical grade, 9.02 mmol) and NaH2PO4 · 2 H2O
(1.88 g, 12.2 mmol) in H2O (4 mL) was added. The mixture was stirred at rt for 10 h, after which
a yellow colour was observed. A second, equal portion of NaClO2 (1.02 g), NaH2PO4 · 2 H2O
(1.88 g) and 2-methyl-2-butene (2 mL) was added, and stirring continued at 30 °C for 6 h. The
reaction mixture was then diluted with EtOAc (10 mL) and brine (10 mL), and the aqueous phase
was extracted with EtOAc (3 × 5 mL). The organics were dried over Na2SO4 and concentrated
in vacuo to give crude seco-acid 130 as a pale yellow oil. The yield was determined at the next
step.
Rf 0.28 (25:75:1 EtOAc/PE/AcOH); 1H NMR (500 MHz, CDCl3) δH 7.31 (1H, dd, J = 15.1,
9.3 Hz, H3), 7.25 (2H, d, J = 8.7 Hz, ArH), 6.88 (2H, d, J = 8.7 Hz, ArH), 6.26–6.14 (2H, m,
H4, H5), 5.79 (1H, d, J = 15.3 Hz, H2), 5.31 (1H, t, J = 6.9 Hz, H15), 4.44 (2H, s, ArCH2O), 3.94
(1H, dd, J = 8.4, 4.8 Hz, H23), 3.80 (3H, s, ArOMe), 3.67–3.61 (1H, m, H7), 3.55–3.49 (2H,
m, H9, H27a), 3.47 (1H, dd, J = 8.9, 3.6 Hz, H27b), 3.45 (3H, s, C25OMe), 3.34 (1H, t, J = 7.0
Hz, H13), 3.19 (1H, dd, J = 8.9, 2.7 Hz, H25), 3.14 (3H, s, C13OMe), 2.33–2.21 (2H, m, H6 × 2),
2.12–2.01 (2H, m, H16a, H26), 2.01–1.93 (1H, m, H16b), 1.75–1.66 (2H, m, H8, H24), 1.61–1.44
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(4H, m, H10, H12 × 2, H22a), 1.49 (3H, s, Me14), 1.44–1.19 (12H, m, H11a, H17 – 21, H22b), 1.04
(3H, d, J = 7.1 Hz, Me24), 0.97–0.91 (1H, obs m, H11b), 0.95 (3H, d, J = 6.7 Hz, Me26), 0.95
(9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.88 (3H, d, J = 6.8
Hz, Me10), 0.85 (3H, d, J = 6.8 Hz, Me8), 0.59 (6H, q, J = 8.4 Hz, Si(CH2CH3)3), 0.58 (6H, q,
J = 8.4 Hz, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC 170.9, 159.1, 146.5, 142.7, 133.6,
130.6, 130.0, 129.8, 129.2, 118.9, 113.7, 89.1, 88.1, 77.2, 74.2, 72.8, 72.0, 70.8, 61.7, 55.5, 55.3,
41.3, 39.1, 37.1, 36.6, 36.3, 34.6, 31.7, 29.7, 29.7, 29.4, 29.3, 28.3, 27.6, 26.1, 15.6, 14.9, 11.5,
10.2, 10.0, 7.1, 7.0, 5.6, 5.2; [α]20D −6.0 (c 0.99, CHCl3); IR (thin film) ν max (cm
– 1) 2948, 2931,
2876, 2853, 1712, 1690, 1643, 1614, 1513, 1459, 1415, 1377, 1302, 1246, 1173, 1084, 1038,











Crude seco-acid 130 (ca 285 mg, 0.302 mmol) was dried azeotropically with C6H6 and dis-
solved in THF (10 mL). Et3N (420 μL, 3.01 mmol) and 2,4,6-trichlorobenzoyl chloride (330 μL,
2.11 mmol) were added at rt. The mixture was stirred for 1.5 h, then diluted with toluene (28 mL)
and added via syringe pump to a solution of DMAP (369 mg, 3.02 mmol) in toluene (82 mL)
over 12 h. The cloudy orange solution was stirred for a further 3 h, then filtered through a plug
of silica, rinsed with Et2O (80 mL), and concentrated in vacuo. The resulting oil was purified
by flash chromatography (1:15 EtOAc/PE) to give macrocycle 132 as a pale yellow oil (197 mg,
70% over 2 steps).
Rf 0.56 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.28 (1H, dd, J = 15.4, 10.0 Hz, H3),
7.23 (2H, d, J = 8.6 Hz, ArH), 6.86 (2H, d, J = 8.7 Hz, ArH), 6.25–6.13 (2H, m, H4, H5), 5.83
(1H, d, J = 15.3 Hz, H2), 5.38 (1H, dt, J = 10.8, 2.4 Hz, H23), 5.24 (1H, dd, J = 8.2, 6.0 Hz,
H15), 4.42 (1H, d, J = 11.5 Hz, ArCHaHbO), 4.39 (1H, d, J = 11.7 Hz, ArCHaHbO), 3.79 (3H, s,
ArOMe), 3.67–3.62 (1H, m, H7), 3.56–3.49 (2H, m, H9, H27a), 3.44 (3H, s, C25OMe), 3.32 (1H,
dd, J = 9.1, 7.8 Hz, H27b), 3.30 (1H, t, J = 7.2 Hz, H13), 3.13 (3H, s, C13OMe), 2.90 (1H, dd, J
= 8.2, 3.6 Hz, H25), 2.35–2.26 (1H, m, H6a), 2.18–2.02 (3H, m, H6b, H16a, H26), 1.89–1.80 (1H,
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m, H16b), 1.80–1.73 (1H, m, H24), 1.73–1.64 (2H, m, H8, H22a), 1.63–1.54 (2H, m, H10, H12a),
1.53–1.45 (1H, m, H12b), 1.47 (3H, s, Me14), 1.44–1.34 (2H, m, H21a, H22b), 1.34–1.15 (10H,
m, H11a, H17 – 20, H21b), 1.06 (3H, d, J = 7.0 Hz, Me26), 0.98–0.93 (1H, obs m, H11b), 0.95 (9H,
t, J = 8.0 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.91 (6H, app d, J = 7.0
Hz, Me10, Me24), 0.88 (3H, d, J = 6.8 Hz, Me8), 0.59 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.58
(6H, q, J = 7.9 Hz, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC 167.2 (C1), 159.0 (Ar C),
144.9 (C3), 141.5 (C5), 133.2 (C14), 130.8 (Ar C), 130.1 (C15), 130.0 (C4), 129.0 (Ar C), 119.8
(C2), 113.6 (Ar C), 88.0 (C13), 85.7 (C25), 77.2 (C9), 73.4 (C7), 73.2 (C23), 72.7 (ArCH2O), 71.6
(C27), 61.1 (OMe25), 55.4 (OMe13), 55.2 (ArOMe), 41.0 (C8), 40.8 (C24), 39.5 (C10), 36.4 (C6),
35.9 (C26), 33.5 (C22), 31.4 (C12), 29.0, 28.6, 28.3, 27.9, 27.8, 27.6 (C11, C16, C17, C18, C20, C21),
24.6 (C19), 16.2 (Me26), 14.5 (Me10), 11.7 (Me8), 11.2 (Me24), 9.8 (Me14), 7.1, 7.0, 5.4, 5.2 (TES
× 4); [α]20D +11.4 (c 1.04, CHCl3); IR (thin film) ν max (cm
– 1) 2952, 2935, 2875, 2857, 1712,
1643, 1614, 1513, 1459, 1364, 1301, 1245, 1211, 1172, 1134, 1092, 1040, 1002, 820, 810, 762,
739, 725; HRMS calc. for C54H100O8Si2N [M+NH4]+ 946.6982, found 946.6986.











The fully protected macrocycle 132 (81.3 mg, 0.0875 mmol) was dissolved in CH2Cl2 (4 mL)
and pH 7 buffer (2 mL) and cooled to 0 °C. DDQ (40.0 mg, 0.176 mmol) was added, then
the rapidly stirring biphasic solution was warmed to rt. After 2 h, the mixture was quenched
with NaHCO3 (4 mL), extracted with CH2Cl2 (3 × 3 mL), dried over MgSO4 and concentrated
in vacuo. The crude material was purified by flash chromatography (1:4 EtOAc/PE) to yield
alcohol 139 as a colourless oil (63.8 mg, 90%).
Rf 0.19 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 7.28 (1H, dd, J = 15.3, 10.1 Hz,
H3), 6.25–6.13 (2H, m, H4, H5), 5.83 (1H, d, J = 15.3 Hz, H2), 5.37 (1H, dt, J = 10.7, 2.6
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Hz, H23), 5.24 (1H, dd, J = 7.9, 5.8 Hz, H15), 3.79 (1H, dt, J = 11.0, 3.6 Hz, H27a), 3.64
(1H, ddd, J = 7.8, 5.5, 3.0 Hz, H7), 3.58–3.48 (2H, m, H9, H27b), 3.52 (3H, s, C25OMe), 3.30
(1H, dd, J = 8.2, 5.9 Hz, H13), 3.13 (3H, s, C13OMe), 2.99 (1H, dd, J = 8.1, 3.6 Hz, H25),
2.91 (1H, dd, J = 6.7, 4.0 Hz, C27OH), 2.36–2.26 (1H, m, H6a), 2.18–2.06 (2H, m, H6b, H16a),
1.93–1.80 (3H, m, H16b, H24, H26), 1.75–1.65 (2H, m, H8, H22a), 1.63–1.53 (2H, m, H10, H12a),
1.53–1.42 (2H, m, H12b, H22b), 1.46 (3H, s, Me14), 1.42–1.34 (1H, m, H21a), 1.33–1.16 (10H,
m, H11a, H17 – 20, H21b), 1.12 (3H, d, J = 7.2 Hz, Me26), 0.98–0.92 (1H, obs m, H11b), 0.95 (9H,
t, J = 8.0 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.91 (3H, d, J = 7.1 Hz,
Me24), 0.91 (3H, d, J = 7.2 Hz, Me10), 0.88 (3H, d, J = 6.8 Hz, Me8), 0.59 (6H, q, J = 7.9 Hz,
Si(CH2CH3)3), 0.58 (6H, q, J = 8.0 Hz, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC 167.2
(C1), 145.1 (C3), 141.8 (C5), 133.3 (C14), 130.1 (C15), 129.9 (C4), 119.6 (C2), 88.6 (C25), 88.0
(C13), 77.2 (C9), 73.4 (C7), 73.1 (C23), 65.0 (C27), 61.5 (OMe25), 55.4 (OMe13), 41.2 (C24), 41.1
(C8), 39.6 (C10), 36.5 (C6), 36.2 (C26), 33.6 (C22), 31.4 (C12), 29.0, 28.6, 28.3, 27.9, 27.8, 27.7
(C11, C16, C17, C18, C20, C21), 24.5 (C19), 16.3 (Me26), 14.5 (Me10), 11.7 (Me8), 11.2 (Me24), 9.8
(Me14), 7.1, 7.0, 5.4, 5.2 (TES × 4); [α]20D +22.6 (c 1.02, CHCl3); IR (thin film) ν max (cm
– 1)
3422, 2952, 2933, 2875, 1712, 1642, 1458, 1300, 1261, 1237, 1212, 1174, 1134, 1092, 1056,











To oxalyl chloride (13 μL, 0.156 mmol) in CH2Cl2 (1.5 mL) at −78 °C was added DMSO (22 μL,
0.311 mmol), followed after 15 min by alcohol 139 (42.0 mg, 0.0519 mmol) in CH2Cl2 (1.5 mL),
then after a further 15 min Et3N (65 μL, 0.467 mmol). The reaction was warmed to rt and stirred
for 20 min, then quenched with NH4Cl (3 mL) and diluted with H2O (15 mL) and Et2O (15 mL).
The biphasic mixture was shaken vigorously and the layers separated. The aqueous phase was
extracted with Et2O (3 × 5 mL), and the combined organics washed with HCl (12 mL, 0.5 M)
and H2O (10 mL), then dried over MgSO4 and concentrated in vacuo. The resulting pale yellow
oil containing crude 31 (41.1 mg, 98%) was used directly in the aldol reaction to minimise the
risk of epimerisation.
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Rf 0.56 (1:5 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 9.72 (1H, s, H27), 7.28 (1H, dd, J =
15.3, 10.0 Hz, H3), 6.24–6.13 (2H, m, H4, H5), 5.82 (1H, d, J = 15.3 Hz, H2), 5.44 (1H, br d, J
= 10.9 Hz, H23), 5.23 (1H, dd, J = 7.9, 6.0 Hz, H15), 3.67–3.60 (1H, m, H7), 3.55–3.48 (1H, m,
H9), 3.42 (3H, s, C25OMe), 3.32–3.25 (2H, m, H13, H25), 3.12 (3H, s, C13OMe), 2.73–2.64 (1H,
m, H26), 2.35–2.24 (1H, m, H6a), 2.17–2.04 (2H, m, H6b, H16a), 1.88–1.75 (2H, m, H16b, H24),
1.75–1.63 (2H, m, H8, H22a), 1.63–1.52 (2H, m, H10, H12a), 1.52–1.43 (1H, obs m, H12b), 1.45
(3H, s, Me14), 1.43–1.33 (2H, m, H21a, H22b), 1.33–1.17 (10H, m, H11a, H17 – 20, H21b), 1.15 (3H,
d, J = 7.1 Hz, Me26), 0.98–0.91 (1H, obs m, H11b), 0.94 (18H, t, J = 8.2 Hz, Si(CH2CH3)3 × 2),
0.90 (3H, d, J = 6.8 Hz, Me10), 0.87 (3H, d, J = 6.8 Hz, Me8), 0.81 (3H, d, J = 7.1 Hz, Me24),
0.58 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 8.0 Hz, Si(CH2CH3)3); 13C NMR
(125 MHz, CDCl3) δC 203.9, 167.2, 145.2, 141.9, 133.3, 130.1, 129.9, 119.4, 88.0, 83.4, 77.2,
73.4, 72.6, 59.2, 55.4, 48.1, 40.8, 39.5, 36.4, 33.2, 31.4, 29.7, 29.0, 28.6, 28.3, 27.8, 27.8, 27.6,
24.6, 14.5, 11.6, 10.4, 9.9, 9.8, 7.0, 7.0, 5.4, 5.2; [α]20D −1.9 (c 1.00, CHCl3); IR (thin film) ν
max (cm– 1) 2948, 2932, 2876, 1714, 1641, 1615, 1458, 1413, 1361, 1300, 1260, 1236, 1171,














Ketone 32 (48.1 mg, 0.212 mmol) and aldehyde 31 (ca 63 mg,0.0788 mmol) were each dried by
forming an azeotrope with C6H6 and dried under high vacuum for 16 h. With rigorous exclusion
of moisture, the ketone was dissolved in Et2O (1.8 mL) and cooled to 0 °C. Cy2BCl (56 μL,
0.256 mmol) and NEt3 (35 μL, 0.251 mmol) were added. The enolising mixture was stirred
for 1.5 h, then cooled to −78 °C, and the aldehyde was added dropwise as a solution in Et2O
(1.8 mL). After stirring at low temperature for 1 h, the flask was transferred to a −50 °C bath,
and allowed to gradually warm to −20 °C over 1 h. This temperature was maintained for 1 h,
whereupon TLC analysis showed that the aldehyde had been consumed. Silica gel (ca 400 mg)
and Et2O (2 mL) were added, and the slurry was stirred for 1 h under ambient air while warming
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to rt. The mixture was filtered, rinsed with Et2O (5 mL) and EtOAc (5 mL), and concentrated
in vacuo. The resulting crude was subjected to flash chromatography (1:2 → 1:1 EtOAc/PE)
and all fractions containing the aldol adduct were collected. The resulting oil containing desired
product 144 and excess ketone 32 (ca 88 mg) was carried through to the next step as a mixture.
Rf 0.38 & 0.33 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.29 (0.66H, s, NCHO),
[8.07] (0.34H, s, NCHO*), 7.28 (1H, dd, J = 15.5, 10.1 Hz, H3), [7.13] (0.34H, d, J = 14.7
Hz, H34*), 6.46 (0.66H, d, J = 14.2 Hz, H34), 6.25–6.13 (2H, m, H4, H5), 5.83 (1H, d, J
= 15.3 Hz, H2), 5.39 (1H, br d, J = 10.9 Hz, H23), 5.24 (1H, dd, J = 7.6, 5.5 Hz, H15),
[5.13] (0.34H, dd, J = 14.4, 9.5 Hz, H33*), 5.10 (0.66H, dd, J = 14.2, 9.2 Hz, H33), 4.49–
4.42 (0.25H, m, H27†), 4.25–4.13 (0.75H, m, H27), 3.69–3.62 (1H, m, H7), 3.58–3.49 (1H,
m, H9), 3.45 (3H, s, C25OMe), 3.41–3.38 (1H, m, C27OH), 3.36 (3H, s, C31OMe), 3.33–3.28
(2H, m, H13, H31), 3.13 (3H, s, C13OMe), [3.08] (1H, s, NMe*), 3.03 (2H, s, NMe), 2.96
(1H, dd, J = 8.0, 3.9 Hz, H25), 2.82–2.68 (2H, m, H28a, H30), 2.65–2.56 (1H, m, H28b), 2.48–
2.35 (1H, m, H32), 2.35–2.26 (1H, m, H6a), 2.18–2.06 (2H, m, H6b, H16a), 1.97–1.80 (3H, m,
H16b, H24, H26), 1.80–1.48 (5H, m, H8, H10, H12 × 2 ,H22a), 1.47 (3H, s, Me14), 1.44–1.34 (1H,
m, H22b), 1.34–1.18 (11H, m, H11a, H17 – 21), 1.17 (3H, d, J = 6.5 Hz, Me32), 1.00–0.93 (28H,
m, H11b, Me24, Me26, Me30, Si(CH2CH3)3 × 2), 0.91 (3H, d, J = 7.0 Hz, Me10), 0.88 (3H, d, J =
7.4 Hz, Me8), 0.60 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 7.9 Hz, Si(CH2CH3)3);
13C NMR (125 MHz, CDCl3) δC [215.7] (C29*), 215.6 (C29), 167.2 (C1), 162.2 (NCHO),
[160.9] (NCHO*), 145.0 (C3), 141.7 (C5), 133.3 (C14), 130.2 (C15), 130.0 (C4), 128.9 (C34),
[124.9] (C34*), 119.7 (C2), [113.0] (C33*), 111.2 (C33), 88.0 (C13), [87.6] (C31*), 87.5 (C31), 86.6
(C25), [86.4] (C25*), 77.2 (C9), 73.4 (C7), 73.0 (C23), 68.6 (C27), 66.2 (C27†), [61.4] (C31OMe*),
61.3 (C31OMe), 60.9 (C25OMe), 55.5 (C13OMe), 49.6 (C30), 48.5 (C28), [48.4] (C28*), 41.6
(C24), [41.5] (C24*), 40.2 (C26), [40.1] (C26*), 39.6 (C10), [37.7] (C32*), 37.5 (C32), 37.2 (C8),
36.5 (C6), 33.6 (C22), [33.1] (NMe*), 31.4 (C12), 29.7, 29.0, 28.6, 28.3, 28.0 (C11, C17 – 20),
27.7 (C16), 27.6 (NMe), 24.6 (C21), 19.4 (Me32), 14.5 (Me10), 14.3 (Me26), [14.1] (Me26*),
[13.4] (Me30*), 13.3 (Me30), 11.7 (Me8), 11.4 (Me24), 9.8 (Me14), 7.1, 7.0, 5.4, 5.2 (TES × 4);
[α]20D −22.7 (c 1.03, CHCl3); IR (thin film) ν max (cm
– 1) 3209, 2931, 2876, 2853, 1697, 1656,
1457, 1413, 1378, 1260, 1237, 1093, 1069, 1003, 969, 941, 808, 741, 725; HRMS calc. for
C58H111N2O10Si2 [M+NH4]+ 1051.7772, found 1051.7774.
Distinguishable resonances of the minor rotamer (ca 2:1 ratio) are given in brackets and marked
with an asterisk (†). The diastereomeric ratio of the product at C27 is approximately 3:1, and














A mixture of aldol adduct 144 and ketone 32 (ca 88 mg, ≤ 0.0788 mmol 144) was dissolved
in THF (1.8 mL) and added to Burgess salt (methyl N-(triethylammoniumsulfonyl)carbamate,
26 mg, 0.109 mmol). The mixture was warmed to 30 °C and stirred for 16 h. The reaction
was quenched with NH4Cl (1 mL) and stirred for 10 min as a white precipitate formed. The
aqueous was extracted with EtOAc (3 × 1 mL), dried over MgSO4, and concentrated in vacuo.
The resulting colourless oil was resubmitted to the same reaction conditions, following which
the crude was purified by flash chromatography (1:4 EtOAc/PE). This resulted in isolation of the
enone 147 (50.7 mg, 63% over 3 steps) and recovered ketone 32 (28 mg, 93% recovery).
Rf 0.74 & 0.68 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.29 (0.66H, s, NCHO), [8.08]
(0.34H, s, NCHO*), 7.28 (1H, dd, J = 15.4, 10.0 Hz, H3), [7.14] (0.34H, d, J = 15.2 Hz, H34*),
6.90 (0.66H, dd, J = 16.0, 8.4 Hz, H27), [6.88] (0.34H, dd, J = 15.8, 8.6 Hz, H27*), 6.48 (0.66H,
d, J = 14.1 Hz, H34), 6.24–6.16 (2H, m, H4, H5), 6.15 (0.66H, d, J = 15.7 Hz, H28), [6.13]
(0.34H, d, J = 16.0 Hz, H28*), 5.83 (1H, d, J = 15.4 Hz, H2), 5.39 (1H, br d, J = 10.6 Hz, H23),
5.23 (1H, dd, J = 7.9, 5.8 Hz, H15), [5.16] (0.34H, dd, J = 14.6, 9.5 Hz, H33*), 5.14 (0.66H, dd,
J = 14.1, 9.3 Hz, H33), 3.67–3.60 (1H, m, H7), 3.57–3.50 (1H, m, H9), 3.48 (3H, s, C25OMe),
3.32–3.26 (5H, m, H13, H31, C31OMe), 3.13 (3H, s, C13OMe), [3.09] (1H, s, NMe*), 3.05 (2H,
s, NMe), 3.03–2.95 (1H, m, H30), 2.95–2.87 (1H, m, H25), 2.66-2.56 (1H, m, H26), 2.50–2.36
(1H, m, H32), 2.36–2.26 (1H, m, H6a), 2.19–2.04 (2H, m, H6b, H16a), 1.88–1.78 (1H, m, H16b),
1.75–1.65 (2H, m, H8, H22a), 1.65–1.53 (3H, m, H10, H12a, H24), 1.53–1.45 (1H, m, H12b), 1.46
(3H, s, Me14), 1.42–1.32 (1H, m, H22b), 1.32–1.18 (11H, m, H11a, H17 – 21), 1.16 (3H, d, J = 6.7
Hz, Me26), 1.15 (3H, d, J = 6.9 Hz, Me32), 0.98–0.91 (1H, obs m, H11b), 0.95 (9H, t, J = 8.0 Hz,
Si(CH2CH3)3), 0.95 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.94 (3H, obs d, Me30), 0.91 (3H, d, J =
6.9 Hz, Me10), 0.88 (3H, d, J = 6.9 Hz, Me8), 0.83 (3H, d, J = 7.0 Hz, Me24), 0.59 (6H, q, J = 8.0
Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 7.9 Hz, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC
[203.5] (C29*), 203.4 (C29), [167.3] (C1*), 167.3 (C1), 162.2 (NCHO), [160.9] (NCHO*), 149.3
(C27), [149.2] (C27*), 145.1 (C3), 141.9 (C5), 133.3 (C14), [130.6] (C28*), 130.5 (C28), 130.1
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(C15), 129.9 (C4), 128.8 (C34), [124.8] (C34*), 119.6 (C2), [113.3] (C33*), 111.5 (C33), 88.0
(C13), [87.6] (C31*), 87.5 (C31), [86.0] (C25*), 86.0 (C25), 77.1 (C9), 73.4 (C7), [73.0] (C23*),
72.9 (C23), [61.2] (C31OMe*), 61.2 (C31OMe), 61.0 (C25OMe), 55.5 (C13OMe), [46.2] (C30*),
46.1 (C30), 41.5 (C24), 41.2 (C8), 39.6 (C26), 39.5 (C10), [37.9] (C32*), 37.7 (C32), 36.5 (C6),
33.5 (C22), [33.0] (NMe*), 31.4 (C12), 29.0, 28.6, 28.3, 27.9, 27.8 (C11, C17 – 20), 27.7 (C16), 27.5
(NMe), 24.6 (C21), [19.6] (Me32*), 19.5 (Me32), 17.5 (Me26), [17.4] (Me26*), 14.5 (Me10), 13.8
(Me30), [13.7] (Me30*), 11.7 (Me8), 10.4 (Me24), [10.4] (Me24*), 9.8 (Me14), 7.1, 7.0, 5.4, 5.2
(TES × 4); [α]20D −47.6 (c 0.50, CHCl3); IR (thin film) ν max (cm
– 1) 2931, 2876, 2857, 1694,
1657, 1619, 1458, 1415, 1371, 1359, 1316, 1304, 1260, 1237, 1133, 1095, 1070, 1004, 985, 740,
725; HRMS calc. for C58H105NO9Si2Na [M+Na]+ 1038.7220, found 1038.7228.














Stryker’s reagent (280 μL, 0.025 M in toluene, 7.0 μmol) was added to enone 147 (35.5 mg,
34.9 μmol) in toluene (700 μL). The mixture was stirred for 2 h at rt, then a further aliquot of
the reagent solution (280 μL, 7.0 μmol) was added. After a further 2 h, the reaction mixture was
loaded directly onto a silica column. Ketone 148 eluted from the column (1:5→ 1:3 EtOAc/PE)
and was concentrated to a colourless oil (29.3 mg, 82%).
Rf 0.74 & 0.57 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 8.28 (0.66H, s, NCHO),
[8.07] (0.34H, s, NCHO*), 7.27 (1H, dd, J = 15.4, 9.8 Hz, H3), [7.12] (0.34H, d, J = 14.7
Hz, H34*), 6.45 (0.66H, d, J = 14.2 Hz, H34), 6.24–6.13 (2H, m, H4, H5), 5.83 (1H, d, J =
15.3 Hz, H2), 5.41 (1H, br d, J = 10.8 Hz, H23), 5.24 (1H, dd, J = 7.9, 5.9 Hz, H15), [5.12]
(0.34H, dd, J = 14.3, 10.5 Hz, H33*), 5.10 (0.66H, dd, J = 14.1, 9.4 Hz, H33), 3.67–3.59 (1H,
m, H7), 3.56–3.48 (1H, m, H9), 3.47 (3H, s, C25OMe), 3.33 (3H, s, C31OMe), 3.32–3.27 (2H,
m, H13, H31), 3.13 (3H, s, C13OMe), [3.07] (1H, s, NMe*), 3.03 (2H, s, NMe), 2.82–2.72 (1H,
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m, H25), 2.71–2.62 (1H, m, H30), 2.62–2.51 (1H, m, H28a), 2.49–2.40 (1H, m, H28b), 2.40–
2.34 (1H, m, H32), 2.34–2.26 (1H, m, H6a), 2.18–1.95 (2H, m, H6b, H16a), 1.87–1.79 (1H,
m, H16b), 1.79–1.48 (8H, m, H8, H10, H12 × 2 ,H22a, H24, H26, H27a), 1.46 (3H, s, Me14), 1.41–
1.17 (13H, m, H11a, H17 – 21, H22b, H27b), 1.15 (3H, d, J = 6.9 Hz, Me32), 1.01–0.84 (34H, m,
H11b, Me8, Me10, Me24, Me26, Me30, Si(CH2CH3)3 × 2), 0.59 (6H, q, J = 7.4 Hz, Si(CH2CH3)3),
0.58 (6H, q, J = 7.4 Hz, Si(CH2CH3)3); 13C NMR (125 MHz, CDCl3) δC [214.3] (C29*), 214.2
(C29), 167.3 (C1), 162.1 (NCHO), [160.8] (NCHO*), 144.9 (C3), 134.8 (C5), 133.2 (C14), 130.2
(C15), 129.9 (C4), 128.7 (C34), [124.7] (C34*), 119.8 (C2), [113.1] (C33*), 111.3 (C33), 88.0,
87.4, 87.3 (C13, C25, C31), 74.3 (C9), 73.4 (C7), 73.2 (C23), 61.4 (C31OMe), 61.3 (C25OMe),
55.5 (C13OMe), [49.2] (C30*), 49.0 (C30), 42.0 (C28), [42.0] (C28*), 41.0 (C24), 40.9 (C26), 39.5
(C10), [37.7] (C32*), 37.5 (C32), 36.4 (C6), 34.4 (C8), 33.7 (C22), [33.1] (NMe*), 31.4 (C12), 29.7,
29.0, 28.6, 28.3, 27.9, 27.8 (C11, C16 – 20), 27.6 (NMe), 24.6 (C21), 23.4 (C27), [19.4] (Me32*),
19.4 (Me32), 17.4 (Me8), 14.5 (Me30), 13.5 (Me10), 13.5 (Me24), 10.8 (Me26), 9.8 (Me14), 7.1,
7.0, 5.4, 5.2 (TES × 4) ; [α]20D −25.8 (c 0.859, CHCl3); IR (thin film) ν max (cm
– 1) 2952, 2932,
2876, 2857, 1698, 1657, 1458, 1412, 1371, 1318, 1302, 1258, 1239, 1135, 1094, 1069, 1004,
970, 943, 915, 801, 739, 726; HRMS calc. for C58H111N2O9Si2 [M+NH4]+ 1035.7823, found
1035.7840.
Distinguishable resonances of the minor rotamer (ca 2:1 ratio) are given in brackets and marked
with an asterisk.













A stock solution of HF · pyridine was prepared by diluting 70% HF · pyridine (100 μL) into THF
(1 mL) and pyridine (200 μL). An aliquot (600 μL) was added to bis-TES ether 148 (3.3 mg,
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3.2 μmol) at 0 °C. The reaction was warmed to rt and stirred for 16 h, then quenched cau-
tiously with NaHCO3 at 0 °C and stirred at rt for 30 min. The aqueous was extracted with
EtOAc (3 × 5 mL), dried over Na2SO4, and concentrated in vacuo. Flash chromatography (1:1
EtOAc/CH2Cl2→ 5:5:1 EtOAc/CH2Cl2/MeOH) to give diol 153 as an oil (2.1 mg, 82%).
Rf 0.54 (5:5:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500 MHz, CDCl3) δH 8.28 (0.66H, s, NCHO),
[8.07] (0.34H, s, NCHO*), 7.28–7.23 (1H, obs dd, H3), [7.12] (0.34H, d, J = 14.7 Hz, H34*),
6.45 (0.66H, d, J = 14.2 Hz, H34), 6.27 (1H, dd, J = 15.1, 11.1 Hz, H4), 6.11 (1H, dt, J = 15.0,
7.5 Hz, H5), 5.85 (1H, d, J = 15.3 Hz, H2), 5.36 (1H, br d, J = 10.3 Hz, H23), 5.30 (1H, t, J = 6.9
Hz, H15), [5.12] (0.34H, dd, J = 14.8, 10.6 Hz, H33*), 5.11 (0.66H, dd, J = 14.2, 9.5 Hz, H33),
3.88–3.81 (1H, m, H7), 3.70–3.64 (1H, m, H9), 3.45 (3H, s, C25OMe), 3.38–3.32 (1H, obs m,
H13), 3.34 (3H, s, C31OMe), 3.31 (1H, br d, J = 9.5 Hz, H31), 3.15 (3H, s, C13OMe), [3.08] (1H,
s, NMe*), 3.04 (2H, s, NMe), 2.85–2.73 (2H, m, C7OH, H25), 2.72–2.62 (1H, m, H30), 2.62–
2.50 (3H, m, H6 × 2,H28a), 2.50–2.33 (3H, m, C9OH, H28b, H32), 2.11–1.93 (2H, m, H16 × 2),
1.80–1.53 (8H, m, H8, H10, H12 × 2 ,H22a, H24, H26, H27a), 1.53–1.46 (4H, m, H11a, Me14), 1.46–
1.38 (2H, m, H22b, H27b), 1.38–1.19 (10H, m, H17 – 21), 1.16 (3H, d, J = 6.9 Hz, Me32), 1.05
(3H, d, J = 7.1 Hz, Me24), 0.99–0.95 (1H, obs m, H11b), 0.97 (3H, d, J = 6.9 Hz, Me8), 0.91
(3H, d, J = 7.1 Hz, Me30), 0.90 (3H, d, J = 7.0 Hz, Me26), 0.79 (3H, d, J = 6.8 Hz, Me10);
13C NMR (125 MHz, CDCl3) δC [214.3] (C29*), 214.2 (C29), 167.0 (C1), 162.2 (NCHO), 144.2
(C3), 138.9 (C5), 133.7 (C14), 131.0 (C15), 129.9 (C4), 128.7 (C34), [124.7] (C34*), 120.6 (C2),
[113.2] (C33*), 111.4 (C33), 87.9, 87.5, 87.3 (C13, C25, C31), 75.3 (C9), 75.2 (C7), 73.8 (C23),
61.4 (C25OMe), 61.3 (C31OMe), 55.7 (C13OMe), [49.2] (C30*), 49.1 (C30), 42.1 (C28), [42.0]
(C28*), 40.7 (C24), 39.0 (C6), [37.7] (C32*), 37.5 (C32), 37.0 (C26), 37.0 (C10), 34.5 (C8), 33.7
(C22), [33.1] (NMe*), 30.9 (C12), 29.7, 28.8, 28.7, 28.4, 27.8 (C11, C17 – 20), 27.6 (NMe), 27.3
(C16), 25.1 (C21), 23.5 (C27), 19.4 (Me32), 17.4 (Me8), 15.8 (Me10), 13.5 (Me30), 11.6 (Me24),
10.9 (Me26), 10.3 (Me14); [α]20D −49.3 (c 0.035, CHCl3); IR (thin film) ν max (cm
– 1) 3365, 2924,
2853, 1704, 1655, 1462, 1375, 1276, 1258, 1240, 1137, 1092, 1074, 1002, 969, 808, 800, 737,
723; HRMS calc. for C46H83N2O9 [M+NH4]+ 807.6093, found 807.6106.



















(S)-Trimethylserine (3.9 mg, 26.5 μmol) and DMAP (3.2 mg, 26.2 μmol) were dissolved in
CH2Cl2 (3 mL), and TCBC (8 μL, 51.2 μmol) and NEt3 (11 μL, 78.9 μmol) were added to
form a yellow stock solution. Diol 153 (2.1 mg, 2.66 μmol) was dissolved in C6H6 (0.3 mL),
and an aliquot of the mixed anhydride solution (0.3 mL) was added at 0 °C. After 30 min, a
second aliquot (0.15 mL) was added, and stirring continued at the same temperature. After
a further 30 min, another aliquot (0.15 mL) was added, and the mixture was warmed to rt.
The reaction was quenched with MeOH (0.3 mL) after a further 30 min, then concentrated in
vacuo. Flash chromatography (1:1 EtOAc/CH2Cl2 → 10:10:1 EtOAc/CH2Cl2/MeOH) gave the
esterified product 154 as an oil (0.7 mg, 29%, 99% brsm).
Rf 0.34 (5:5:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500 MHz, CDCl3) δH 8.28 (0.66H, s, NCHO),
8.07 (0.34H, s, NCHO*), 7.25 (1H, obs dd, H3), 7.12 (0.34H, d, J = 14.7 Hz, H34*), 6.45 (0.66H,
d, J = 14.2 Hz, H34), 6.26 (1H, dd, J = 14.7, 10.9 Hz, H4), 6.03 (1H, dt, J = 14.8, 7.4 Hz, H5),
5.86 (1H, d, J = 15.3 Hz, H2), 5.38 (1H, br d, J = 10.6 Hz, H23), 5.29 (1H, dd, J = 14.3, 7.2
Hz, H15), 5.12 (0.34H, dd, J = 14.3, 10.2 Hz, H33*), 5.10 (0.66H, dd, J = 14.1, 9.5 Hz, H33),
4.98 (1H, dd, J = 9.4, 6.7 Hz, H7), 3.68 (1H, dd, J = 9.4, 7.0 Hz, H3′a), 3.63 (1H, dd, J = 9.5,
5.8 Hz, H3′b), 3.62–3.57 (1H, m, H9), 3.46 (3H, s, C25OMe), 3.44–3.39 (1H, m, H2 ′), 3.38 (1H,
br d, J = 6.7 Hz, H13), 3.36 (3H, s, C3 ′OMe), 3.34 (3H, s, C31OMe), 3.31 (1H, br d, J = 9.2
Hz, H31), 3.14 (3H, s, C13OMe), 3.08 (1H, s, NMe*), 3.04 (2H, s, NMe), 2.78 (1H, dd, J =
8.7, 2.5 Hz, H25), 2.72–2.62 (1H, m, H30), 2.58–2.50 (2H, m, H6a, H28a), 2.50–2.32 (10H, m,
H6b, H28b, C9OH, H32, C2 ′NMe2), 2.13–2.03 (1H, m, H16a), 1.95–1.85 (2H, m, H8, H16b), 1.80–
1.70 (3H, m, H24, H26, H27a), 1.70–1.59 (4H, m, H10, H12 × 2 ,H22a), 1.50 (3H, s, Me14), 1.46–
1.35 (2H, m, H22b, H27b), 1.35–1.18 (11H, m, H11a, H17 – 21), 1.16 (3H, d, J = 6.9 Hz, Me32),
0.98 (3H, d, J = 6.9 Hz, Me8), 0.97 (3H, d, J = 6.7 Hz, Me10), 0.91 (3H, d, J = 6.7 Hz, Me30),
0.91–0.86 (1H, obs m, H11b), 0.89 (3H, d, J = 7.0 Hz, Me24), 0.88 (3H, d, J = 6.9 Hz, Me26);
177
13C NMR (125 MHz, CDCl3) δC [214.3], 214.3, 170.2, 167.0, 162.2, [160.9], 143.9, 137.8,
133.8, 131.4, 129.9, 128.7, [124.7], 121.1, [113.2], 111.4, 87.8, 87.4, 87.4, 87.3, 74.0, 73.7,
70.5, 67.4, 61.4, 61.4, [61.3], 59.2, 55.6, [49.2], 49.1, 42.4, 42.1, [40.8], 40.8, [37.7], 37.5, 36.7,
36.4, 36.4, 34.5, 33.8, [33.1], 30.6, 29.7, 29.4, 28.9, 28.4, 28.1, 27.7, 27.6, 27.4, 22.7, [19.4],
19.4, 17.4, 15.5, [13.6], 13.5, 11.8, 10.9, [10.9], 10.1; [α]20D −15.7 (c 0.032, CHCl3); IR (thin
film) ν max (cm– 1) 3408, 2956, 2920, 2896, 2853, 1718, 1670, 1657, 1605, 1548, 1508, 1466,
1379, 1363, 1252, 1220, 1084, 1000, 955, 899, 854, 834, 695; HRMS calc. for C52H91N2O11
[M+H]+ 919.6617, found 919.6630.
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Selected 1H and 13C NMR spectra
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